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Abstract
Ganglioside GM3, a glycosphingolipid found in the outer membrane of all 
mammalian cells, is expressed at much higher concentrations than normal in cancer 
cells. It has been reported that GM3 can inhibit signal transduction via the EGF 
receptor kinase, ultimately down regulating cell growth. In contrast to this, de-A- 
acetyl GM3, another ganglioside that has been found in a number of cancer cell lines, 
is reported to be a potent promoter of cell growth. Evidence suggests that GM3 and 
de-A-acetyl GM3 are inter-converted by enzymes that remove and replace the N- 
acetyl group on sialic acid.
In this thesis, the syntheses of a number of simplified analogues of gangliosides are 
described, including some in which an inter-glycosidic oxygen atom is replaced by 
sulfur. Synthesis of O-linked ganglioside analogues was achieved by both a totally 
chemical route and also by a chemo-enzymatic route, involving the use of a 
recombinant construct of Trypanosoma cruzi ^ra«5-sialidase for glycosylation with 
sialic acid. A novel strategy for the synthesis of ganglioside analogues that contain a 
sialic acid a(2->3) galactose thioglycosidic linkage, is also described. These 
compounds were evaluated as substrates and inhibitors for Clostridium perfringens 
neuraminidase and Trypanosoma cruzi trans-sialidase. Some of the ganglioside 
analogues described herein were used to develop biochemical assays for detecting the 
putatative de-JV-acetylase and A-acetyltransferase activities that would be required 
for the inter-conversion of gangliosides GM3 and de-A-acetyl GM3.
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Abbreviations Used in the Text
All carbohydrates are named in accord with lUPAC recommendations {Carbohydr. 
Res., 1997, 243, 1). Abbreviations for gangliosides (GMl, GM2, GM3, GM4, GD3 
etc.) are as suggested by lUPAC and lUBMB {Pure Appl Chem., 1997, 69, 2475) 
and are based on those originally suggested by Svennerholm {J. Neurochem, 1963, 
10, 613). The structures of common gangliosides are illustrated in Scheme 1.1.
A. ureafaciens Arthrobacter ureafaciens
Ac acetyl
ATP adenosine triphosphate
Bn benzyl
BSA bovine serum albumin
Bz benzoyl
C, perfringens Clostridium perfringens
Cer ceramide
CMP cytidine 5’-monophospho
CoA co-enzyme A
COD cyclooctadiene
cpm counts per minute
15-crown-5 1,4,7,10,13-pentaoxacyclopentadecane
18-crown-6 1,4,7,10,13,16-hexaoxacyclohexadecane
DAG diacylglycerol
deNAc de-A-acetyl
deNAcGM3 de-A-acetyl GM3
deNAcGD3 de-A-acetyl GD3
DBU 1,8 -diazabicyclo [5.4.0]undec-7-ene
DDQ 2,3 -dichloro-5,6-dicyano-1,4-benzoquinone
DIG detergent-insoluble glycolipid-enriched complex
DMF A,A-dimethylformamide
DMTST dimethyl(methylthio)sulfonium trifluoromethanesulfbnate
dpm disintegrations per minute
EGF epidermal growth factor
EGF-RK epidermal growth factor receptor kinase
ES-MS electrospray mass spectroscopy
FACS fluorescence activated cell scanning
FAB-MS fast atom bombardment mass spectroscopy
Gal galactose
GalNAc ^acetylgalactosamine
GEM glycosphingolipid-enriched microdomain
Glc glucose
GlcNAc A-acetylglucosamine
GPI glycosyl-phosphatidylinositol
GSL glycosphingolipid
HMPA hexamethylphosphorustriamide
HPLC high performance liquid chromatography
IC50 50% inliibition concentration
KDN 2-keto-3-deoxy-D-glycero-D-galacto-2-nonulopyranosylonic acid
kryptofix 21 1,7,10-trioxa-4,13-diazacyclopentadecane
Lac lactose
LacNAc A-acetyllactosamine
lit. literature (reference)
ManNAc A-acetylmannosamine
MAPK mitogen activated protein kinase
Ms methanesulfonyl
MTC macrophage-mediated tumour cytotoxicity
Neu5Ac A-acetylneuraminic acid
Neu5Ac2en 2,3-dehydro-A-acetylneuraminic acid
Neu5Gc A-glycolylneuraminic acid
Neu5NH2 neuraminic acid
NIS A-iodosuccinimide
NMR nuclear magnetic resonance
Oct octyl
PKC protein kinase C
/>NP /7-nitrophenyl
SAP sphingolipid activator protein
SE (2-trimethylsilyl)ethyl
Sia unspecified sialic acid
sLex sialyl Lewis x
T. cruzi Trypanosoma cruzi
TBA tributylammonium
TBDMS ^-butyldimethylsilyl
Tf trifluoromethanesulfonyl (triflyl)
TEA trifluoroacetic acid
THE tetrahydrofuran
TLC thin layer chromatography
TMSOTf trimethylsilyltrifluoromethanesulfonate
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Chapter 1 
Ganglioside Biology
1.1 Cell Surface Glycosylation
In recent yeais there has been a growing awareness of the biological importance of 
carbohydrates in molecular recognition processes and in the control of biological 
eventsd In all organisms from bacteria to mammals, the cell surface is covered with 
a variety of complex carbohydrates (glycans) that form the first line of interaction 
with other cells, bacteria, bacterial toxins and viruses. ^  The glycans show great 
diversity in both size and structure despite comprising only a handful of common 
monosaccharide units. The common cell surface glycans can be classified into the 
following categories: A-linked and O-linked glycoproteins, proteoglycans, glycosyl- 
phosphatidylinositol (GPI) anchored proteins and glycosphingolipids (Figure 1.1). 
This project concerns the biological properties of a group of glycosphingolipids, the 
de-A-acetyl gangliosides. The structures, biosynthesis and biological properties of 
gangliosides and glycosphingolipids in general, will now be described in more detail.
Ser/Thr Ser/Thr
Protein
Protein
Glc 0  Gal 
I I GalNAc Fuc
O Man
Inositol
(d) (e)
g  GlcNAc ^  Sia 
^  sulfate % phosphate
Figure 1.1 Schematic examples o f  carbohydrate-containing cell surface molecules: (a) N-linked 
glycoprotein, (b) O-linked glycoprotein, (c) proteoglycan (keratan sulfate II), (d) GPI anchored 
protein and (e) glycosphingolipid (GM l).
1.2 Glycosphingolipids
Glycosphingolipids (GSL) (Figure 1.2) are amphiphilic molecules found in the 
plasma membrane of all eukaryotic cells. The lipophilic ceramide portion is attached 
to a diverse range of oligosaccharides which can be divided into seven main classes 
on the basis of their root oligosaccharide structures: the ganglio-, lacto-, neolacto-, 
globO", isoglobo-, mollu- and arthro-series (Appendix 1).2
Fatty Acid
 ^ Ceramide
OH
Sphingosine
Figure 1.2 Schematic glycosphingolipid. Typically, x=0-8, y=12-22.
The ceramide portion also shows some degree of variation in the length of the fatty 
acid derived amide chain and 20-carbon sphingosine is also known in some of the 
more complex GSLs.^» 4
1.3 Glycosphingolipid Metabolism (Figure 1.3) 3,4,5
1.3.1 GSL Biosynthesis. GSL biosynthesis begins with the assembly of the 
ceramide portion by enzymes bound to the cytosolic face of the endoplasmic 
reticulum. The lipid is then transported to the Golgi apparatus where glucose is first 
added, also on the cytosolic face. As all subsequent glycosylations occur on the 
lumenal face of the Golgi, glucosyl ceramide must be translocated to the interior of 
the Golgi compartment. This is thought to be facilitated by a “flippase” protein. 
Further elaboration of the glycosphingolipids inside the Golgi occurs under 
transcriptional control of the necessary glycosyl transferases^ i.e. the relative 
activities of the various transferases present will deteimine which GSL core structure 
will predominate. Even within a particular class of GSL there are certain key 
biosynthetic branching points which restrict the GSLs to follow specific pathways. 
One such example is the action of GalNAc transferase I in committing the ganglio- 
GSLs to follow the A, B, C or 0-series pathways (Scheme 1.1).
Cell surface
Cytosol
Golgi
Glycosyl-
transferases
Glc-T
Lysosome
Glycosidases
E.R
Figure 1.3 Biosynthesis and degj'adation o f  GSLs within a cell.
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Scheme 1.1 Biosynthesis o f  A, B, C  and O series gangliosides.
As GSLs travel through the Golgi compartments, they cluster together to form 
specialised “rafts”'^  or GSL-enriched microdomains (GEMs) which may also be 
associated with specific membrane bound proteins.^ On fusing with the plasma 
membrane, the Golgi compartment is turned inside out, thus delivering the “rafts” of 
GSLs specifically to the outer leaflet of the plasma membrane (Figure 1.3).
1.3.2 GSL Catabolism. Degradation of GSLs usually requires their reinternalisation 
and transport to the lysosomes through a series of endosomal compartments (Figure 
1.3). Typically, degradation is performed in a similar stepwise manner to 
biosynthesis, by a series of exoglycosidases^ but an endoglycosylceramidase which 
removes the intact oligosaccharide is also known.^ Removal of the innermost sugar 
residues requires the assistance of specific sphingolipid activator proteins (SAPs) 
which lift the GSLs out of the membrane allowing the relevant glycosidases to act 
more efficiently.^ These processes ultimately release sphingosine (not produced in its 
free form during biosynthesis) which may either re-enter the biosynthetic pathway or 
be further degraded.
1,4 Gangliosides
Gangliosides are GSLs with one or more sialic acid residue(s) attached to the 
oligosaccharide core.^
1.4.1 Structure and Biosynthesis of Sialic A c i d s . Sialic acid (Sia) is the 
generic name for a family of 9-carbon monosaccharides based on neuraminic acid, 
the most common of which is A-acetyl neuraminic acid (Neu5 Ac), 1 (Figure 1.4).
A c H N ^ 5 ;^ 0 H  1 
OH
Figure 1.4 N-acetylneuraminic acid, 1, and its numbering scheme.
The first key step in the biosynthesis of sialic acids (Scheme 1.2) is the épimérisation 
of A-acetyl glucosamine (GlcNAc; synthesised by A-acetylation of glucosamine-1- 
phosphate) to A^acetyl maimosamme ( M a n N A c ) . ManNAc is then phosphorylated 
at the 6-position before condensation with phosphoenolpyruvate to give Neu5Ac-9- 
phosphate. The phosphate must then be removed and NeuSAc converted to the 
nucleotide sugar cytidine 5’-monophospho-A-acetylneuraminic acid (CMPNeuSAc) 
before it can be incorporated into glycans by a variety of sialyl transferases. 
CMPNeuSAc is also the substrate for 7V-acetyl neuraminate monooxygenase, an 
enzyme which converts the A-acetyl group into an A^-glycolyl (2-hydroxyacetyl) 
group and leads to the second major series of sialylated glycans, i.e. those containing 
NeuSGc. Although Neu5Gc is the predominant sialic acid in many mammals {e.g. 
pig, cow), it is not normally detectable in human tissues. However, Neu5Gc has been 
detected in gangliosides present in both human colon^^ and lung tumours.
Glc GICNH2-I-P GlcNAc-1-P UDP-GlcNAc
HQ
.OH
AcHN OH 
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Further Further
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Scheme 1.2 Biosynthesis o f  sialic acids.
The CMPSias are the only examples of naturally occurring p-linked sialic acids. All 
sialic acid O-glycosides are a-linked, typically to position 3 or 6 of a galactose 
residue or position 8 of another sialic acid, although other linkages are known. 
Sialosides are not usually further glycosylated (apart fi*om Siaa(2->8)Sia which 
forms the repeat unit of the so-called poly sialic acid), however a wide range of 
alternative modifications to the basic NeuSAc or NeuSGc structures have been 
reported. These derivatives foim the ever growing family of the sialic acids (Figm*e 
l.S).
R^ 'O,
= 3Gal, 6Gal, 8Sia  
R  ^= H. Ac
R® = NHAc, NHz, OH (KDN), NHGc, NHGcAc, 
NHGcMe, NHGcSiaa2 
R  ^= H, Ac
R® = H, Ac, CH3, SO3-, S iaa2 
R  ^= H, Ac, SO3-, POs^', Lt 
O
G c = ^ J1 ^ 0 H  Lt =
OH 
CH3
O
Figure 1.5 Some modifications o f  sialic acid found in glycoconjugatesJ^-
The most common modification is acétylation which may be found at any of the 4 
Sia hydi'oxyls (positions 4, 7, 8 and 9). Acetyltransferases and esterases have been 
extensively s t u d i e d ,  although non-enzymatic acetyl migration along the glycerol 
side-chain can also occur under physiological conditions. 1 ^  Other modifications so 
far obseiwed include a lactyl ester at 0-9, méthylation at (9-8, sulfate groups at 0-8 
and 0-9 and phosphate at 0-9, The acetamido group at position 5 can be de- 
acetylated to give the amino sugar and the 2-hydroxyacetyl group of NeuSGc 
can be acetylated, methylated or even sialylated. 10 2,7 and 4,8 anhydro sialic acids 
have been identified and also lactones formed by cyclisation of the Sia carboxyl 
group onto a hydroxyl group of the neighbouring sugar residue. Although only few 
of the enzymes which perfoim these modifications have been characterised, it is 
believed that these transferases only act on glycan-bound Sia in the Golgi or other 
post-Golgi compartments. Although sialic acids are found in some bacteria, viruses, 
Drosophila melanogaster and, phylogenetically, all animals from starfish upwards, 
many of the modified Sias mentioned above, are both species and tissue specific and 
may only be expressed at certain points during the development of the organism.
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Recently, a new family of sialic acids, which have a hydroxyl group at C-5 (instead 
of the amino group present in neuraminic acid), was discovered. 2-Keto-3-deoxy- 
D-gfycero-D-galacto-2-normlopyranosyiomc acid (KDN) is biosynthesised in a 
manner analogous to NeuSAc, but starting fiom mamiose rather than A-acetyl 
mannosamine. This novel sialic acid, first detected in fish, has been shown to be 
present in a wide range of organisms fi*om bacteria to mammals including hum ans.20  
KDN occurs in both glycoproteins and glycolipids, but its discovery and much of the 
subsequent research concerned its presence as an a(2->8) polymer which is 
expressed temporally during cell development and also in cancer cell l in e s .K D N
glycosides are resistant to most neuraminidases, but are cleaved by a specific 
“KDNase”, which itself, does not recognise NeuSAc,22
1.5 Biological Functions of Gangliosides
Gangliosides are found at the surface of all mammalian cells, but the composition 
and distribution of different gangliosides varies according to cell type. There are 
marked changes in these “ganglioside profiles” during foetal development, cell 
differentiation and ageing^ and also during die process of oncogenesis.23. 24 indeed, 
virtually all cancer cells exhibit aberrant ganglioside profiles and the over- or under­
expression of various gangliosides is associated with morphological changes of the 
cell.25 Gangliosides have been implicated in a wide range of biological activities: 
cell-cell recognition and adhesion;24,26 induction of both an antigenic response27 and 
suppression of the immune system;28, 29 modulation of various membrane-bound 
enzymes, including those involved in signal transduction, thus controlling both cell 
proliferation and cell death.^^» 21
One such biologically important molecule is ganglioside GM3, 2 
(Neu5Aca(2-^3)Gaip(l->4)Glc(3(l-^l)Cer; Figure 1.6), a common glycolipid 
which is often expressed in high concentrations in cancer cells.
O H  OHO, ÇO2' OHLOH /O H  ÜU G o HN-^ (CH2)yCH3
A 0 H N - . . / 7 Ü /  ----- (CH2)i2CH3
OH OH OH z
OH
2
Figure 1.6 Ganglioside GM3. Typically y=^12-22.
GM3 provides a good illustration of most of the common roles of the gangliosides:
1.5.1 Immunosuppression. Tumour cells often actively shed gangliosides from their 
membranes, thus surrounding themselves with a high local concentration of 
glycolipids. This has been implicated in inliibiting the immune response to tumours 
by inhibiting T-cell proliferation29,32 whilst enhancing T-suppressor activity.28 GM3 
is one of the most potent glycolipids involved in these processes.
1.5.2 Macrophage-Mediated Tumour Cytotoxicity. In apparent contradiction to 
section 1.5.1, GM3 can activate macrophage-mediated tumour cytotoxicity (MTC).33 
The ganglioside acts by stimulating nitric oxide production by the macrophages. This 
process is analogous to bacterial lipopolysaccharide stimulation of MTC.
1.5.3 Tumour Associated Carbohydrate Antigens. Although GM3 is present in all 
mammalian cells, it has been demonstrated to be the antigen recognised by 
antibodies raised against melanoma cells.27 However, the immune response to this 
antigen is density dependent and will only be triggered above a threshold 
concentration that is only observed in cancer cells. There has been much interest in 
the use of ganglioside antigens, conjugated to protein carriers, as potential anti­
cancer vaccines. 24
1.5.4 Cellular Recognition and Adhesion. Minimum energy conformational 
models of gangliosides in membranes indicate that the axis of the oligosaccharide 
portion is oriented perpendicular to the axis of the ceramide moiety, such that the 
oligosaccharide lies in the plane of the membrane surface (Figure 1 .7 ) .2 2  Various 
biophysical studies have shown that many such molecules come together in large 
clusters, interspersed with cholesterol molecules (the so-called GSL-enriched 
microdomains, GEMs) rather than being evenly dispersed across the membrane 
(Figure 1 .7 ) .^ *  8, 23 These clusters may form ideal sites for carbohydrate-protein or 
carbohydrate-carbohydrate interactions with bacteria,26 v i m s e s , 2 5  or with other 
c e l l s . 2 4 , 36
^  GSL
phospholipi 
cholesterol
Figure 1.7 GSL-enriched microdomain in a lipid bilayer.
1.5.4.1 Bacterial adhesion to Neu5Gc-GM3. Many bacterial adhesion proteins and 
toxins recognise specific cell surface g a n g l i o s i d e s . 2 7  Ganglioside GM3 with N- 
glycolylated sialic acid has been shown to be the receptor for the enterotoxigenic E. 
coli K99 b a c t e r i u m .2 6  This bacterium causes severe diarrhoea in piglets, lambs and 
calves, all of which express GM3 principally with NeuSGc. Older animals mainly 
carry the inactive Neu5Ac-GM3, and are thus less susceptible to this particular 
bacterial infection.
1.5.4.2 Viral adhesion to GM3 and CD4/GM3. GM3 is highly expressed on the 
surface of CD4+ lymphocytes and macrophages. Recent studies have shown that 
GM3 could act as a cell surface receptor for HIV-1 through its interaction with HIV- 
1 glycoprotein gp 120.25 Alternatively, the ganglioside may also act as a “fusion co­
factor” in association with C D 4 .2 8
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1.5.4.3 Modulation of a5(31 integrin adhesion to fibronectin. It has been known 
for some time that gangliosides can affect the adhesion of cells to others expressing 
fibronectin at their surfaces.29 GM3 has a biphasic effect on adhesion of fibronectin 
to the aSpl integrin receptor; at low concentrations of GM3, integrin adhesion is 
considerably enhanced (relative to no GM3), whereas at higher concentrations, GM3 
mildly inhibits the recognition event.26
1.5.4.4 GSL-GSL interactions in metastatic deposition. It has been proposed that 
interactions between GEMs of GM3 on melanoma cells and gangliotriaosylceramide 
(Gg3*) 3, or lactosylceramide 4 (Figure 1.8) on the surfaces of lymphoma or 
endothelial cells form the basis for initial adhesion prior to metastatic deposition of 
the cancer cells.40.4i
H O / O H
O
NHAc 1 ^ 0
HO- - O ,
O
° 0  HN'^(CH2)yCH3
OH HO- OH
OH
H O / O H
HO- - O ,
OH HO:
O
°Q  HN'^(CH2)yCH3
(^^2)1 2CH;
OH
OH
Figure 1.8 Gangliotriaosylceramide and lactosylceramide. Typically y = 12-22.
GSL-GSL interactions are considerably weaker than those involving adhesion 
proteins such as integrins. However, under dynamic flow conditions, designed to 
mimic the microvascular environment under which metastatic depostion of tumour 
cells occurs, the much more rapid GSL-GSL interactions predominate over the 
slower acting, but higher affinity integrin based adhesion.24 It has also been 
demonstrated that liposomes containing either GM3 or Ggg can reduce metastasis in 
vivo and could prove to be an effective anti-adhesion therapy against tumour
progression. 42
* Gangliotïiaosylceramide (Ggg) and lactosyl ceramide (LacCer) may also be thought of as asialo- or 
0-series gangliosides GA2 and GA3, respectively. However, in the literature, they are more 
commonly referred to as Ggg and LacCer.
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1.5.5 Modulation of Membrane Transporters. The flow of ions and metabolites 
across membranes is often facilitated by specific membrane bound transporter 
proteins. Incorporation of GM3 into membranes containing either the human 
erythrocyte glucose transporter (GLUT 1)43 or the sarcoplasmic reticulum Ca2+- 
ATPase,44 has been shown to cause conformational changes in each of these 
proteins. In both cases, the conformational changes are accompanied by an increase 
in the activity of the transporter.
1.5.6 Signal Transduction. In order to maintain normally functioning healthy 
tissues all aspects of individual cell function must be tightly controlled. Such control 
throughout a tissue requires an external stimulus to be recognised by receptors on 
each cell and the information contained in this recognition event to be amplified and 
relayed to the nucleus, usually by a complex protein kinase cascade e.g. the mitogen 
activated protein kinase (MAPK) cascade.45 Changes in cell function can then be 
effected by expression of appropriate genes. This process of conveying information 
from a point outside the cell to the nucleus is called signal transduction.
There have been many reports on the role of gangliosides in controlling signal 
transduction.8,23,34,46,47 Modulation of signal transduction probably fonns the basis 
for GM3 induced inhibition of angiogenesis aroimd tumours (growth of new blood 
vessels required to supply the growing tumour with nutrients),47, 48 qM3 promoted 
cell differentiation46 and GM3 stimulated apoptosis (programmed cell death) in 
thymocytes,49 and probably also several of the biological activities listed above. 
Gangliosides alone do not appear to activate or inhibit intracellular kinases and 
phosphatases.30 The two general mechanisms for the involvement of gangliosides in 
signal transduction that have been proposed are that (i) they act as signal transducing 
molecules for extracellular messengers,31 and (ii) they modulate growth factor 
induced activation of growth factor receptor kinases.46
1.5.6.1 Gangliosides as signal transduction molecules. Low density detergent- 
insoluble glycolipid-enriched complexes (DIGs) prepared from B16 melanoma cells 
contained 90% of cellular GM3 and <2% of total cellular proteins.8 However, 50- 
90% of the total amount of several signal transducer proteins {c-src, rho and ras) 
were found in the DIGs. These transducer proteins were found to be activated when 
the B16 cells bound to Gg3 covered plates (see section 1.5.4.4).8 Similarly, the src 
family kinase lyn was found associated with DIGs from rat brain, principally 
comprising GD3.31 Anti-GD3 antibodies were able to activate lyn and also other 
substrates including MAPK. Therefore GEMs associated with intracellular protein
12
kinases may widely act as transduction receptors for various antibodies, lectins and 
GSL patches on other cells (Figure 1.9).
Interaction of complementary GSLs
kinase
GSLs 
phospholipid 
cholesterol
Signal transduction via kinase cascade
V
Figure 1,9 Gangliosides act as signal transducing molecules.
1.5.6.2 Gangliosides modulate growth factor receptor kinases. Several growth 
factor receptor kinases are affected by the presence of specific g a n g l i o s i d e s .46 The 
signal transduction pathway initiated by the interaction of the epidermal growth 
factor (EGF) peptide and its receptor (EGF-RK), has been shown to be controlled by 
gangliosides G M 3  and de-A-acetyl G M 3  ( d e N A c G M 3 ) .^ 7 ,  30, 52 roles of EGF- 
RK, GM3 and deNAcGM3 in this process will now be discussed in more detail.
1.6 Control of the EGF Receptor Kinase by GM3 and DeNAcGM3
1.6.1 EGF Receptor Kinase. The EGF receptor is a ISOkDa transmembrane 
glycoprotein composed of three distinct d o m a i n s .33, 54 The extracellular domain has 
12 possible sites for asparagine-liiiked glycosylation and it is expected that most of 
these sites do have pendant carbohydrate g r o u p s .35 This is the domain that binds the 
6kDa EGF peptide and is connected via a single membrane spanning region of 23 
hydrophobic amino acids to the internal kinase domain which has a src type 
structure. The EGF-RK is over expressed in some tmnours and monoclonal 
antibodies directed against the receptor are in clinical trials as potential anti-cancer 
d ru g s .3 6
On binding EGF, a conformational change allows receptor dimérisation to occur and 
subsequent autophosphorylation of a tyrosine residue on the internal domain 
activates the kinase (Figure 1.10). The nature of the conformational change is not
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fully understood, but there is considerable evidence that dimérisation is noimally 
required for the a u t o p h o s p h o r y l a t i o n , possibly by aligning the kinase domains for 
an intermolecular reaction (although under certain conditions the monomer can 
autophosphorylate^^). Once activated, the EGF receptor kinase acts, via a series of 
transducer molecules, to initiate the MAPK cascade which conveys the message to 
the nucleus, ultimately enhancing cell growth and division (Figure 1.10).
It has also been shown that EGF-RK is associated with phosphatidylinositol 4-kinase 
and phosphatidylinositol-4-phosphate 5-kinase.^^ The activities of these two 
enzymes are enhanced on EGF-RK activation, thus up-regulating the production of 
inositol 1,4,5-trisphosphate and diacylglycerol which in turn increase cytosolic Ca^+ 
concentration and activate protein kinase C (PKC). PKC is also capable of activating 
the Raf-1 kinase which leads into the MAPK cascade.^^
Raf-1iGTI
MAPKK MAPKK
ATP
MAPKMAPK
ATP
GENE EXPRESSION NUCLEUS
Figure 1.10 Activation o f  EGF-RK.
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1.6.2 Modulating Receptor Kinase Activity. There me several lines of evidence 
that cell proliferation due to gi'owth factor receptor kinases can be regulated by 
gangliosides.3^ There are a number of ways in which these glycolipids could 
modulate growth factor receptor kinase activation:
(a) Direct interaction with the extracellular domain could prevent growth factor 
binding, possibly due to a confonnational change of the receptor binding site.
(b) Gangliosides are detergent like molecules and may thus have an effect on the 
fluidity of the membrane which could alter the ability of the receptors to 
dimerise.
(c) Either through direct interactions or by changing the membrane environment, 
gangliosides could prevent kinase activation by inducing a confonnational 
change in protein (see section 1.5.5).
(d) As the sialic acid residue is negatively charged, it could potentially act as a 
competitive inliibitor with respect to ATP binding on the intracellular 
domain.
1.6.3 GM3 and DeNAcGM3. Ganglioside GM3 and the stmcturally similar 
compound de-A^-acetyl-GM3 (deNAcGM3; Figure 1.11) 5 have been obseiwed to 
modulate the activation of EGF-RK.
OH OH OH i
ÔH
5
F ig u r e l . i l  Modified ganglioside deNAcGMS. Typically y== 12-22.
1.6.3.1 GM3 inhibits EGF-RK activation. GM3 has the ability to inliibit EGF 
stimulated cell growth in a variety of cell lines derived from different tissues.^o, 58,59 
It acts by preventing autophosphorylation of EGF-RK at tyrosine residues.^^ The 
mechanism of this inliibition is not Imown, but extensive investigations in this area 
have been carried out by Hakomori, Bremer and others.'^  ^Vesicles containing EGF- 
RK molecules show selective binding to GM3 coated plates.*^  ^ Sialyl lactose 
conjugated to BSA also has the ability to block the autophosphorylation event.^o 
GM3 does not affect intracellulm* protein phosphatases, which could reduce EGF-RK 
phosphorylation, nor does it have any direct effect on purified intracellular kinases. 
EGF binds to its receptor with the same affinity in both the presence and absence of 
GM3.^i There are conflicting reports regarding the effect of GM3 on receptor
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dimérisation,46, 52 but GM3 inhibits EGF-RK phosphorylation in both monomeric 
and dimeric EGF-RK.^^ The inhibitory effect of GM3 may be part of a larger 
feedback loop control, as addition of EGF to retinal Müller glia has been shown to 
stimulate ganglioside synthesis tw o - f o ld A ^  gM3 constituted over 50% of the 
gangliosides produced.
Many of the studies mentioned above have relied on the use of membrane fractions 
prepared in the presence of the detergent Triton X I00 and/or the addition of high 
concentrations of exogenous gangliosides. In the presence of low concentrations of 
detergent GM3 showed inhibitory properties, but at high detergent concentration, 
GM3 actually stimulated EGF-RK phosphorylation on addition of EGF.6*3 However, 
experiments using only a fireeze-thaw cycle to permeablise the cells confirmed that 
exogenous GM3 does inhibit EGF-RK activation.<^4
A number of studies have also addressed the question of whether addition of high 
concentrations of exogenous GM3 simply give rise to a pharmacological effect, or 
one that is physiologically relevant.Gangliosides added to cell growth medium 
become incoiporated into the cell by a two step mechanism;^* an initial fast adhesion 
to cell surface proteins is followed by a much slower insertion into the membrane. 
Even after 48 hours, much less than 10% of exogenous gangliosides may be 
incorporated. An elegant study by Weis and Davis demonstrated that endogenous 
GM3 can have the same effect as exogenously added ganglioside. They transfected 
the gene for human EGF-RK into a cell line deficient in the epimerase required to 
synthesise galactose from glucose. Therefore, the cells could not express any GSLs 
other than glucosyl ceramide in the absence of galactose and GalNAc in the growth 
medium. On supplementing these two sugars in the growth medium, the cells were 
able to synthesise GM3 and showed a concomitant reduction in EGF stimulated 
receptor phosphorylation.
Also, it has been demonstrated that exogenous addition of Clostridium perfringens 
neuraminidase to human skin fibroblasts stimulates cell g r o w t h .^6 This has been 
rationalised as enzymatic degradation of GM3 relieving the inhibitoiy effect of the 
ganglioside on EGF-RK. Although, in this case, the sialidase could also be operating 
by a mechanism as outlined in section 1.5.6.1, several endogenous extracellular 
sialidases have been characterised.^^ It may transpire that these have a role in 
modulating the GM3/EGF-RK interaction.
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1,6.3.2 deNAcGM3 enhances EGF-RK activation. DeNAcGMS 5 is another 
physiological membrane component which has been identified in a wide variety of 
cancer cell l i n e s . I t  was isolated by HPLC of the monosialoganglioside fraction, 
extracted from B16 melanoma cells (and other cell types) with detection by N- 
acetylation with [i^CJacetic anhydride or immunoblotting with a specific monoclonal 
antibody. DeNAcGMS occurs only in very low concentrations (~lpmo 1/5x10  ^B16 
cells), but in some tumour cell types it has been observed in higher concentrations 
than GM3.52 However, this ganglioside is not observed at the cell surface by 
immunoblotting techniques. Either deNAcGMS is present in too low a concentration 
for detection, or it is simply not expressed at the cell surface, except, perhaps 
transiently.
The biology of deNAc gangliosides has not been investigated widely, other than the 
role of deNAcGMS in modulating EGF-RK activation. 52, 64 Hakomori and co­
workers discovered that deNAcGMS could enhance cell growth when added 
exogenously to a cell culture. ^ 7 They also reported that this modified ganglioside 
strongly enliances phosphoiylation of EGF-RK in membranes solubilised with the 
detergent Triton XI00. DeNAcGMS had no effect on the affinity of EGF for its 
receptor. As mentioned in section 1.6.3.1, the results of such experiments may be 
influenced by detergent concentration. Other investigators were able to confirm the 
effect of deNAcGMS on EGF-RK in the presence of Triton XI00, but not in the 
absence of detergent.46, 64 Hakomori subsequently published further convincing 
evidence in favour of EGF-RK modulation by deNAcGMS. 2^ jjg showed that in the 
absence or in the presence of minimal amounts of detergent (<0.001 %), exogenous 
deNAcGMS increased total EGF-RK phosphorylation two fold. This was principally 
due to increased phosphorylation at serine rather than at tyrosine residues. However, 
at higher detergent concentration, >0.025% (i.e. above the critical micellar 
concentration for Triton XI00), enhanced phosphorylation was mainly of tyi'osine 
residues. Enhanced phosphorylation of serine residues would imply the involvement 
of a different protein kinase. For example, protein kinase C enhances serine and 
tlireonine phosphorylation and inhibits tyrosine phosphoiylation of EGF-RK.*^  ^Thus 
deNAcGMS may modulate EGF-RK activation by enhancing an alternative kinase 
that is serine specific.
The stimulatory effect o f deNAcGMS on EGF-RK activation is in strildng contrast to 
the inhibitory effect o f GM3 on the same system; a simple de-N-acetylation creates a 
potent compound which is strongly antagonistic towards the action o f the parent 
ganglioside.
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Curiously, deNAcGMS inhibited phytohaemagglutinin-induced lymphocyte 
proliferation by 37% at an exogenous ganglioside concentration of 50 nmol/cm^.^s 
This is in apparent contradiction to the stimulatory effect of deNAcGMS described 
above, but the ganglioside literatuie is not without contradictions.
1.6.3.3 Other sphingolipids that affect signal transduction. Several other 
degradation products of gangliosides have potent effects on signal transduction. A 
GMS analogue which has lost the fatty acyl chain from ceramide (lysoGMS, 6; 
Figure 1.12) inhibits EGF-RK activation in the same manner as GMS.<53
CO2 OH OH
AcHN
NH2
(0H2)i20H3
ÔH
Figure 1.12 M odified ganglioside lyso-GM3.
However, ceramide and sphingosine both stimulate EGF-RK phosphorylation at 
serine and threonine residues.Diacylglycerol (DAG), which activates protein 
kinase C (PKC), is the classic example of a lipid degradation product acting as a 
secondary messenger. Both lactosylsphingosine and A,A-dimethylsphingosine act in 
contrast to DAG, by down-regulating PKC activity.^» It was noted in section
1.6.3.1 that, because exogenous GSLs are inefficiently incorporated into the 
membrane, high concentrations of GSLs (~50pM) are often required to observe 
biological effects. In the case of ceramide, IpM or less can can induce changes in 
signal transduction.^*  ^Therefore, even slight contamination of GSL preparations with 
other sphingolipids may give misleading results.
1.6.4 Biosynthesis of de-A-acetyl Gangliosides. The ganglioside deNAcGDS, 7 
(Figure I.IS) has been identified in Melur melanoma cells by Varki and co- 
workers.^^
OH COg-HO.
R^ HN OHOH HO.
O HO OCer
OH OH OH
1 ,2
Figure 1.13 Modified ganglioside deNAcGDS; either, or possibly both sialic acid residues may have
a free  amino group.
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Whilst studying the turnover of sialic acid 0-acetyl groups using tritiated acetate or 
acetyl CoA, they found that the radio-label accumulated in the acetamido group of 
the sialic acid. As the experiments using [^HJ-acetyl CoA were performed using 
washed Golgi-enriched vesicles, the possibility of [^HjAc incorporation at the 
GlcNAc stage of sialic acid biosynthesis (see section 1.4.1) was considered unlikely 
in the absence of the required cytosolic enzymes and their associated co-factors. By 
doubly labeling cells with [l-^"^C]GlcNAc and [^H]-acetyl CoA, they were able to 
show that there was a higher rate of W-acetyl turnover than Sia turnover for both 
GM3 and GD3 in Melur cells. However, the expression of deNAc gangliosides 
appears to be “transient and variable” which has complicated further studies. 
Genistein, 8, a tyrosine kinase inhibitor, was able to increase the amoimt of 
deNAcGD3 in Melur cells. It has been suggested that genistein may stop the cell 
cycle at a stage when deNAcGD3 expression is elevated. Immunochemical studies 
have indicated the presence of deNAcGD3 in lymphocytes and in human melanoma 
tumours and cell lines.^^ Although GD3 is abundant at the cell surface, deNAcGD3 
was only found in an intracellular compartment. However, nocodazole, 9, an 
inhibitor of microtubule assembly, caused deNAcGD3 to accumulate at the cell 
surface,suggesting that it may be transiently expressed outside the cell and then 
rapidly internalised. No physiological role for deNAcGD3 has been proposed.
N H 
H
9
Figure 1.14 Genistein and nocodazole affect expression o f  deNAcGDS.
The above studies show that deNAc gangliosides are naturally occurring components 
of cell membranes and may have potent biological activities. Evidence suggests the 
presence of specific de-W-acetylase and acetyltransferase enzymes which would 
catalyse the synthesis and degradation of deNAc gangliosides. De-A-acetylase 
enzymes which act on sugars have been reported in the biosynthesis of Nod 
factors,"^ ® lipid A,"^  ^ heparin/heparan sulfate (combined A-deacetylase/iV- 
sulfotransferase)'72 and GPI anchored proteins.^^ iV-Acetyltransferases are involved 
in the synthesis of GlcNAc and in the degradation of heparin and hepaian sulfate.24 
The latter case is an unusual example of a biosynthetic enzyme involved in a 
lysosomal catabolic process.
HO.
OH O OH
8
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Acetyl-coeiizyme Aia-glucosaminide A-acetyltransferase is one of at least eight 
enzymes involved in heparin degradation, the others being sulfatases and exo- 
glycosidases7^ As there is no glycosidase capable of hydrolysing either GlcN-sulfate 
or glucosamine, A-sulfated glucosamine residues must be desulfated and then N- 
acetylated prior to further degradation of the heparin chain (Scheme 1.3).
HQ
OH
QHO
OH
A/-sulfatase ^^HO
OH
Q 0:=:^0'
SO42-
AcCoA -n. 
C o A ^
OH
A/-acetyltransferase
.OH
GlcNAc. V AcHN I
a-A/-acetylglucosamlnidaseOH ' OH
Scheme 1.3 Degradation o f  heparin/heparan sulfate involves a N-acetyltransferase.
Free neuraminic acid is physiologically unstable, degrading by intramolecular 
condensation to give pyrrole-2-carboxylic acid (Scheme 1.4) It is thus unlikely 
that de-A-acetylation would occur for free sialic acids, or that deNAc gangliosides 
should be subject to degradation by a specific neuraminidase which could release 
Neu5NH2.
OH
OH OHHO. OH
HO
C O ,-
H N ^
CO2'
N:
CO2
+
OH
HO O
HO H
OH
OHHO.
-HoO
HO
002-
Scheme 1.4 Degradation o f  neuraminic acid to pyrrole-2-carboxylic acid.
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It is thus more likely that the putative de-7V-acetylase and A-acetyltransferase act on 
glycan bound sialic acids (Scheme 1.5), with re-A/-acétylation a requirement prior to 
hydrolysis of sialic acid cf. heparin degradation. Evidence suggested that free amine 
groups were present on either of the external or internal Sia residues of 
deN A cG D S.It is perhaps reasonable, therefore, to assume that the same enzyme is 
capable of synthesising both deNAcGMS and deNAcGDS.
de-A /-acetylase
GM3 2    deNAcGM S 5
A/-acetyltransferase
Scheme 1.5 Putative enzymes fo r  the metabolism o f  deNAcGMS.
Further advances in studying the biological roles of deNAc gangliosides will 
probably require the identification and isolation of the de-A-acetylase and N- 
acetyltransferase. This is the ultimate aim of this project, and to this end we decided 
to synthesise a number of analogues of GMS and deNAcGMS which could be used 
to set up an assay for the de-A-acetylase and A-acetyltransferase activities. Such 
assays could be used to monitor the purification of the relevant enzymes and also to 
screen potential inhibitors for the enzymes. It should be possible to get a better 
picture of the biological relevance of deNAc gangliosides by inliibiting the de-A- 
acetylase and/or A-acetyltransferase in whole cell systems and then studying any 
resulting physiological changes.
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Chapter 2 
Synthesis and Biological Properties 
of Thioglycosides
2.1 Thioglycosides in Carbohydrate Chemistry and Glycobiology
Thioglycosides have been extensively studied in both carbohydrate chemistiy and 
glycobiology. Simple alkyl and aryl thioglycosides have proven to be highly versatile 
glycosyl donors which show excellent stability under a wide range of reaction 
conditions, but may be selectively activated by a range of “thiophilic” promoters.^ 
These include dimethyl(methylthio)sulfonium triflate (DMTST),^ N~ 
iodosuccinimide/triflic acid (NIS/TfOH),^ and iodine.^ On the other hand, ^S-linked 
oligosaccharides have attracted considerable interest as potential inhibitors for 
glycosidases and lectins, due to their widely reported resistance to enzymatic 
c l e a v a g e .3, 4  The synthesis and biological activities of thio-glycosides have been 
reviewed r e c e n t l y .^  This section is intended as an overview of this topical area of 
carbohydrate chemistry.
2.2 Synthetic Strategies^» ^
There are two basic strategies for the synthesis of thioglycosides, which may be 
classed by the origin of the inter-glycosidic sulfur atom (Scheme 2.1); i.e. the S- 
linkage can either be formed by reaction of a glycosyl donor, bearing a leaving group 
at its anomeric centie, with a thiol functionality present in the acceptor molecule 
(thio-glycosylation), or by alkylation of a thiol at the anomeric position of the donor,* 
using an acceptor with a suitably positioned leaving group (anomeric ^'-alkylation).
T h i o - g l y c o s y l a t i o n ' ' ^ ^ » ^ ^ n o m e r i c  S-aikylation
+  HS
L
-A.-.— \ - ^SH +  \p-——
Scheme 2.1 Two strategies fo r  thioglycoside synthesis: thio-glycosylation and anomeric S-all(ylation.
L = leaving group, e.g. Cl, Br, OTf
* Strictly speaking, a thioglycose is not a “glycosyl donor” as it does not donate a “glycosyl group” 
during the coupling reaction. However, this incoiTect use of the traditional donor/acceptor 
teiminology is to be found repeatedly in the literature and so it is also used here for simplicity.
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2.2.1 Thio-glycosylation. Thio-glycosylation may be sub-divided further into acid- 
promoted and base-promoted glycosylation (Scheme 2.2). The former is the 
traditional approach towards forming both O- and ^'-glycosides. This involves the use 
of Lewis acids to promote the loss of the anomeric leaving group from the donor, 
which would be a glycosyl halide or trichloroacetimidate or an anhydro-sugar. As 
this type of glycosylation has a S^l type mechanism, stereochemistry must be 
controlled by the anomeric effect or by neighbouring group participation of an ester 
adjacent to the anomeric centre.
(a)
BF3 
NH 1 \  ®  
BnO
(b)
BFc
c )
Me—^  
O M e—
Bn =
HS
/O
Me—rt
O
Schem e 2.2 A cid prom oted thio-glycosylation (a) without neighbouring group participation and (b)
with neighbouring group participation.
Base-promoted glycosylation of thiol containing sugars has also been widely 
employed. The thiol is deprotonated to give, typically, the sodium or caesium thiolate 
which is used to displace chloride or bromide from the donor. The base-promoted 
reaction proceeds by a Sn2 type mechanism which allows the stereochemistiy of the 
glycosylation to be determined in advance; i.e. a p-halide will give an a-glycoside, 
regardless of the presence or absence of a participating group at the adjacent carbon 
atom (Scheme 2.3).
(a) N â s ^ : : ^  ..oMe — Me —^  S A - - —A  
O O
C) ; o p  >
M e—^  M e—^
O O
Scheme 2.3 Base prom oted thio-glycosylation to give (a) a-glycosides and (b) /3-glycosides.
2.2.2 Anomeric 5-Alkylation. Anomeric iS-alkylation is usually perfonned under 
base-promoted conditions with either a halide or sulfonate as the leaving group in the 
acceptor (Scheme 2.4). For hindered secondary positions, triflate is usually the 
preferred leaving group. In this approach, the anomeric configuration has previously 
been set whilst introducing sulfui* into the donor, and the S^2 coupling reaction 
inverts the configuration of the acceptor at the site of the leaving group.
A
Scheme 2.4 Anomeric S-alkylation.
Initial introduction of sulfur into either the donor or acceptor is usually accomplished
by an Sn2 type reaction. Typically potassium thioacetate is the chosen nucleophile,
although thiourea and potassium thiocyanate have also been used (Scheme 2.5). It 
has been reported that thiourea may react by an S^l mechanism.^ Thioacetates are 
converted to the corresponding thiols by selective deprotection using either sodium 
methoxide/MeOH at low temperature^ or hydrazinium acetate in DMF,^ prior to the 
coupling reaction. Alternatively, they may be deprotected in situ using cysteamine in 
HMPA^ or diethylamine in DMF.i^> Pseudothioureas and thiocyanates may be 
reduced to tliiols using potassium metabisulfite and zinc/acetic acid, r e s p e c t i v e l y .  ^ 2 ,  
13
29
AcO,
NHpBr
NHOAc
O SAc
OAc
Q SH
OAc
A cs
NOS
HS
Scheme 2.5 Introduction o f  sulfur into donor and acceptor. Typical reagents: i, thiourea, acetone; ii, 
KSAc, TBAHSO4 , NaOH(aq), CH2 CI2 , or KSAc, DMF; iii, KSCN, DMF; iv, K2 S2 O5 ; v, NaOMe, 
MeOH or N 2 H4 .ACOH, DMF; vi Zn, AcOH.
2.3 Solution Conformations
The conformations of several thioglycosides in aqueous solution have been 
determined using a combination of NMR spectroscopy, molecular mechanics 
calculations and X-ray crystallography. The C-S bond is approximately 0.4 Â longer 
than the C-0 bond (1.8 Â vs. 1.4 Â) and the C-S-C angle is smaller than the 
corresponding C-O-C angle (-100° vs. -116°).^^ The net effect is an increase in the 
distance between adjacent sugar residues of 0.35-0.4 Â (Figure 2.1). The increase in 
length is accompanied by a decrease in steric interactions between the 
monosaccharide residues and an increase in the flexibility of the glycosidic linlcage.^^
Figure 2.1 comparison of 0-glycoside and S-glycoside bond lengths and angles.
2.3.1 Maltose and Galabiose. Methyl 4-thio-a-maltoside 11^  and 2- 
(trimethylsilyl)ethyl 4-thio-p-galabioside 13 both adopt the same overall 
conformation (albeit with greater flexibility) as the parent O-linked disaccharides, 10
30
and 12, respectively (Figure 2,2). However, both compounds show the loss of an 
interglycosidic hydrogen bond that was present in the O-linked compounds. For the 
thio-galabioside 13, this has been linked to a 8 kJmol'i decrease in the binding 
affinity of the disaccharide for the PapGjgg adliesin of class I E. coliJ^
OH
OMe"°OMe 
10
Q S D
11
OH O-
HQ
HO
OHO s
^ %  O SE
13
O SE = q ' ' " \ / S K C H 3)3 
Figure 2.2 Thio-maltoside 11 and thio-galabioside 13 both show loss o f  an interglycosidic H-bond
2.3.2 Sialyl Lewis x. The conformation of a fully ^'-linked analogue of sialyl Lewis x 
14 showed considerable deviation from that of 0-linked sLex 15 (Figure 2.3).
AcHN
AcHN
OH HO
S^CZ^-^S(CH2)6CH3
J  HOV % O y .n H  HO OH ^ O H
14 15
OH HO
Me
/ S s P y  NHAc ) nw
3G alp4G lcpiC er
H 0°^
Figure 2.3 conformations o f  S-linked and 0-Linked sialyl Lewis x.
The natural compound has a well defined, fairly rigid conformation in which the 
galactose and fucose residues are stacked 4 Â apart, stabilised by hydrophobic 
interactions. The same residues in the thio-analogue are over 5 Â apart, and each
31
apparently adopts several different confoimations in solution. No comparative 
analysis was performed with the Neu5Aca(2->3)Gal linkage, as studies of the O- 
linked compound had shown no well defined conformation.
2 .4  B io lo g ic a l A c tiv it ie s
When considering the biological activities of these compounds, it should be noted 
that there is a distinction between being “resistant to enzymatic hydrolysis” and 
being an “enzyme inhibitor”. Sialic acid C-glycoside analogues {e.g. 16, Figure 2.4) 
have been reported to be inhibitors of influenza virus haemagglutinin, and also to be 
resistant to cleavage by neuraminidase.^^ However, as these compounds do not bind 
to the neuiaminidase, they are not neuraminidase inhibitors.
OHHO.
AcHN
HO
NH
Figure 2.4 Aciylam ide based co-polymer, bearing sialic acid C-glycosides, is an influenza virus
haemagglutinin inhibitor.
Numerous 6 "-glycosides have been shown to interact with lectins and glycosidases 
with KjS and IC50S in the pM-mM range (many glycosidases bind their natural 
substrates with Kms in the low mM range).^ Thio-oligomers of a- and (3-linlced 
glucose have been used to study amylases and cellulases. The fully ^'-linked 
trisaccharide 17 (Figure 2.5) has been co-crystallised with pancreatic a-amylase and 
was effective in identifying both the active site of the enzyme and also a second 
binding site on the surface of the protein.*^ P-Linlced trisaccharide 18 is a 
competitive inhibitor for cellulase from Trichoderma reesei. The analogous amino 
compound was coupled to CH-Sepharose 4B to provide an affinity chromatography 
column 19 (Figure 2.5) which was used to purify the cellulase from a crude T. reesei 
p reparat ion.As most of the known glycosidases are exo-hydrolases {i.e. they
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remove monosaccharide residues in a stepwise manner from the non-reducing 
terminus of oligosaccharides), it is not always necessary to replace all of glycosidic 
linkages with sulfur. Hemithiocellodextrin 20 with alternating thio- and oxo-linkages 
is hydrolytically stable in the presence of cellulases, which it inhibits with a Kj in the 
pM range.5
OH
HQ OHHO'
HO OHHO'
HO
HO
HO NO2
S — ^ —  N H Ac
r CH \  
S ep h aro se  
V 4 B y
HQ
20 HO
Figure 2.5 Some S-linked analogues o f  amylose and cellulose.
2 .5  T h io g ly c o s id e s  o f  S ia lic  A c id
2 .5 .1  S y n th e s is . Sialic acid is often found at the non-reducing terminal of cell surface 
glycans (section 1.4.1) and it forms part of the recognition sites for many vhiises, 
bacteria and bacterial toxins (section 1.5.4). Therefore, thioglycosides of sialic acid 
have drawn considerable attention, in particular, as potential inhibitors of viral lectins 
and neuraminidases. Hasegawa and co-workers have synthesised a range of thio- 
ganglioside analogues via the anomeric *S-alkylation approach (section 2 . 2 . 2 ) . This 
approach gave a(2 ^ 6 ) thio-sialosides in good yield but, synthesis of the blinked
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ganglioside GM4 analogue 26, which contains the Neu5Aca(2->3)Gal linkage, 
proved more difficult. Condensation of sodium thiolate 21 with 3-0- 
triflylgulopyranose acceptors 22 and 24 gave the thio-disaccharides 23 and 25 in 
30% and 22% yield, respectively (Scheme 2.6). Although the compound 23 was 
formed in better yield, considerable problems were then encountered on trying to 
remove the protecting groups.
AcO. OAc G02Me
Me
COsMe '^o
AcHN 8 Na^  +
OAc
Me
21
Me
AcHN
OTf ro
21
DMF AcO.y -^ -^ O A c
OTf
24
22%
s^OAc ^02Me Y OAcHN OAc
OH
U r ° 0  HN-^(CH2)yCH3
Ac HN— ( CH2) i 2^H3
OH OH
26 OH
y = 16 or  22
Schem e 2.6 H asegaw a’s synthesis o f  S-linked ganglioside GM4.
Sabesan and co-workers found it more convenient to prepare their Neu5Aca(2->6)- 
6 -C-methyl-6 -thio-Gal analogues 34i?&5 (Scheme 2.7) by the base promoted thio- 
glycosylation approach (section 2,2.1).20 The secondaiy 6 -O-triflyl compounds 
21R&S are less reactive than the analogous, primary 6 -O-triflyl-galactose 28. 
Triflate 21S underwent facile displacement with potassium thioacetate to give the 6 - 
i?-thioacetate 29R in 83% yield, however, the 6 -i?-triflate isomer 21R proved 
considerably less reactive and more prone to elimination, giving the 6-5'-thioacetate 
isomer 29S in only 46% yield. Thio-glycosylation of the corresponding thiolates
34
30R&S, on the other hand, proceeded in comparable yields (both over 60%). The 
thio-disaccharide products 32R&S were each contaminated with about 10% of the 
elimination product 33, which proved difficult to remove at this stage, but partial 
deprotecting of the disaccharides then allowed easy purification of the 
thioglycosides.
w 11
27R&S .. 2QR&S R=Ac 
" V 30f?& SR=N a
28
OAcAcO,DMF
AcHN
OAc
OAcAcO, p A c
OAcAcHN AcO,OAc COoMeMe + AcHN
Z2R&S
OHHO, P H
AcHN
OH H O f
HO
OH OH34R&S
Scheme 2.7 Sabesan's synthesis ofN eu5A ca(2—>6)-6-C-methyl-6-thio-Gal analogues 34R&S
Von Itzstein and co-workers have reported a novel procedure for synthesising sialic 
acid thio-glycosides from the 2-thioacetate 35 (Scheme 2.8). A combination of 
DMF and diethylamine as solvent allows in situ deprotection of the thioacetate 35. 
Whereas the alkylation step works efficiently using simple alkyl bromides and 6 - 
bromo-glucose derivatives, synthesis of sterically hindered disaccharides requires the 
use of the more reactive triflate derivatives. Using this approach, 3- and 4-
35
thiosialosides of glucose have been synthesised in 84% and 74% yields, 
respectively. ^  ^
OAcOAc AcO.AcO. P A cP A c HNEÎ2 _AcNEt AcHNAcHN
OAc OAc
35 R rB r
OAcAcO.
AcHN
Scheme 2.8 von Itzstein’s procedure fo r  synthesising sialic acid thio-glycosides.
Sclunidt and co-workers have recently described the synthesis of GM3 analogue 36^^ 
and the corresponding sialyl Lewis x analogue 14.6. 22 These were both synthesised 
in a block-wise approach from the intennediates indicated in Schemes 2.9 and 2.10.
OH
AcHN'CZy'Sy
OH 36
ÇO2 OH^OH 
O
AcO OAc
AcHN
C02M e OAg q Ac
OAc
Ph
AcO. OAc
AcHN
OAc 31
+ HS OTDS
OBz37
OAg q a c
AcO
AcO, NH
C C I3
Scheme 2.9 Schm idt’s retrosynthesis o f  fully S-linked GM3 analogue 36.
36
OH CO2" OhLOH OHHQ
AcHN
OH OH OH
Me' OH14
OBz
OAcAcO. HSsQAc
OBzAcHN MeAcO BzO, OAc
AcO
Ph
OAcAcO. sOAc
AcHN HS OTDSOAc OBz37
CI3C Ph
NH
Me OMPM HS OTDSAcO OBz37
Scheme 2.10 Schm idt’s retrosynthesis o f  fully S-linked sLe^ analogue 14.
They reported that Hasegwa’s anomeric ^'-alkylation strategy, using donor 21 and 
acceptor 38, gave the key sialylgalactoside 39, in only 30% yield, whereas the same 
disaccharide could be made in up to 85% yield by base promoted thioglycosylation 
of intermediate 37 using kryptofix 21 as co-activator (Scheme 2 .1 1 ).^  ^ Attempted 
anomeric -S-alkylation under von Itzstein’s conditions gave the elimination product
40.
37
Ph
AcQ OAc CO2M6
(a) AcHN + OTDS
OBzOTf 38
DMF
3 0 % 2 5 %
OAcAcO OAcOA c AcO.
AcHN AcHNOTDSOAc OBz39
NaH, THF, Kryptofix 21 
\  8 5 %
Ph
OAcAcQ(b) OA c
AcHN HS OTDS
OAc OBz
31 37
Ph
AcQ OAc
(c) AcHN
CO2M©
SAc + OTDS
OBzOTf
38
Ph
OTDS
OBz
40
Scheme 2.11 Synthesis o f  Schm idt’s key sialylgalactoside 39 by (a) H asegawa's strateg)>, (b) 
Schm idt’s startegy and (c) attempted synthesis o f  39 by von Itzstein’s method.
2.5.2 B io lo g ic a l A c tiv it ie s . Several sialic acid a(2->6) thio-disaccharides have been 
tested as neuraminidase inhibitors. Suzuki and co-workers have reported that 
ganglioside analogues 41, 42 and 43 (Figure 2.6) are all competitive inliibitors for 
influenza virus neuraminidases.23 Galactosyl ceramide based compound 42 was the 
weakest of these inhibitors (Ki =100  pM). Inhibition increased on extending the 
length of the oligosaccharide chain (43, Ki = 15 pM), but was greatest for the 
glucosyl ceramide based compound 41 (Kj = 2.8 pM). This is surprising, as the
36
natural substrates for the influenza neuraminidases are thought to be glycans 
containing Neu5Aca(2—>3)Gal and Neu5Aca(2~>6)Gal epitopes.^o Compound 41 
was a much poorer inhibitor for neuraminidases from the bacteria Clostridium 
perfringens and Arthrobacter ureafaciens (C. perfringens Ki — 49 pM; A. 
ureafaciens K[ = 400 pM).
AcHN O
HN'^(CH2)i5CH3
(CH2)l2CH;
41
AcHN
OH
OA,H O /|A  o  HN" -(CH2)16CH3
(CH2)i2CH3
OH :
42 ÔH
AcHN O
H N '^(C H 2)i6CH3
(CH2)i2CH
6 h
OH C0 2 "HO OH
AcHN HOOH 4 4
HO OHOH
Figure 2.6 Some sialic acid thio-glycoside neuraminidase inhibitors.
Sabesan and co-workers found the sialic acid a(2->6)-6-thio-Gal reducing sugar 44 
to be a weak inhibitor of influenza virus neuraminidase, even at 8 mM .20 The 
conformationally constained 6-C-methylgalactose analogue 345 was also a poor 
inhibitor, but the corresponding i?-isomer 34if inhibited both influenza virus and C. 
perfringens neuraminidases with a Ki of 300 pM. They proposed that the difference 
observed for the R- and 5-isomers results from the different conformations which 
these two compounds adopt in aqueous solution. Although the presence or absence of
39
a ceramide moiety may make a difference to the recognition of such thioglycosides 
by the neuraminidases, these two studies can not be directly compared as different 
substrates were used for the inhibition studies (ganglioside GM3 by Suzuki, 
Neu5Aca(2->6)Gaip(l->4)GlcNAc by Sabesan).
9-0-acetyl derivatives of a number of Siaa(2->6)-6-thio-hexoses (Figure 2.7; 45, 46, 
47) described by von Itzstein and co-workers were found to inhibit bovine rotavirus 
infection in a primate cell line. ^  ^  Both the 6 -thioglucose 45 and 6 -thiogalactose 47 
derivatives had IC50 values ~lmM.
OH OHAcO.AcO,
AcHN AcHN
OH OH
HQ HQHQ HQ
OH OMe AcHN OMe
45 4 6
AcO.
A cH N ^^-r^  'S
OH OMe
47
Figure 2.7 Some sialic acid thio-glycoside rotavirus inhibitors.
No neuraminidase inhibition data has been reported for Neu5Aca(2-^3)-3-thio-Gal 
compounds, nor for the binding of Schmidt’s sLex derivative 14 to Selectins. 
However, Hasegawa’s -S'-linked GM4 analogue 26 (Scheme 2.6) exhibits potent 
immunosuppresive activity; tetanus toxoid induced lymphocyte proliferation was 
95% inliibited by 5pM 26 (detennined by [^H]thymidine u p t a k e ) .
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2.6 Concluding Statement
Thioglycosides have proven to be useful, glycosidase-resistant analogues of 
oligosaccharides and, over recent years, much effort has been invested in the 
synthesis of such compounds. The subtle change of replacing oxo-linkages with 
sulhu, increases the flexibility of the glycosidic linkage and, in some cases this may 
alter the conformation of the saccharide to the detriment of its biological activity. 
However, there are many examples of thioglycosides that have been used 
successfully as oligosaccharide mimics and interest in this subject is certain to grow 
in the future.
41
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Chapter 3
Design of Substrates for de-iV-Acetylase and 
A-Acetyltransferase Assays
3.1 Assay Design
Substi'ate specificity and sensitivity of detection must both be considered when 
designing an enzyme assay. The substrate to be used in the assay must be sufficiently 
similar to the enzyme’s natural substrate so that it will show a reasonable rate of turn­
over with the enzyme. Also, there must be some means of detecting and 
distinguishing between the substrate and products of the enzyme reaction. The 
detection method must be as sensitive as possible and preferably, it should not 
involve a lengthy work-up following the enzyme incubation.
Often, either a radio-label or a flourescent tag are introduced into the assay substrate, 
as the means of detection. Radio-labeling, although intrinsically more hazardous than 
using fluorescent tags, has the advantage of not altering the substrate structure, as it 
involves replacing only individual atoms with unstable isotopes. The synthesis of 
radio-labeled gangliosides has been reviewed recently.^ The principal methods that 
have been used are: enzymatic oxidation (galactose oxidase) of the oligosaccharide 
portion or oxidation of the sphingosine alcohol with DDQ, each followed by 
reduction with NaB^H4 ; reduction of the ceramide double bond using NaB^H4 and 
palladium (II) chloride; selective de-A-acetylation of sialic acid or de-A-acylation of 
ceramide followed by re-A-acetylation/acylation using [^H]acetic anhydride or 
stearic acid (Scheme 3.1).
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Scheme 3.1 Methods o f  introducing radio-labels into gangliosides. Reagents: i, galactose oxidase, 
catalase; ii, NaB^H^; iii, Me^NOH, aq. n-BuOH; iv, C6F5 0 2 ^^CCnH23, DMF; v, NaB^H^, PdC^; vi, 
DDQ, toluene; vii, [^H]Ac2 0 , MeOH.
3.1.1 De-TV-Acetylase Assay. As we were interested in studying the release of the 
sialic acid TV-acetyl group, it seemed that introduction of a [^H]acetyl group onto the 
sialic acid amino function, would be the method of choice. However, preparation of 
deNAc gangliosides required for radio-labeling (Scheme 3.1) is complicated by 
hydrolysis of the ceramide TV-acyl chain to give the “lyso-ganglioside” derivative. ^  
Therefore, we decided that it would be advantageous to synthesise ganglioside 
analogues in which the ceramide portion was replaced by a simple octyl tail. Such 
compounds have greater water solubility than GSLs and have been used extensively, 
in conjunction with reverse phase columns, for glycosyl tiansferase assays.^. 3 it is
4d
quite possible that deNAcGMS and deNAcGDS are synthesised by the same enzyme 
(see section 1.6.4). As the Neu5Aca(2->8)Neu5Ac linkage is notoriously difficult to 
synthesise/ it was preferable to make only GM3 analogues. Thus, we chose to make 
radio-labeled GM3 analogue 48 for the de-TV-acetylase assay (Scheme 3.2).
COT OH OH
/H]AcHNC/^y^
OH 48 OH
/H ]A cO'
de-A/-acetylase
OH CO? OH^OH
OH 4 9  OH OH
Scheme 3.2 Proposed substrate 48 for the de-N-acetylase assay.
Following incubation of the substrate with the de-TV-acetylase enzyme, it would be 
necessary to separate free acetate from the ganglioside analogue. This could easily be 
achieved using a C-18 reverse phase column. Thus, the hydrophobic glycolipid 48 
would stick to the C-18 column whereas the acetate could be washed off with water 
(Figure 3.1).^ Unaltered 48 could then be recovered by washing the column with 
aqueous methanoP and the fraction of “hot” acetate which has been released, could 
be determined by liquid scintillation counting of each of the elutions.
Assay mixture water Aq. MeOH
C-18 cartridg
[2-^H]acetlc
acid
Figure 3.1 Separation o f  the de-N-acetylase assay mixture by C-18 reverse phase chromatography.
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3.1.2 TV-Acetyltransferase Assay. DeNAcGMB analogue 49 was chosen as the 
substrate for the A-acetyltransferase assay (Scheme 3.3).
OH CO2 OH.OH
OH 49
/H ]A c C oA
CoA'
O HO'
OH OH
A/-acetyltransferase
L\ ^ 0/H]AcHN~~-Z7^
OH 48 OH
Scheme 3.3 Proposed substi'ate 49 fo r  the N-acetyltransferase assay.
This assay would involve incubation of 49 with the enzyme and [^H]-acetyl CoA 
(acetyl CoA is the putatative acetyl donor for the Y-acetyltransferase). The product of 
this reaction would be identical to the synthetic substrate 48 for the de-A-acetylase 
assay. Reverse phase chromatography could be used, as described before, to separate 
excess -acetyl CoA from any 48 synthesised by the enzyme (Figure 3.2).
Assay mixture water Aq. MeOHI
C-18 cartridg
f  H-acetyl] CoA
Figure 3.2 Separation o f  the N-acetyltransferase assay mixture by C-18 reverse phase
chromatography.
3.1.3 Thioglycoside Analogues. It is possible that these assays could be complicated 
by enzymatic cleavage of sialic acid from 48, i.e. the substrate for the de-A-acetylase 
assay and the product from the TV-acetyltransferase assay. Radio-labeled sialic acid, 
thus produced, could not be distinguished easily from either [^H]acetate or pH]-
acetyl CoA by means of a reverse phase assay. Similarly, any potential enzyme 
inhibitors based on these compounds could also be subject to cleavage by 
neuraminidases. This problem could be avoided by using the analogous thio- 
glycoside compounds 50 and 51 which should be resistant to enzymatic hydrolysis
(Figure 3.3) A 7
CO2 OH OH
H]AcHN
ÇO2 OH OH
o - A ^ s
OH 51 OH OH
Figure 3.3 Thioglycoside analogues o f  GM3 and deNAcGMS.
As was described in section 2.5.2, ^'-linked ganglioside analogues can have 
interesting biological activities. Simple thio-glycoside ganglioside analogues such as 
compound 51 could be useful scaffolds on which to design neuraminidase inhibitors, 
and even immunosuppressants, in addition to their intended functions as de-A- 
acetylase substrates and inhibitors. In the next chapter, studies towards the synthesis 
of the non-radio-labeled GM3 analogues 52 and 53 (Figure 3.4) are described in 
detail and also a number of thio-sialosides are evaluated as neuraminidase inhibitors.
HO. CO2 OH^OH
AcHN
CO2 OH OH
AcHN
OH 53 OH OH
Figure 3.4 Non-radio-labeled target GM3 analogues.
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Chapter 4 
Results and Discussion
4.1 Studies Towards the Synthesis of Thio-GM3 Analogue 53
At the time of starting this project, the only published procedure for synthesis of the 
Neu5Aca(2-^3)Gal thio-glycosidic linkage was Hasegawa’s iS-linked GM4 synthesis 
(Scheme 2 .6 ) .h 2
4.1.1 Approach 1: the Disaccharide Acceptor
HQ OH COo QH^QH
AcHN
Thio-glycosylationy y
OH
Anomeric S-alkylation
AcO GAc pAc
AcHN'ZZy^y^ COgMe 
OAc
AcO OAc
AcHN
GO2M6
SAc
31 OAc 35
A cs
Q BpoBn
OBn
OBnO^
64
OBn
OOct
OBn
O^OBn 
OTf 63
OBn
0 OOct
OBn
O^OBn .OBn
OOct
61 OBn OBn
OI^OH
o -^o
58 OH
OH 
Q OOct
OH
HO
QH^OH 
■0
OH
O HO
OH
0 OOct
57 ' OH
Scheme 4.1 Retrosynthetic analysis o f GM3 thioglycoside analogue.
4.1.1.1 Retrosynthesis. The original plan for preparation of the GM3 thioglycoside 
analogue was to make octyl lactoside and then to selectively protect and then re­
expose the galactose 3-OH, leaving it free for introduction of sulfur via a double
52
inversion (Scheme 4.1). Allyl ether formation via tin acetal chemistry^ was chosen 
for the selective, temporaiy 3b protection (monosaccharide residues are labeled a, b, 
c from the reducing terminus for di- and trisaccharides), to be followed by 
benzylation of the other positions. It was anticipated that inversion of the galactose 3- 
OH would be achieved using sodium acetate in the nucleophilic displacement of the 
triflate group in lactoside 61. Benzyl protection would be compatible with the 
subsequent deprotection and reactivation of the gulose derivative, thus obtained, to 
give triflate 63. Sulfur could then be introduced using either potassium thioacetate 
(giving 64 for subsequent base promoted thio-glycosylation) or the known sialic acid 
derivative 35^ (by anomeric 5-alkylation). Although catalytic hydrogenolysis of the 
benzyl ethers may not have proven compatible with a sulfur linkage in the molecule,^ 
there are many alternative cleavage procedures in the literature;^ e.g. reduction by 
sodium in liquid ammonia has been used to deprotect sulfur-containing 
cai'bohydrates.^
4.1.1.2 Synthesis. Lactose 54, being inexpensive and readily available, was chosen 
as the starting material (Scheme 4.2). This was converted in a one pot reaction to the 
heptaacetyllactosyl bromide 55 in 95% yield with acetic anhydride and 30% 
HBr/AcOH.
H O /O H i. 95%
AcO
HO OH
54
61
BnO
R'
.OBn
X, 64%
O
OBn
Q
A c O /O A c
ii, 56%
OOct
OR O R '
R‘2 OBn
BnO^ ■OOct 56 R^=Ac, R^=Ac
OBn
XI
62 R^=H, r 2=0H
63 R^=H, R^=OTf 
C .64  R^=SAc, R^=H
52%
'" '^ ^ '^ ^ 5 7  R'"=H, R^=H
^ 5 8  R^=H, R^=CH2CH=CH2
,9 2 % ^
/ " iv ,  V
V  Vi C 59 R^=Bn, R^=CH2CH=CH2
vii, viii, 53% Q  gg R'‘=Bn, R^=H 
ix, 86% Q  61 R^=Bn, R^=Tf
Scheme 4.2 Synthesis o f  lactose acceptor. Reagents: i, HBr/AcOH, AC2O; ii, AgClO^., Ag2C0 3 , 
OctOH, CH2CI2; iii, NaOMe, MeOH; iv, Bu2SnO, MeOH; v, H2C=CHCH2Br, TBAI, toluene; vi, 
BnBr, NaH, DMF; vii, [COD(MePli2P)Ir]PF6, H2 , THF; viii, TFA(aq), CH2CI2; ix, Tf^O, pyridine, 
CH2CI2; X, TBANO2, toluene; xi, Tf^O, pyridine, CH2CI2; xii, KSAc, DMF.
Glycosylation of octanol with compound 55 gave variable results. Removal of 
bromide by the promoter (silver perchlorate/silver carbonate) gives an initial 
carbocation which is stabilised by the participation of the acetyl group at position 2
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to give cyclic carbocation 65 on theaface of the molecule (Scheme 4.3). Subsequent 
attack by octanol should regenerate the 2 -0 -acetyl group and form the(3-glycoside 
56.
.O A c A c O A Z ^ ^ ^ v ^ O A ^ 3 C :^ ^ ^ ^ O O c t
OAc OAc
“  —  r “ c S K ^ <
y% AcOAZ^^-A_-OX^O^Z^ 06
OAC
^.J^OOct
Scheme 4.3 Mechanism for the formation of P-glycoside 56 and orthoester 66.
However, it was found that a 10% excess of AgC1 0 4 .H2 0  and 2.5 equivalents of 
octanol, dried overnight with 4Â molecular sieves prior to addition of 55 gave a 56% 
yield of the desired product, 56, but also a considerable quantity of the orthoester 6 6  
[6 h (CDCI3) 4.62 (1 H, d, Jib,2b 8.0, Ib-H), 5.64 (1 H, d, Jia.2a 5.2, la-H)], formed by 
trapping 65 with octanol. Although formation of the orthoester creates a new 
stereogenic centre, only one diastereomer was observed and was tentatively assigned 
as the exo-isomer. The orthoester and glycoside were not easily separated by flash 
chromatography and so the mixture was treated with 50% aqueous TFA to hydi'olyse 
the orthoester to the hemiacetal prior to chromatography.
It was noted that the AgC1 0 4  suffered some degradation during overnight drying to 
give a brown solution. This reaction was partially attributed to light sensitivity, but 
also seemed to be enhanced by the presence of octanol. Repeating the reaction 
without adding octanol until directly before the bromide, gave no orthoester but a
different byproduct identified as octyl 2,3,4,6-tetra-O-acetyl-P-D-galactopyranosyl-
(l~M)-3,6-di-0-acetyl-a-D-glucopyranoside, 67 was formed in 27.5% yield along 
with 43.5% of the desired product, 56. Compound 67 presumably forms by loss of 
octyl acetate from the orthoester and attack by octanol to give the thermodynamically 
favoureda-lactoside, there being no participating groups present on C-2  (Scheme 
4.4). Increasing the concentration of AgC1 0 4  to 1.5 equivalents was similarly 
affected by the timing of the addition of octanol; drying AgC1 0 4  overnight with 
octanol present gave 34% yield of (3-glycoside 56 plus some orthoester 6 6 , whereas 
drying in the absence of octanol gave a 24% yield of (3-glycoside 56 and 25% yield 
of a-glycoside 67.
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V O  AcO
OAc<0
66
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AcO /O A c
HO-Oct
67
OOct
+ AcO-Oct
Scheme 4.4 Mechanism fo r  the formation o f  a-glycoside 67
Following deacetylatioii of compound 56 in near quantitative yield, selective allyl 
protection of the 3b position of compound 57 was achieved via the staimylene acetal, 
6 8 . In non-polar solvents stannylene acetal 6 8  dimerises (Figure 4.1) with 
concomitant stereoelectronic enhancement of the nucleophilicity of the divalent 3b 
oxygen over the trivalent 4b oxygen.^ The stannylene acetal is formed exclusively 
across the 3b and 4b oxygens on refluxing lactoside 57 with dibutyltin oxide in 
methanol. Iodide promoted reaction of the stannylene acetal with allyl bromide in 
toluene gave, on work-up, a 2:1 mixture of allyl ether 58 and recovered lactoside 57. 
A similar incomplete reaction of methyl lactoside has been reported. ^%
V s .
, 0 / O H
Bu2Sn^4blA^O
OH
OOct
Figure 4.1 Regioselective stannylene acetal formation and dimérisation.
Allyl ether 58 was fully characterised as the hexaacetate {octyl 2,4,6-tri-0-acetyl-3- 
0~allyl-J3-D-galactopyranosyl-(l ->4)-2,3, ô-tri-O-acetyl-jd-D-glucopyranosidé). 
However, for ease of purification, the crude allyl ether was benzylated with 
NaH/BnBr in DMF before chromatography, giving the fully protected compound 59 
in 52% yield from lactoside 57.
In order to remove the allyl group it was first isomerised to the ^ra^j-propenyl ether 
69 using cyclooctadienebis(methyldiphenylphosphine)iridium (I) 
hexafluorophosphate {[COD(MePh2?)Ir]PFg} in THF (Scheme 4.5).^ It has been 
reported that this catalyst is less prone to reduce allyl groups to hydrolytically stable 
propyl ethers than rhodium based catalysts. The reported procedure of 0.1 mol% of 
the catalyst gave no reaction, but by increasing the amount of catalyst to 0.65 mol%,
55
the isomérisation occured overnight at room temperature. Subsequent hydrolysis in 
CH2CI2 with aqueous TFA gave 60 (Scheme 4.5) in a disappointing 53% yield for a 
reaction which had appeared to have proceeded cleanly by TLC.
OOct
OBn OBn
59
[COD(MePh2P)lr]PF6, 
Hz, THF
BnO ^OBn OBn
O
BnO /O B n  
0TFA(aq)^BnoC -lr^O O ct ^  HOA^ -^i^^A^OgiiO
OBn OBn OBn69 60
Scheme 4.5 Two step removal o f  the allyl ether protecting group.
OBn
Q OOct
OBn
Introduction of sulfur in the equatorial configuration, requires position 3b to be 
converted first to the axial, gwZo-configuiation. It was decided to proceed via acetate 
inversion of triflate 61 with subsequent deacetylation to give mono-alcohol 62.
Although the triflate could be made in good yield and proved sufficiently stable for
characterisation, reaction with tetrabutylammonium acetate in DMF, gave the desired 
axial acetate 70 in only 39% yield as a competing elimination reaction gave
compound 71 in 52% yield (Scheme 4.6).
BnO /O B n  
TfO ° OBnO
OBn
Q
inversion 
39%
BnO /O B n
OBnO
OBn
O OOct
OOct OAc
OBn OBn
70
OBn OBn61 elimination 52% BnO
OOct
Scheme 4.6 Competing inversion and elimination reactions o f  triflate 61.
Elimination presumably occurs by an E2-type mechanism with acetate acting as base. 
The required trans-diaxial arrangement of proton and leaving group (triflate) can 
only be achieved following a ring-flip into the conformation (Scheme 4.7).
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BnO^OBn
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Schem e 4.7 Mechanism o f  triflate elimination from  compound 61.
Reaction of compound 61 with tetrabutylammonium nitrite (TBANO2) was more 
successful. 5 The initial product is the nitrite ester 72 hydrolyses on aqueous work-up 
to give mono-alcohol 62 directly in 64% yield (Scheme 4.8).
B n O /O B n
TfO OBnO
OBn
Q
TBANO2 ,
toluene
OOct
OBn OBn61
B n O /O B n
OBnO
OBn
Q OOct
OBn OBn
72
B n O /O B n
A queous work-up
OBnO
OBn
Q OOct
OH OBn OBn62
Scheme 4.8 Nitrite inversion o f  triflate 61.
Compound 62 was easily converted to triflate 63 which again proved surprisingly 
stable. Problems were however encountered on reaction with potassium thioacetate 
to give 64. The two products which formed were found to be inseparable by 
chromatography. An attempted de-&acetylation of the mixture with NaOMe gave a 
sticky precipitate with the characteristic smell of thioacetate implying that 
elimination had occurred. The products of this reaction also proved inseparable.
In consideration of the problems encountered and also the (potentially low yielding) 
removal of benzyl groups in the presence of the thioglycosidic linkage, a new 
approach was considered, based on Schmidt's recently published synthesis of a fully 
thio-linlced analogue of sialyl Lewis x (Scheme 2.10).^
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4 .1 .2  A p p r o a c h  2: th e  G a la c to p y r a n o sy l/G u lo p y r a n o sy l A c c e p to r
4 .1 .2 .1  R e tr o sy n th e s is . The second approach to the synthesis of 53  was to construct 
the trisaccharide in a stepwise manner from the non-reducing end; i.e. to construct 
the Siaa(2->3)Gal disaccharide first, and then to activate this as a glycosyl donor for 
further extension to the trisaccharide (Scheme 4.9),
PH^OH
AcHN
Ph
OAc OBzAcO,
O w ^SiM ea +AcHN OOct
AcO OBz OBz73 74
Ph
OAcAcO,
C02M e +  KSAc +AcHN
OAc OBzOTf
Ph
HO
OBz
84
Scheme 4.9 Retrosynthetic analysis o f  GM3 thioglycoside analogue after Schmidt.
Target disaccharide 73 can be disconnected to the known glycosyl chloride 31 and 
triflate 87  with thioacetate being introduced into one or other of these electrophiles 
prior to base promoted coupling. Gulose derivative 87  could be prepared by the 
triflate/TBAN0 2  method^ fi'om known compound 84.^  ^At the time of starting this 
synthetic scheme, Schmidt’s sLex synthesis^. 12 had only been published as a 
preliminary communication, but on paper it appeared to be a considerably more 
efficient synthesis than that of Hasegawa and co-workers.^ It was decided, therefore, 
to use the same protecting groups as Schmidt in both the donor and acceptor (see 
Scheme 2.10), except for the anomeric blocking group in the galactose derivative. 
Here, (2-trimethylsilyl)ethanol was chosen as the aglycon rather than Sclimidt’s 
thexyldimethylsilyl protecting group. This change would allow the option of
deprotecting at the disaccharide stage to give an analogue of the smaller ganglioside 
GM4 which may also be suitable for the deacetylase assay. Alternatively, the 
trimethylsilylethyl group can be easily removed^^ and 73 converted into a suitable 
donor for glycosylation of an octyl glucoside acceptor (e.g. 74), thus giving 
trisaccharide 53 on deprotection. This new approach would have the advantage of 
allowing the synthesis of a wider range of compounds for study, especially in varying 
the aglycon used.
4.1.2.2 Synthesis of Acceptors. 3-Thio-galactose derivative 8 8  was prepared as 
outlined in Scheme 4.10. Acetobromogalactose, 76, was obtained from galactose, 75, 
in two steps by iodine catalysed acétylation^^ followed by bromination with 45% 
HBr/AcOH. Two procedures for glycosylation of 2-(trimethylsilyl)ethanol with 
donor 76 were used. The traditional Koenigs-Knorr method, using silver carbonate as 
promoter, gave galactoside 77 in 74% yield and a new procedure being developed in 
our research gi'oup, using 2,3-dichloro-5,6-dicyano-l,4-benzoquinone (DDQ) and 
iodine as activators gave the same product 77 in 71% yield.
A cO/°^^ 
l A ^ O  i. ii, 93% iii or ivHO'-Pi-—•'V'A. AcO'-~\---'-'^ ^A| 740^ RO'-A—
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O K O H
01OMe
OR 
.. .  79 R=H 
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81 R^=H, R^=H 
^ L 8 2  R^=TBDMS, R^=Bz
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1 ^ 0HO'-A—v A / O SE
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% f  ^ " > 8 5  R^=OTf, r 2=H 
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Scheme 4.10 Synthesis o f  galactopyranose acceptor. Reagents: i, AC2O, I2 ; ii, HBr/AcOH, CH2CI2; 
iii, Me3SiCH2CH2ÜH, DDQ, I2, MeCN; iv, Me3SiCH2CH2 0 H, A g2C0 3 , toluene; v, NaOMe, 
MeOH; vi, Pr'(OMe)2, 7>-toluenesulfonic acid; vii, BzCl, pyridine; viii, TFA(aq), CH2CI2 ; ix, 
TBDMSCl, pyridine; x, BzCl, pyridine; xi, 80% AcOH(aq); xii, PhCH(0 M e)2 , camphorsulfonic acid, 
MeCN; xiii, Tf^O, pyridine, CH2CI2 .
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Following deacetylation to give 78, the 2-O-benzoyl compound 83 was prepared 
according to Lowaiy et However, this route gave the target triol in much poorer 
yield than reported. This problem was largely due to hydrolysis of the unstable 6-0- 
(2-methoxyisopropyl) group in bis-acetonide 79 prior to, or during the benzoylation
step, to give 2-(trimethylsilyl)ethyl 2,6~di-0-benzoyl-3,4-0-isopropylidene-p-D- 
galactopyranoside (^H NMR identical to lit.^^).
An alternative approach was devised and is also outlined in Scheme 4.10. Tetraol 78 
was converted to the 3,4-O-isopropylidene ketal, 81, before treating, first with t- 
butyldimethylsilyl chloride (TBDMSCl) and then benzoyl chloride in a one pot 
reaction in pyridine. The crude mixture was deprotected with 80% aqueous acetic 
acid before column chromatography to give the 2-0-benzoyl compound 83 in 62% 
fi'om GalOSE 78. 4,6-Benzylidene derivative 84 was then prepared according to the 
literature procedure but was found to crystallise on work-up to give the product in 
94% yield without need for chiomatography.
Compound 84 was readily activated as the triflate, 85, and inversion with 
tetrabutylammonium nitrite as described above gave the gw/o-configured sugar 8 6  in 
65% yield. The configuration was confirmed by treating a small sample of 8 6  with 
acetic anhydride/pyridine to give the 3-O-acetate; ^H NMR, CDCI3 ; J \^2 8.5 Hz, J 2,3 
3.6 Hz, u/3^4 3.6 Hz. Alcohol 8 6  was activated as the triflate 87 for inversion back to 
the gaZac^o-configuration. For thio-glycosylation reactions, sulfur was introduced 
using potassium thioacetate in DMF to give the 3-6"-acetyl galacto-configmed 
compound 8 8  in 82% yield (^H NMR, CDCI3; J\p_ 7.7 Hz, ^2,3 115 Hz, J 3 4 3.3 Hz). 
Having synthesised the required acceptor compounds, synthesis of the donors was 
then pursued.
4.1.2.3 Synthesis of Donors. 2-Chloro-sialic acid 31 was made in good yield from 
A-acetylneuraminic acid, 1, by a modification of the original literature procedure 
(Scheme 4.11).^ ® Briefly, A-acetylneuraminic acid was converted to its methyl ester 
using an acid ion exchange resin in dry methanol and then acetylated in acetic 
anhydride/pyridine. The peracetate, 89, was then converted to the thermodynamically 
more stable p-chloride with HCl in acetyl chloride. The chloride 31 was used without 
further purification in subsequent reactions, following ffeeze-drying from dioxan. 
For anomeric ^'-alkylation reactions, sulfur was introduced in an Sn2 reaction using 
potassium thioacetate in CH2CI2 to give 35 in 76% yield.4 Attempting the reaction in 
DMF, in which the thioacetate was more soluble, led to poor anomeric control, 
suggesting an S^l type reaction in the more polar solvent.
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SAcAcHN AcHN
OAc OAc
35 31
Scheme 4.11 Synthesis o f  sialic acid donors 31 and 35. Reagents-, i, D owex 50W X8-200 (H^), 
MeOH; ii, pyridine, AC2O; iii, AcCl, HCl; iv, KSAc, CH2CI2 .
Selective de~5'-acetylation of 3-thio-galactoside 8 8  was achieved using one 
equivalent of sodium methoxide in MeOH at -40 °C. The starting material and 
product showed identical mobility on TLC (hexane-EtOAc, 1:1; RyQ.dO), but it was 
possible to follow the reaction by NMR spectroscopy. By quenching the reaction 
with an acidic ion exchange resin after 30 minutes, one hour and two hours, signals 
for thioacetate 8 8  were seen to diminish and to be replaced by a new set of signals for 
the thiol compound 90 (see experimental section for spectral data). Reaction was 
complete after 2.5 hours. Prolonged reaction, especially in the presence of air, led to 
a third set of signals appearing, and a new spot on the TLC (hexane-EtOAc, 1:1; Ry 
0.52). This product was assigned as the disulfide, 91. The same product was obtained 
in high yield by treating thiol 8 8  with diethylamine in DMF under aerobic conditions 
(Scheme 4.12). FAB-MS gave a signal at m/z 991 corresponding to M+Na for the 
disulfide.
PhPh Ph
OSE HS OSE OSE,AcS
OBz OBz OBz
O S E =  O ' .SiMec
Scheme 4.12 Selective deprotection and oxidation o f  3-thiogalactose compound 88. Reagents-, i, 
NaOMe, MeOH, -40°C; ii, Et2NH, DMF.
4.1.2.4 Attempted reaction of glycosyl chloride 31 and 3-thio-galactoside 92 - 
base-promoted thioglycosylation [Scheme 4.13 (a)]. Whereas Schmidt and co­
workers had achieved de-5"-acetylation of their 3-thio-galactose derivative using
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hydi'azinium acetate in DMF to give the thiol, which they then treated with sodium 
hydride to give the sodium thiolate, it appeared more convenient to use the thiolate 
92 obtained directly from the Zemplén reaction in subsequent reactions. However, on 
attempting to perform the glycosylation reaction with glycosyl chloride 31 under the 
conditions described by Schmidt (THF, kryptofix 21, room temperature),^ no 
reaction was observed. After 48 hours, only a small amount of the disulfide was 
starting to appear, despite careful attempts to ensure the total absence of oxygen in 
the flask. It was noted that thiol 90 and thiolate 92 were not very soluble in THF, 
even in the presence of the aza-crown ether kryptofix 21. Repeating the reaction in 
the presence of the more common complexing reagent, 15-crown-5, still gave no 
product. Attempted reaction in DMF was similarly unsuccessful, despite the fact that 
the reactants were fully in solution.
Ph
OAcAcO,
(a) AcHN Na 8 OSEOAc OBz
92Ph
OAcAcO,
(b) 8  NaAcHN 0 8 EOAc
OTf 87
or DMF to disulfide
DMF degradation 
of thiolate
AcO. OAc C0 2 Me
(c)
Ph
V o
,sOAc I - O
AcHN-CZy^^V 8A c +
' ' ' ' '  I OBZ
Ph
0 8 E
35 OTf 87
0 8 E67%
OBz 93
AcO,
(d) AcHN
COaMe BnO /O B n EtzNH, DMF
OOct
BnO /O B n
OOct
OBn OBn94
Scheme 4.13 Attempted coupling reactions.
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4.1.2.5 Attempted reaction of 2-thio-siaiic acid 35 and 3-triflyl-guloside 87 - 
anomeric *S'-alkylation (Scheme 4.13). Sialic acid thioacetate 35 was selectively de- 
^'-acetylated as described by H a s e g a w a /  in a manner analogous to that used for 
galactoside 88. Attempted reaction of the sodium thiolate with triflate 87 in DMF 
was unsuccessful [Scheme 4.13 (b)]; after 5 days at room temperature, the thiolate 
had partially degraded, and no thio-disaccharide had formed, von Itzstein’s procedure 
for in situ de-^S-acetylation and base-promoted coupling (diethylamine/DMF) ^ ^  was 
also unsuccessful [Scheme 4.13 (c)], giving only the guloside elimination product, 2-
(trimethylsilyl)ethyl 2-0-benzoyl-4,6-0-benzylidene-3-deoxy~p~D-i\iXQO-hex-2-
enopyranoside, 93, in 67% yield. A similar result was subsequently reported by 
Schmidt and c o -w o r k e r s [see section 2.5.1 and Scheme 2.11 (c)] but these 
eliminations should be compared with von Itzstein’s successful synthesis of the 
Neu5Aca(2->4)-4-thio-Glc linkage from a 4-O-triflyl galactose derivative which 
proceeded in 74% yield.
A similar result was obtained on treating disaccharide triflate 63 and thioacetate 35 
with diethylamine in DMF [Scheme 4.13 (d)]. Here, the elimination compound octyl
2,4,6-tri-0-benzyl-3~deoxy-p-D-\hïQO-hex-2-enopyranosyl-(I —>4)~2,3,6-tri-O-benzyl-
(3-D-glucopyranoside 94 was obtained in 62% yield based on the amount of triflate 
reacted (15% of compound 63 was recovered unchanged).
Thus, all attempts at forming the sialic acid-galactose thioglycoside, by literature 
p rocedu res^ . 5 proved fruitless in my hands.
4.1.3 The Gulopyranosyl Problem?
All synthetic approaches to the Neu5Aca(2->3)Gal thio-glycosidic linlcage reported 
so far, have relied on the introduction of sulfur into a suitably activated gulopyranose 
derivative. As ^H NMR coupling constants indicate (87, CDCI3 ; J\y^ 8.5 Hz, ^2,3 3.0 
Hz, J 3 4 3.0 Hz), the gulopyianosyl unit principally adopts the ^Ci conformation. As 
such, it is perfectly set up for elimination of triflate with the trans-àidixidX 
arrangement of H-2 and the leaving group [Figure 4.2 (a)]. Overlap of the (C-4)-0 
bonding orbital with the (C-3)-0 antibonding orbital may further facilitate the loss of 
triflate by weakening the (C-3)-0Tf bond. This effect may explain the difference in 
reactivities observed for the 3-O-triflyl gulose derivative and von Itzstein’s 4-O- 
triflyl galactose derivative, The 2-chloro-sialic acid derivative 31 is similarly prone 
to an elimination reaction which may compete with nucleophilic displacement of 
chloride [Figure 4.2 (b)].^o
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Figure 4.2 Mechanism o f  base elimination fo r  87 and 31.
The sterically crowded ketose anomeric centre of sialic acid, whether as the chloride 
or thiolate, will be less reactive to Sn2  reactions than analogous derivatives of 
aldoses. The problems in the syntheses described so far may be attributed to the 
relative reactivities of the carbohydrate derivatives to substitution and competing 
reactions, i.e. elimination and/or oxidation of thiolate to disulfide.
Similar problems were experienced by Hindsgaul and co-workers in their synthesis 
of the thiogycoside analogue of l-deoxy~3-0-(a-D-glucopyranosyl)-mannojirimycin 
(Scheme 4.14).21
OAc
BnO
+  BnO
OTf
95 96
HO
95
1 DMF 
H C ):/: ! :! : /"  55%, ^ ,3  r
98
OMs
97
HO
OH
O .OH
H O V - ^  HO
99
Scheme 4.14 Synthesis o f  l-deoxy-3-0-(a-D-glucopyranosyl)-mannojirimycin 99.
Here also, the axial triflate leaving group is flanked by an axial and an equatorial 
sustituent. They concluded that the benzylated compound 96 {c.f. 63) was too 
sterically hindered to react with 2,3,4,6-tetra-O-acetyl-1 -tliio-a-D-glucopyranose. 
However, they found that the partially deprotected mesyl derivative 97 reacted quite 
efficiently with glucosyl thiolate 95 giving disaccharide 98 in 55% yield.
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In the same way, guloside 62 was converted to the mesylate, 100, under standard 
conditions and then subjected to catalytic hydrogenolysis (Pd on charcoal/IÎ2/acetic 
acid) to give the analogous gulosyl glucoside 101 in 73% over two steps (Scheme 
4.15). However, an attempt to reproduce the coupling reaction with the sialic acid- 
gulopyianosyl system proved fruitless. Also, reaction of the mesylate 101 with 
potassium thioacetate in DMF gave rise to many products, and so this line of 
investigation was not pursued further.
BnO /O B n  ^OBn
O OOct
OBn OBnOR
ii. 89%
OH
OOctHQ
101OH OHOMs
KSAc ► Many productsDMF
Scheme 4.15 Attempted synthesis o f  S3 after Hindsgaul. Reagents: i, MsCl, pyridine; ii, H2, Pd on C, 
AcOH; iii, 35, EtaNH, DMF.
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4.1,4 Approach 3: the Galactofuranosyl/Gulofuranosyl Acceptor
Gulose, as with all aldohexoses, can exist in a six-membered (pyranose) ring, an 
open chain form and a five-membered (furanose) ring (Scheme 4.16). The furanose 
form of gulose exhibits a number of structural properties that suggest that a 3 -0 - 
triflyl-D-gulofuranose derivative should be more suitable for Sn2 reactions than a 
corresponding gulopyranose derivative.
OH OH
OHHO
OH
HO HO°HHO
HO
Gulopyranose Acyclic Form Gulofuranose
Scheme 4.16 The structures o f  gulose.
For an a-gulopyranose, all ring sustituents are pointing to the lower face of the 
molecule, which should allow a relatively unhindered line of attack for an incoming 
sulfur nucleophile. In order to achieve the anti-periplanar arrangement of H-2 and 
triflate as described above, the furanose ring would have to adopt a less favoured 
conformation in which other ring sustituents would be eclipsed. Therefore, the 
furanose ring should be less prone to elimination. In addition, Sn2 reactions aie 
usually more facile in five-membered rings than six-membered rings as the former 
experiences a reduction of substituent eclipsing in proceeding to the transition state, 
whereas for the latter, the converse is tnxe.
von Itzstein and co-workers have described the synthesis of a number of ^-linlced 
disaccharides in which sialic acid is connected to a secondary carbon of the other 
monosaccharide residue. One of these involves the displacement of triflate from an 
allofuranose derivative. It is worth noting that although von Itzstein and co-workers 
report the synthesis of a number of ^'-linked analogues of sialic acid-containing 
disaccharides, they omitted the synthesis of Neu5Aca(2—>3)Gal, one of the most 
commonly occurring sialic acid linkages to be found in nature.
4.1.4.1 Retrosynthesis. Our third approach to the synthesis of compound 53 is thus 
based on formation of the sialic acid-galactofuranose thioglycosidic bond. Here, 
reaction of a sialic acid 2 -thiolate with an activated gulofuranose would give the 
Neu5Aca(2~>3)Gal/’ thio-glycoside, which would first be transfoimed back into the 
galactopyranose form before further elongation to the trisaccharide (Scheme 4.17).
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Scheme 4.17 Retrosynthetic analysis o f  GM3 thioglycoside analogue via gulofuranose 108.
4.1.4.2 Synthesis. 1,2:5,6 -Di-O-isopropylidene-a-D-gulofuranose, 107, was chosen 
as a suitable gulose derivative. The fused bicyclic ring system, wliich has C-1 and C- 
2  as its bridgeheads, should be even less prone to elimination because of the reduced 
flexibility of the furanose ring and the increased ring strain that would result on 
foimation of an sp2 centre at C-2. Although gulofuranose 107 is commercially 
available (retailing at £296 per g), it was preferable to prepare it from diacetone 
glucose (46p per g) by a modified four step literature procedure (Scheme 4.18).22 
Briefly, the 3-OH of diacetone glucose is oxidised to the ketone, the enol of which is 
trapped as its acetate. Subsequent stereoselective hydrogenation of the C-3:C-4 
double bond from the exo-face of the molecule, effects the required inversion of 
configuration at C-3 and C-4 required to give gulofuranose. Finally, deacetylation 
gave l,2:5,6-di-0-isopropylidene-a-D-gulofuranose in 54% overall yield.
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O'" \HO
G lucofuranose
ii, 61%  from 1 0 2
O OVi, 85% iii. 90%
AcO
105 ^ 109
G alactofuranose Gulofuranose
^ 106 R=OAc iv. 98% C l07 R=OH 
V, 98%  C 108 R=OTf
Scheme 4.18 Synthesis o f  gulofuranose and galactofuranose from  glucofuranose after Lemieux. 
Reagents: i, RUO2 , KIO4, K2CO3, CH2CI2, H2O; ii, AC2O, Et^N; iii H2, Pd on C, EtOAc; iv, NaOMe, 
MeOH; v, Tf]%0, pyridine, CH2CI2; vi, KSAc, DMF.
Several reagents were tried for the oxidation of diacetone glucose 102. No reaction 
was observed on treating the alcohol with tetrapropylammonium perruthenate and N- 
methylmorpholine-A^-oxide in either CH2CI2 or acetonitrile.^^ Treatment with 
pyiidine/chromium trioxide/acetic anhydride gave the desired product, but in low 
yield.24 The preferred oxidation procedure used potassium periodate/potassium 
carbonate/hydrated ruthenium (IV) oxide in a biphasic reaction.25 The colour of the 
reaction mixture indicates the major ruthenium species present and hence the 
progress of the reaction: the orange-brown colour present during most of the reaction 
results from the water soluble perruthenate ion, which may be further oxidised to the 
CH2CI2 soluble ruthenium tetroxide which has a pale yellow colour. The reaction 
mixture turning black, indicates that there is no periodate left; the reaction mixture 
turning pale yellow indicates that there is no substrate left. It has been reported that 
the lower solubility of potassium periodate over sodium periodate, can give greater 
control over the rate of reaction, and thus reduce over oxidation.25
The initial product of the oxidation reaction, l,2:5,6-di-0-isopropylidene-a-D-n6o- 
hexofuranos-3-ulose 103, readily hydrates and most publications report the use of the 
crystalline hydrate 104 in further reactions. However, in my hands, the initially 
product mixture of ketone and hydrate could not be completely converted into either
component and so it was found to be more convenient to use the partially crystalline, 
initial product mixture in the next step without purification.
Again a modified procedure for the énolisation/acétylation was to prove more 
convenient that the published procedure. Rather than acétylation in pyridine/acetic 
anliydride for 15 hours at 70 °C, the same reaction could be carried out in the more 
basic mixture of triethylamine/acetic anhydride in 5 hours at room temperature 
giving a similar yield of enol acetate 105 (-60% from diacetone glucose). 
Hydrogenation and deacetylation were performed using standard procedures to give 
gulofuranose 107.^^
The gulofuranose compound was easily activated as the triflate 108. Reaction with 
potassium thioacetate under phase transfer conditions gave the 3-«S'-acetyl 
galactofuranose compound 109 in good yield. On subjecting a mixture of 109 and 2- 
chloro-sialic acid 31 to von Itzstein’s coupling conditions of diethylamine/DMF,^^ 
only the disulfide 110 and the sialic acid 2,3-elimination product 33 were recovered 
(Scheme 4.19).
OAcO A cAcO
AcHN
AcO
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i, 83% (disulfide)
110
OAc
AcO
AcHN
G0 2 Me
Scheme 4.19 Attempted coupling o f  31 and 109. Reagents: i, Et2NH, DMF.
However, treatment of sialic acid thioacetate 35 and 1.3 equivalents of the triflate 
108 under the same conditions, gave the desired thio-disaccharide in 6 8 % yield, 
along with 14% umeacted triflate, and surprisingly, the galactofuranose disulfide 110 
in 4% yield (Scheme 4.20). The disaccharide was contaminated with a small amount 
of the sialic acid elimination product 33 which proved impossible to remove by flash 
chromatography. An analytical sample was obtained, however, by gel peimeation 
chromatography on lipophilic Sephadex LH20 in methanol. This technique allows 
separation of components based on molecular size, rather than polarity. As the 
impurity was easily removed by flash chromatography following partial deprotection
of the disaccharide (removal of either the acetates or acetonides), the product was 
used in subsequent steps without further purification.
OAcpAcAcO
SAc +AcHN /  ^OTf O
AcO
35 108
i, 6 8 %
OAc
AcO,
AcHN-
OAc O-T—S^O
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33 +  110
Scheme 4.20 Synthesis o f  thio-disaccharide 111,
Although the 5,6-isopropylidene group of 111 is very acid labile, the 1,2-ketal was 
only slowly removed on treatment with hot 80% aqueous acetic acid. Treatment with 
90% TFA at room temperatuie for 15-30 minutes readily hydrolysed both ketals in 
an acceptable 70% yield. The product mixture gave complex NMR spectra in a 
variety of deuterated solvents. The clearest spectrum was recorded in pyridine-dg and 
showed four anomeric signals coiTcsponding to the a  and p anomers of both 
pyianose and fiuanose ring forms. A 4:1 pyranose:furanose mixture of peracetates, 
ll'ip /f, was obtained on acétylation of the crude 1 1 2  mixture in pyiidine/acetic 
anhydride (Scheme 4.21).
OAcOAc ÇOsMe 
O'T'-S^O.
AcO
AcHN
ii, 70%
COoM ePR^OR OAc
AcHN AcHN
OAc 9 ° 2Me
AcO OR OR
RO OR OR
^ 112 R=H
111, 8 6 % R=Ac
Scheme 4.21 Attempted conversion o f  compound 111 to its pyranose ring form. Reagents: i, Et2NH,
DMF; ii, TFA(aq); iii, AC2O, pyridine
70
In order to confirm which signals were due to fuianose and pyranose isomers, the a  
and p furanose peracetates were synthesised separately (Scheme 4.22). Briefly, the
5,6-isopropylidene group was selectively hydrolysed with aqueous acetic acid and 
the 5- and 6 -hydroxy gi'oups acetylated prior to removal of the 1,2-isopropylidene 
group with 90% TFA. Acétylation of the 1- and 2-hydroxy groups gave a 1:2 mixture 
of the a  and p anomers 113/in 45% yield from 111 (NMR spectra: Appendix 2).
OAc
AcO. OAc OAc 0 - 7 ^  S^O.AcHN AcHN
RO OR
^ 114 R=H 
ii, 58%  from 111 (^115  R=Ac
III
OAc
AcO
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DAc C O jM e
O v ^ s ^ o .
AcO
^RO bR^ OR^
116 R^=Ac, R^=H 
iv, 78% from 115 C 113 f  R'* =Ac, R^=Ac
Scheme 4.22 Synthesis o f  a J f galactofuranose peracetates. Reagents: i, AcOH(aq); ii, AcgO, 
pyridine; iii, TFA(aq); iv, AC2O, pyridine.
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Scheme 4.23 Synthesis o f  118 and 119. Reagents: i, Et2NH, DMF; ii, TFA(aq); iii, AC2O, pyridine.
71
6 '-(Methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-g-/ycero“a-D-g-a/acto-2- 
nonulopyranosylonate)-(2->3)-l,2:5,6-di-0-isopropylidene-3-thio-a-D- 
glucofuranose, 118, the g/wco-isomer of disaccharide 1 1 1 , was prepared according to 
von Itzstein’s procedure (Scheme 4.23)7 ^  Hydrolysis of the acetonides and 
acétylation under the same conditions used for 1 1 1  gave a mixture of only two 
isomers. Both and NMR (CDCI3) were consistent with the a  and p 
glucopyranose structures 119; ôy 5.98 (d, /  2 8.2, la-H p), 6.22 (d, J ]^2 3.8, la-H a); 
6 c 88.7 (la-C a), 92.5 (la-C P).
4.1.5 The Galactofuranosyl/Galactopyranosyl Problem?
The difference in configuration at C-4, seems to be sufficient to govern whether the 
compound should adopt either the pyranose or furanose structure. For the gluco- 
configuration, the molecule can avoid the cis interaction of the sulfur linkage and C- 
5, present in the furanose ring, by adopting, exclusively, the pyranose form with its 
fully equatorial arrangement of sustituents (Scheme 4.24). In other words, there is a 
large difference in the relative energies of the pyranose and furanose forms, and the 
equilibrium therefore lies very much in favour of pyranose. However, for the 
ga/<3c?o-configuration, it is the furanose ring that has the trans arrangement of 
sustituents around the thioglycosidic linkage, and the pyranose ring that has a cis 
arrangement of sulfur and 0-4 (Scheme 4.24). The net effect is to bring the relative 
energies of the two ring forms closer together, resulting in the mixture of isomers 
observed. The properties of the furanose ring that were advantageous to the coupling 
reaction, form the basis of the problem encountered in trying to form the pyranose 
ring.
.OH
CiEs>\ < S > O H  OH
Sl a— . OH . OHOH -OV Ctrans)\ .S - A - —
HO b H  OH Sia ^ ^ ^ O H
Scheme 4.24 The cis and trans arrangement o f  substituents in the gluco- and galacto-ring forms.
Many approaches to solving the furanose-pyranose problem were studied; these 
included acylation (acétylation, benzoylation, pivaloylation) with a variety of 
reagents at varying temperatures, acetolysis of the acetonides, lactonisation of the 
sialic acid and stannylene acetal-mediated acylation amongst others, but no
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improvement (or, indeed, any clear major product in some cases) was achieved by 
these methods. The one exception which showed gieat promise was to treat the 112  
mixture with a excess of r-butyldimethylsilyl chloride in pyridine (Scheme 4.25). The 
first silylation occurs at the primary alcohol, as expected, and the second silylation 
takes place at the anomeric position, but it does so to give, almost exclusively, the (3 
pyianose (^H NMR, CDCI3; /ia,2a 7.4 Hz, J 2a,3a H .8  Hz, / 33,4a 3.3 Hz). The second 
silylation occurs much more slowly than the first and perhaps, could be thought of as 
a kinetic resolution of the disaccharide isomers, occumng alongside a re­
equilibration of the other components of the mixture.
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AcO COoM epH^OH
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Scheme 4.25 Synthesis o f  ganglioside GM4 analogue 125. Reagents: i, TBDMSCl, pyridine; ii, 
AC2O, pyridine; iii, TFA(aq) then, AC2O, pyridine; iv, H2SO4 , AC2O, AcOH; v, N 2H4 .ACOH, DMF; 
vi, NCCCI3, DBU, CH2CI2; vii, OctOH, BF3.Et2 0 , CH2CI2; viii NaOMe, MeOH; ix, KOH(aq).
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Having tied up the galactose into the pyranose ring, the remaining hydroxyl groups 
(positions 2 and 4) were acetylated in a one pot reaction to give 120 in 90% yield 
from 112. This would prevent re-equilibration of furanose and pyranose on 
hydrolysis of the TBDMS ethers, as 0-4 which would otherwise become tlie 
furanose ring oxygen was now blocked as an ester. The minor isomer visible in the 
iH NMR spectrum (~5%) could not be clearly identified, but conversion to the 
peracetate would allow comparison with the mixture resulting from the direct 
acétylation of 1 1 2 .
Several procedures for removing the silyl ethers were investigated. 80% Aqueous 
acetic acid at 80 °C, 90% aqueous TFA, tetrabutylammonium fluoride in THF and 
potassium fluoride/18-crown-6 in acetonitrile, all at room temperature readily 
removed the primary silyl ether [the product of which was acetylated to confinn its 
structure; 121 ^H NMR (CDCI3) 5h 5.10 (1 H, d, /ia,2a 7.4, la-H)], but none gave 
complete removal of the anomeric TBDMS group. The harsher conditions of an 
acetolysis reaction (2.5% H2SO4 in acetic acid/acetic anhydride) gave the peracetate 
113 in 76% as a mixture of 83:14:3 (NMR spectra: Appendix 2).
Comparison of published analytical data with those for this product mixture (and 
products of subsequent steps in the synthetic sequence) now becomes possible, as the
p-pyranose peracetate 113p/? is a known compound,^ used by Hasegawa and co­
workers in their synthesis of 6 "-linked ganglioside GM4.*
The peracetate was selectively deprotected using hydrazinium acetate to give the 
hemiacetal 1 2 2  in 70% yield; [a]o +30.0 (c 0.7 in CHCI3) (lit.,^ [p anomer] +33.0). 
The hemiacetal was then converted into an anomeric mixture (p-p:a-p, 92:6) of 
trichloroacetimidates 123 in 90% yield using DBU as base (the anomeric ratio of the 
imidate is unexpected as DBU usually gives principally the a  anomer); [a]o +26.4 (c
1.1 in CHCI3) (lit.,^ [p anomer] +27.5). ^H NMR spectroscopy indicated that this was 
contaminated by only 2 % of a furanose derivative.
Unfortunately, time did not allow for the further extension of this glycosyl donor to 
the original target trisaccharide. Instead, it was decided to make the octyl glycoside 
of the disaccharide, as this would be suitable also for the C-18 reverse phase based 
assay. Thus, the imidate donor 123 was treated with octanol in the presence of boron 
trifluoride etherate to give the octyl glycoside 124. Purification of the peracetate 
proved difficult and so the resulting product mixtuie was de-acetylated and the 
methyl ester saponified prior to purification by reverse phase chromatography. ^H 
NMR spectroscopy showed that the product 125, obtained in 50% yield fiom the 
imidate, was exclusively the p-pyranoside.
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4.1.6 Substrates for the Neuraminidase and ^m/fs-Sialidase Assays. In addition to 
octyl glycoside 125, several other thio-sialosides were prepared for the enzyme 
assays. Portions of sialylated galctofuranose compound 111 and sialylated 
glucofuranose compound 118 were fully deprotected to give the reducing 
disaccharides (Scheme 4.26). Briefly, compounds 111 and 118 were de-O-acetylated 
under Zemplén conditions and then the methyl esters were saponified prior to acid 
hydrolysis of the acetonides to give the reducing disaccharides 126 and 127, each in 
-40% yield from the fully protected disaccharides. Also, a small sample of 125 was 
de-A-acetylated in hot potassium hydroxide solution to give deNAcGM4 thio- 
analogue 128 in almost quantitative yield (Scheme 4.26).
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Scheme 4.26 Synthesis o f  thio-sialosides 126, 127 and 128 fo r  neuraminidase assays. Reagents: i, 
NaOMe, MeOH; ii, NaOH (aq); TFA (aqQj h ,  NaOH (aq), A.
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4.1.7 Conclusions -  Thio-Sialoside Synthesis
Attempts to synthesise the Neu5Aca(2-->-3)Gal thio-disaccharide by literature 
procedures failed in my hands. However, a thioglycoside analogue of ganglioside 
GM4 was successfully synthesised via a novel route involving a sialic acid- 
galactofuranose intermediate (111). The synthesis was completed in a total of 19 
steps from diacetone glucose and sialic acid and in an overall yield of 4%. The 
longest linear sequence was 15 steps which compares favourably with syntheses 
already published in the literature, b 2, 5 However, the sialic acid-gulofuranose 
coupling described here, appears to be a more facile reaction than other procedures 
that have been reported for making the Neu5Aca(2—>3)-3-thio-Gal linkage.
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4.2 Synthesis of O-Linked GM3 analogue 52
4.2.1 Chemical vs. Enzymatic Synthesis. There are two general approaches towards 
the synthesis of O-glycosides: chemical synthesis and enzymatic synthesis. Chemical 
synthesis of oligosaccharides is a very powerful tool in glycobiology, as has been 
demonstrated by a number of prominent laboratories around the world in recent 
years.26 It presents the opportunity of making well defined single compounds in 
multi-gram quantities, free firom the “micro-heterogeneity” found in the lipid 
portions of glycolipids isolated fiom natural sources. Where chemical synthesis truly 
excels is in the construction of unnatural analogues of compounds, specifically 
designed as biological p r o b e s .^ ^  The major drawback of the chemical approach is the 
necessity for extensive (and tedious) protecting group chemistry, which is essential to 
control both the regio- and stereo-selectivity of glycosylation reactions. This 
invariably leads to multi-step reaction sequences and ofien low overall yields.
The alternative is to use the glycosyl transferases and glycosidases, on which Nature 
relies for constructing and remodeling complex glycans in vzvo.28, 29, 30, 3i More and 
more of these highly precise bio-catalysts are becoming available as synthetic tools, 
especially the glycosidases which do not rely on expensive nucleotide sugar donors 
and are often best used in conjunction with organic s o l v e n t s . 2 9 ,  31 , 32 lack of 
protection and deprotection steps allows much shorter reaction sequences which can 
be achieved on a much shorter time scale and in yields which can easily rival 
chemical routes. Where enzymes are used in conjunction with chemical methods, a 
wide range of non-natural compounds can also be s y n th e s is e d .^ ^ ,  33
4.2.2 Retrosynthesis. Two routes were considered for the synthesis of the O-linked 
GM3 analogue 52; one puiely chemical and the other using a combination of 
chemical and enzymatic steps (Scheme 4.27).
There have been several total syntheses of ganglioside GM3,^ >^ 35, 36 and also many 
syntheses of the higher gangliosides of which sialyl lactose is the core unit.32 The 
usual approach is to glycosylate a suitably protected lactose derivative with a sialic 
acid donor and then to introduce the ceramide portion as the final step. This 
convergent approach is in contrast with the biosynthesis of gangliosides which 
occurs by stepwise glycosylation fiom the reducing end, starting with glucosyl 
c e r a m i d e .3 8  As octyl lactoside had already been made as an intennediate in the 
original approach to the thioglycoside synthesis, both syntheses described here, 
involved the sialylation of this acceptor.
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Scheme 4.27 Retivsynthetic analyses fo r  chemical and chemo-enzymatic syntheses o f  52.
The rra«5-sialidase from Trypanosoma cruzi was the enzyme of choice for the 
glycosylation. 39, 40 Most neuraminidases have proven ineffective for use in the 
“reverse direction” and sialyl transferases require CMP sialoside in either 
stoichiometric quantities or to be recyled in situ using a multi-enzyme system.^i The 
rraw5-sialidase is used by the trypanosomatid parasites to steal sialic acid residues 
fr om the surface of its host’s cells in order to cover its own surface (Scheme 4 .2 8 ) .3 9
OH nn
AcHN 0 - H o s t HO
QH^ OH 
■O 0 —Trypanosome
OI^OH
OH
OH
T. cruzi frans-sialidase 
CO2' OH^ OH
AcHN 0 —Trypanosome
Scheme 4.28 The Tiypanosoma cruzi trans-sialidase transfers sialic acid between the trypanosome
and its host.
Thus, the enzyme uses sialylated oligosaccharides as donors, but can also use simple 
glycosides such as 4-methylumbellifeiyH2 and ^-nitrophenyl sialosides There have 
been several reports of the use of this enzyme in synthesis.^^, 43, 44 ^  70  kDa 
recombinant construct of the frzzw.s'-sialidase^  ^ has also been used in our laboratory 
for the sialylation of sulfated and phosphorylated LacNAc compounds,^^ but as these
syntheses were only performed on a very small scale and had involved purification 
by several different chromatographic steps, the synthesis of the GM3 trisaccharide 
was first attempted by a chemical route.
4.2.3 A Chemical Synthesis of 52. The approach adopted was based on Hasegawa’s 
synthesis of ganglioside GM2 .^ ^
4.2.3.1 Acceptor synthesis. Octyl lactoside 57 was protected with an isopropylidene 
ketal across the 3b-, 4b-hydroxy groups to give 129 in 6 6 % yield, using an excess of 
dimethoxypropane and catalytic j9-toluenesulfbnic acid with subsequent selective 
hydrolysis of any 6 a- or 6 b-mixed ketals by aqueous TFA. The position of the 
protecting group was confirmed by acétylation of a small portion of the product. The 
remaining material was benzylated before hydrolysing the acetonide to give the diol 
acceptor 132 in 90% yield (Scheme 4.29). Although two hydroxyl groups are still 
free, glycosylation has shown to be selective for the equatorial 3b position over the 
less reactive, axial 4b-OH.^^
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OOctROOR OR
iv, 98%
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95% f ^  130 R=Ac 
131 R=Bn
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GOoMe
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Scheme 4.29 Syntheses o f  acceptor 132 and donor 134. Reagents: i, PF(0M e)2, /7-toluenesulfonic 
acid; ii, AC2O, pyridine; iii, NaH, BnBr, DMF; iv, AcOH(aq); v, AC2O, pyridine; vi, MegSiSMe, 
MegSiOTf, CICH2CH2CI.
4.2.3.2 Donor synthesis. The donor 134 was prepared in 3 steps by a literature 
procedure in 74% yield from sialic acid (Scheme 4.29).4'7 Briefly, the peracetylated 
sialic acid methyl ester 89, prepared as in the synthesis of 31 (Scheme 4.11), was 
treated with (methylthio)trimethylsilane and TMSOTf to give the methyl 
thioglycoside 134 as an anomeric mixture (a:p, T.l).
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4.2.3.3 Chemical glycosylation. Glycosylation of diol acceptor 132 was performed 
with 2.5 equivalents of donor 134 and A-iodosuccinimide and catalytic triflic acid as 
promoter, according to a literature procedure.'^^ It proved convenient to deacetylate 
the product mixture prior to column cliromatography, which yielded a mixture of 
trisaccharides 135a/b (Scheme 4.30).
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Scheme 4.30 Synthesis o f  GM3 analogue 52. Reagents: i, NIS, TfOH, MeCN; ii, NaOMe, MeOH; iii, 
AC2O, pyridine; iv, H2, Pd(0H)2, MeOH; v, KOH(aq); vi, AC2O, MeOH.
A small sample of the mixture was partially separated by careful cliromatography 
and the fractions reacetylated to give the a-linked 3c->4b lactone 136b and an a/p 
mixture of the methyl ester 136a, identified by comparison of spectral data for 
analogous literature compounds.'^^» It is unclear at what point the lactonisation 
occurred; acid-promoted lactonisation during the glycosylation reaction is one 
possibility, but the partial conversion of sialoside methyl esters to lactones under 
Zemplén deacetylation conditions has also been reported.'^^ Hydrogenolysis of each 
of the deacetylated hactions using palladium hydroxide in MeOH gave a mixture of
lactone 13 7 b  and methyl ester(s) 137a . The remaining product mixture was 
debenzylated in a similar fashion and then treated with hot 1 M potassium hydroxide 
solution to hydrolyse both the ester/lactone and also the sialic acid acetamide, as trial 
experiments had shown the a  and p anomers to be best resolved on TLC as the
amino compounds 49a/p. The deprotected product was obtained in 49% yield from 
acceptor 132  as a 6:1, a:P mixture, whereas the published procedure had claimed 
total anomeric control to give the a-sialoside in similar yield.'^  ^ Although the 
anomers could be separated on a preparative TLC plate, or by repeated flash 
chi*omatogi*aphy, this tedious final purification step gave the desired product in low 
yield (21%). Reacetylation of the amino group was achieved using 3 equivalents of 
acetic anhydride in MeOH solution giving 5 2  in high yield.
4 .2 .4  A  C h e m o -E n z y m a tic  S y n th e s is  o f  52 . The enzymatic procedure was 
investigated for comparison.
4 .2 .4 .1  D o n o r  sy n th e s is . The p-nitrophenyl sialoside 139  was prepared in 49% yield 
by nucleophilic displacement of chloride from compound 31 under phase transfer 
conditions.^o Deacetylation and saponification of the methyl ester gave the required 
NeuSAcapNP donor 139  in almost quantitative yield (Scheme 4.31).
-9 [7 ^ C 0 2 M e A cH N ^C % y-9y^ 0— P— NO2
OAc O
Scheme 4.31 Synthesis o f  donor 139. Reagents: TBAHSO4 , NaOH(aq), CH2CI2; ii, NaOMe,
MeOH; iii, NaOH(aq);
4 .2 .4 .2  E n z y m a tic  g ly c o sy la t io n  (Scheme 4.32). The /ra«5-glycosylation catalysed 
by the /ran.y-sialidase is fully reversible. Therefore, one would expect the equilibrium 
product mixture to reflect the relative concentrations of acceptors present and their 
affinities for the enzyme. After incubating octyl lactoside, 57, and 1.5 equivalents of 
the donor 139 with the /rnn^'-sialidase overnight at 30 °C, TLC indicated that the 
reaction had gone about half way to completion. Although the reaction can be pushed 
further towards completion by using higher concentrations of the donor and enzyme, 
complete consumption of the acceptor was never observed.
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Scheme 4.32 Enzymatic coupling o f  donor 139 with acceptor 57. Reagents: i, ^ran^'-sialidase, sodium
phosphate buffer pH 7.
Therefore, it was more convenient to stop the reaction after a relatively short reaction 
time and separate the product from the reactants. Reverse phase chromatography on 
C-18 silica proved to be liighly efficient in this regard. Having removed most of the 
protein by precipitation with ethanol, the supernatant was concentrated and 
redissolved in water before applying to a C-18 column. The excess NeuSAcapNP 
and virtually all of the yellow /?-nitrophenol eluted off the column with 
approximately four column volumes of water. The product and acceptor were then 
eluted using a fairly crude stepwise methanol gradient; the product coming at the end 
of the 25% MeOH/beginning of the 50% MeOH and the acceptor eluting with 75% 
MeOH. The column was regenerated by washing with four column volumes each of 
methanol and then water. By this method 7 mg (42%) of the tri-saccharide 52 was 
made and purified within 24 hours, from the easily accessible donor and acceptor 139 
and 57 (Scheme 4.32).
4.2.5 C o n c lu s io n s  -  C h e m ic a l vs. E n z y m a tic  S y n th es is  o f  G M 3  A n a lo g u e  52. The
chemo-enzymatic synthesis was completed in 1 0  steps from lactose and sialic acid, in 
an overall yield of 10%. The longest linear sequence was 7 steps from sialic acid. 
This should be compared with the purely chemical approach, which was four steps 
longer and gave an overall yield of only 5%. These two yields would have been 
almost identical had it not been for the poor a-selectivity of the chemical 
glycosylation, which necessitated a difficult and low yielding chromatographic 
separation of the a  and (3 anomers. It is also worth noting that whereas the chemo- 
enzymatic synthesis required only 3 purifications by silica gel or reverse phase 
chromatography, the chemical synthesis required at least 9 chromatographic steps. 
The r^aw5-sialidase is a useful tool in oligosaccharide synthesis, allowing rapid, easy, 
stereo- and regioselective synthesis of sialosides in yields which easily rival those 
attainable by chemical synthesis.
4 .3  N e u r a m in id a se  A ssa y s
As was discussed in section 2.4, thio-oligosaccharides are resistant towards 
enzymatic hydrolysis. Also, some sialic acid thio-glycosides have been evaluated as 
inhibitors for a range of viral and bacterial neuraminidases (section 2.5.2). Of the 
compounds studied, the best reported Ki for an influenza virus neuraminidase was 
2.8 pM for Neu5Aca(2-^6)-6-thio-GlcpCeramide, but this compound was a much 
poorer inhibitor for bacterial neuraminidases.^ ^ The binding affinity of the best sialic 
acid tliio-glycoside inhibitor is comparable to that of the 2,3-dehydro-sialic acid, 
Neu5Ac2en 14 0  (Ki 4 pM)^2  still very low in comparison to Glaxo’s 4- 
guanidino-Neu5Ac2en compound 141 (Ki 1-0.1 nM)^^ which is in clinical trials as 
an anti-influenza drug. These sialic acid glycals are thought to mimic the 
conformation of the oxo-carbonium intermediate 142 which is formed, transiently, 
during enzymatic hydrolysis of sialosides (Figure 4.3).
AcHN AcHN
141 HzNy=NH
AcHN
Figure 4.3 Neu5Ac2en neuraminidase inhibitors mimic oxo-carbonium species 142.
As yet, no data has been reported on the stability of Neu5Aca(2-^3)-3-thio-Gal 
compounds to enzymatic hydrolysis, nor regarding the properties of such compounds 
as neuraminidase inhibitors. Although it may be expected that a(2->3)- 
thioglycosides should prove to be weak inhibitors, like the a (2 ->6 )-compoimds, any 
inhibitory activity would show that at least this class of sialic acid recognising 
enzyme accepts ^'-linked sialosides. Also, it would be interesting to consider 
Neu5Aca(2^3)-3-thio-Gal compounds as inhibitors for the ^raw.s-sialidase from 
Trypanosoma cruzi which is unaffected by Neu5Ac2en based compounds, and thus 
presumably operates by a different mechanism to bacterial and viral 
neuraminidases.^ 3 T. cruzi is a parasite which causes Chagas disease, an incurable 
condition which is endemic in South America. The ifraw^ ’-sialidase is vital to the 
parasites’ ability to invade mammalian cells and is thus a key target for developing 
drugs against Chagas disease.^3
We thus decided to evaluate a number of the thio-sialosides synthesised (Figure 4.4) 
for their resistance to enzymatic hydrolysis by, and as inhibitors for Clostridium 
perfringens neuraminidase and ifra«5-sialidase from T. cruzi. The O-linked
deNAcGM3 analogue 49 was also tested to try to confinn the expectation that it 
would also be resistant to enzymatic hydrolysis. The corresponding O-linked GM3 
analogue 52 was included as a positive control for both enzymatic hydrolysis and as 
a competitive inhibitor with respect to the substrates used in the assays.
CO2 OH OH
OH
52, R = Ac 
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CO2" OH.qh
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128, R = H
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Figure 4.4 Compounds tested as neuraminidase and trans-sialidase inhibitors.
4.3.1 Clostridium perfringens neuraminidase. A UV absorbance assay, using p- 
nitrophenyl a-sialoside (NeuSAcapNP) 139 as substrate, was chosen for the C 
perfringens neuraminidase experiments.^® The assay was performed as a time-course 
experiment, withdrawing aliquots firom the enzyme incubation at regular intervals 
and quenching the reaction by addition of glycine buffer at pH 10. At high pH, p- 
nitrophenol released from the sialoside is deprotonated to give the phenolate salt 
which strongly absorbs light at 400 nm (e = 18,000) (Scheme 4.33). Measuring 
changes in absorbance at this wavelength provides a sensitive assay for enzymatic 
hydrolysis.
AcHN-^^7 ^  O— ^^NOg 
OH 139
neuram inidase 
pH 4.5
A c H N Z % v "$ y ^ O H  +  HO- NO:
glycine buffer 
pH 10
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Scheme 4.33 NeuSAcapNP neuraminidase assay.
Acid hydrolysis of NeuSAcapNP was negligible at pH 4.5 (Figure 4.5), the pH 
optimum for n e u r a m i n i d a s e . ^ ^  However, absorbance measurements needed to be 
taken shortly after quenching with glycine buffer, as base hydrolysis caused a notable 
change in absorbance with time (data not shown).
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Figure 4.5 Timecourse showing NeuSAcapNP hydrolysis in the presence and absence o f
neuraminidase.
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Figure 4.6 Percentage inhibition o f  NeuSAcapNP cleavage by C. perfringens neuraminidase.
All inhibitors are ImM
4.3.1.1 Inhibition results. Both O-linked GM3 analogue 52 and ^'-linked GM4 
analogue 125 showed approximately 50% inhibition at 1 mM (Figure 4.6). This 
would suggest that replacing the interglycosidic oxygen atom with sulfur does not 
greatly affect the affinity of the C. perfringens neuraminidase for a(2^3)-linked 
sialosides. As was expected, the deNAc-thiosialoside 128 showed lower inhibition 
than the A-acetylated 125. Similarly, the reducing disaccharide 126 was a poorer 
inhibitor than the P-octyl glycoside 125, but a better inhibitor than the thio-sialylated 
glucose isomer 127.
At 1 mM concentration, deNAcGM3 analogue 49 showed over 90% inhibition of the 
enzyme. However, a series of ten-fold dilutions of the inhibitor all gave inhibition in 
the region of 15 to 25% (Figure 4.7). Compound 49 is an amphiphilic molecule and, 
as such, it will show detergent-like properties. It is possible that the critical micellar 
concentration of the molecule may lie between 0.1 and 1 mM and that the great 
increase in inhibition that was observed, may result from a detergent effect on the 
protein. However, the properties of compound 49 were not pursued further.
Figure 4.7 Percentage inhibition o f  C. perfringens neuraminidase by compound 49 at various
concentrations.
4.3.1.2 Turnover assay results. All of the compounds in Figure 4.4 were tested as 
substrates for the C. perfringens neuraminidase, following the reaction by TLC. Even 
after 24 hours, only the O-linked GM3 analogue 52 had been cleaved by the enzyme. 
All of the other compounds showed no change.
4.3.2 Trypanosoma cruzi ^m«s-sialidase
Although NeuSAcapNP was used successfully as the donor in the enzymatic 
synthesis of GM3 analogue 52, it is a relatively weak substrate for the fraM -^sialidase 
enzyme.43 Greater sensitivity can be gained by using a radioactive assay for trans- 
sialidase activity.^ 3 The assay uses sialyl lactose as the donor and [l-^^cjj^ctose as 
the acceptor. After incubating a mixture of donor, acceptor, inhibitor and enzyme for 
30 minutes, the reaction is quenched by diluting with water and applying the mixture 
to an anion exchange column. Elution with water gives the neutral, non-sialylated 
lactose, then elution with 1 M ammonium acetate gives the sialyl lactose (Figure 
4.8). The percentage of [l-i'^Cjlactose which has been sialylated can be deteimined 
by liquid scintillation counting of the water and ammonium acetate elutions.
Assay mixture water 1M NH4OAC
NeuSAcLac + ['^4C]Lac
i
I \
frans-sialidase 
Lac + Neu5Ac['l4C]Lac
■>-
Sephadex
A25 I
lactose sialyl lactose
Figure 4.8 Radioactive assay fo r  trans-sialidase activity.
In these experiments, the concentration of donor was -26 times the concentration of 
the “hot” acceptor, therefore at equilibrium 96% of the [l-^^^ji^ctose would
be sialylated. The control incubation, without any inhibitor present, showed -40% 
sialylation in 30 minutes and thus, under the conditions of the assay, the reaction is 
still far h'om equilibrium.
4.3.2.1 Inhibition results. None of the thio-glycosides showed inhibition of the 
fmwi'-sialidase at 1 mM concentration (Figure 4.9). The two O-linked compounds, 52 
and 49 showed an increase in sialic acid incorporation into the radio-labeled lactose. 
The two-fold increase in sialylation of “hot” lactose in the presence of GM3 analogue 
52, is not surprising as this compound was expected to be a substrate for the enzyme. 
Thus, the apparent increase in activity is simply due to an increase in the substrate 
concentration. However, the apparent slight increase in activity with the deNAcGM3 
analogue 49, would imply that this compound is also a substrate for the trans- 
sialidase.
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Figure 4.9 Percentage o f  radio-labeled lactose which is sialylated in the pj-esence o f  the various test
compounds.
4.3.2.2 Turnover assay results. The fact that both 52 and 49 are substrates was 
confirmed on repeating the incubations in the absence of any other sialyl-donor 
(Figure 4.10). Sialic acid was transferred from both GM3 analogue 52 and also from 
deNAcGM3 analogue 49, albeit at approximately a quarter of the rate. As time 
increased, the percentage of radio-labeled lactose which was sialylated decreased. 
This was probably due to the residual hydrolytic activity of the enzyme slowly 
releasing free sialic acid. Increases in radioactivity, above background, in the 
ammonium acetate elutions from the thio-glycoside assays were negligible. Thus the 
thio-glycosides showed much greater stability to the fra«5 -sialidase enzyme than the 
O-linked sialosides.
I .ê  $i lQ. ra 
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22 h Time
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Figure 4.10 Percentage o f  radio-labeled lactose which is sialylated in the presence o f  the test 
compounds, as a function o f  time. N.B. all donors are 1 mM except sialyl lactose which is 0.2 mM.
4.3.3 Conclusions - Neuraminidase and /rans-Sialidase Assays. Siaa(2—>3)-3- 
thio-Gal compounds show greater resistance to enzymatic cleavage than the 
corresponding (9-linked compounds. The thio-sialosides tested were all weak 
inhibitors for C. perfringens neuraminidase, the best of these being compound 125 
which showed approximately 50% inhibition at a concentration of 1 mM. Inhibition 
was greater for an A-acetyl sialoside than for a de-A^-acetyl sialoside. Also, it was 
greater for octyl glycosides than for reducing disaccharides and for a sialyl-galactose 
disaccharide than for a sialyl-glucose disaccharide. None of the compounds tested 
showed significant inhibition of the T. cruzi ^rawi'-sialidase. Therefore, Siaa(2-»3)- 
3-thio-Gal compounds are accepted by a sialoside-recognising enzyme (C. 
perfringens neuraminidase), but apparently not by another sialoside-recognising 
enzyme {T, cruzi ^raws'-sialidase). DeNAcGM3 analogue 49 was found to be resistant 
to cleavage by C. perfringens neuraminidase, but was a substrate for the T. cruzi 
trans-smliàQSQ.
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Chapter 5 
Development of De-A^-Acetylase and 
W-Acetyltransferase Assays
Having prepared the target O-linked compound 49, the next steps were to introduce 
the radio-labeled acetamide and to set up assays, as described in chapter 3 , to detect 
the de-A-acetylase and the A-acetyltransferase activités.*
5.1 Synthesis of radio-labeled GM3 analogue 48
OH ÇO2 OH^OH 
O
LHJAcgO, MeOH
ÇO2 pH^OH 
OH AcHN
Arthrobacter ureafaciens neuram inidase
H]AcHN
2 y
OH H O-A/-'i;^A..^O'^Q
Scheme 5.1 Synthesis and enzymatic digestion o f  radio-labeled GM3 analogue 48.
The amino-compound 49 was treated with two mole equivalents of [^H]acetic 
anhydride in methanoT to yield the required radio-labeled GM3 analogue 48 (163 
GBq/mmol, 1.3 x 10^  ^dpm/mg) (Scheme 5.1). TLC showed -95% coversion to the 
acetamide under the conditions used. There was no evidence of 0-acetylation as 48 
was the fastest running spot on the TLC and this co-ran with the corresponding 
“cold” GM3 analogue 52. The product was purified twice by treating with aqueous 
alkali, to destroy excess [^H]acetic anhydride, and reverse phase chromatography on 
a C-18 “Spice cartridge”. Only 1% of the radioactivity was washed off the cartridge 
with water following re-purification. However, after subjecting a sample of 48 to
* The work described in this chapter was undertaken jointly with Mr Justin Soimenburg at the UCSD  
Cancer Center, La Jolla, CA, USA, under the direction o f  Prof. Ajit Varki.
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enzymatic digestion with Arthrobacter ureafaciens neuraminidase, 98% of the 
radioactivity could be eluted from the cartridge with water.
5.2 Assay development. All experiments were conducted using extracts of Melur 
melanoma cells which have previously been shown to express both gangliosides 
deNAcGM3 and deNAcGD3.2 The cells were lysed by nitrogen cavitation and then 
separated into three jfractions (see section 5.5.2): cytosol, membranes and detergent 
soluble membranes. Addition of detergent to the membrane fraction opens up 
intracellular compartments allowing the radio-labeled substrates access to enzymes 
located within endosomes and lysosomes. As deNAc gangliosides are mainly found 
inside the cell, appearing on the cell surface only transiently,^ it was considered that 
the de-iV-acetylase and A-acetyltransferase would be most likely located within such 
intracellular compartments. The substrates were incubated with the cell fractions at 
37 °C in three different buffers at pH 5, 6  and 7 for 3 hours and then worked-up on a 
C-18 Spice cartridge. For de-A-acetylase assay, divalent metal ions were also 
included in the assay buffers and the growth medium which contained non-adherent 
cells was also tested for activity. Negative controls were also included in all 
experiments. The negative controls for the A-acetyltransferase assay were minus cell 
extract and minus 49 for all conditions. For the de-A-acetylase assay the appropriate 
controls were minus cell extract and minus divalent cations.
5.2.1 A-Acetyltransferase assay
Assay mixture water Aq. MeOH
Spice
cartridge
pH-acetyi] CoA
Figure 5.1 Proposed separation o f  N-acetyltransferase assay products on C-18 Spice cartridge.
Difficulties were encountered when trying to separate the products of the N- 
acetyltransferase assay. It had been anticipated that the excess [^H]-acetyl CoA could 
be washed off the cartridge with water before eluting any products with aqueous 
methanol (Figure 5.1). However, acetyl CoA proved too hydrophobic to be easily 
eluted with water, instead it slowly leached off the column. Elution with 3% 
methanol was more efficient at removing the acetyl CoA, but a control experiment
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using chemically synthesised 48, showed that it was also partially eluted with 3% 
methanol. It is a normal practice to re-use C-18 cartridges for such assays after 
regeneration by washing with methanol and then with water.^ However, this type of 
assay is typically used for purified enzymes rather than crude cell extracts. We found 
that the acetyl CoA and the GM3/deNAcGM3 analogues were more easily separated 
on new than on re-used cartridges suggesting that the cartridges have a much shorter 
useful life span when used with crude cell extracts. Alternatively, we considered that 
exposing the cartridges to detergent, present in some of the samples, could result in 
problems on re-using the cartridges. This was discounted, however, as other 
investigators have reported re-using C-18 cartridges for glycosyl transferase assays 
using enzymes solublised with considerably higher concentrations of detergent than 
we were using.^ Even when using new cartridges, no clear production of 48 was 
observed.
Acetyl CoA is the standard acetyl-donor used by many enzymes within the cell. 
Therefore, there may be many other enzymes which compete with the 
deNAcGM3 :A-acetylti'ansferase for acetyl CoA, and these may give rise to many 
other [^H]-labeled products. We felt that the assay was still not sensitive enough to 
detect small amounts of 48 which may have been produced. Further improvements to 
the assay could probably be gained by increasing the length of the hydrophobic tail in 
the substrate to allow its easier separation from unreacted [^H]-acetyl CoA. 
Alternatively, the excess acetyl CoA could perhaps be destroyed either chemically or 
enzymatically, prior to loading onto the cartridge.
5.2.2 De-A-acetylase assay
Assay mixture water Aq. MeOH
Spice
cartridge
[2-®H]acetic Excess 48
acid
Figure 5.2 Proposed separation o f  de-N-acetylase assay products on C-18 Spice cartridge.
A similar problem was encountered with the de-A-acetylase assay. It had been hoped 
that any [2-^H] acetic acid released during the incubation would be eluted from the 
cartridge with water and then the remaining 48 could be recovered by washing the
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cartridge with aqueous methanol (Figure 5.2). However, the radio-labeled substrate 
48 was gradually eluted from the cartridges with water, even after re-purification by 
reverse phase chromatography (Figure 5.3).
vol. Buent
old splce/water 
spice/water 
old spice/250 mM NaQ
Figure 5.3 Percentage o f  48 eluted from  new and reused (old) Spice cartridges by washing with 
consecutive volumes o f  water or 250 mM NaCl solution.
Again, this problem apparently stemmed from a reduced hydrophobicity of the 
cartridges on re-use. Low background counts could be achieved by using new Spice 
cartridges for each assay. However, it was found that similar results could be 
achieved with re-used cartridges when the samples were applied and eluted with 250 
mM sodium chloride, rather than with water. The higher ionic strength increased the 
hydrophobic interaction between the octyl glycoside and the reverse phase silica 
without greatly affecting the rate of acetate elution (Figure 5.4). Unfortunately, no 
enzymatic release of acetate was detected whilst using this assay.
Vol. B uen t
AcOH/NaO
Ac0H/H20
Figure 5.4.. Percentage o f  [^HJacetate eluted from Spice cartridges by washing with consecutive 
volumes o f  water or 250 mM NaCl solution
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5.2.3 Two phase scintillation counting: the “shake and bake” assay. An
alternative assay was also considered for detecting de-A-acetylase activity. The so- 
called “shake and bake” assay was originally developed for monitoring the release of 
acetate from acetylcholine.^ This assay relies on the different solubilities of 
acetylcholine and acetic acid in organic and aqueous solution. Following the 
incubation period, the reaction is stopped by addition of a chloroacetic acid buffer at 
pH 1. This has the dual effect of stopping the reaction and protonating the [2- 
^H]acetic acid (pKa 4.8) which can then be extracted efficiently into a toluene/wo- 
amyl alcohol based scintillation mixture. The [^H]-acetyl choline, however, remains 
in the aqueous phase from which the weak (3-particles, emitted by the decaying 
tritium atoms, can not escape to excite the scintillants in the organic phase. Thus only 
the released [2-^H] acetic acid is detected by the scintillation counter.
AcOH
“Shake and bake” 
scintillation fluid
Only [2-^H]acetic acid can 
enter the hydrophobic phase 
and excite the scintillants
48 stays in aqueous 
phase
48
AcOH
“Shake and bake” 
+ Scintiverse BD 
scintiilation fiuids
Single phase after adding 
standard scintillation fluid: all 
- radioactive components can 
excite the scintillants
Figure 5.5 The "shake and bake” de-N-acetylase assay.
The shake and bake assay could not be used for radio-labeled GM3 because the lipid 
portion is too large and would pull the compound into the organic phase along with 
any released acetate.^ However, octyl glycoside 48 is much more water soluble than 
GM3 and should thus remain largely in the aqueous phase (Figure 5.5). A trial 
experiment confinned that almost all of 48 remained in the aqueous phase and only 
4% of the 48 radioactivity could be detected by liquid scintillation counting. At pH 1, 
a significant portion of the sialic acid will be protonated (pKa 2.15)P increasing the 
solubility of 48 in the organic phase. By adjusting the pH of the stopping buffer to 
3.75, i.e. half way between the pKaS of the two acids, it was possible to optimise the 
desired solubilities of 48 and acetate to give a background reading of less than 1%. 
Furthermore, it was found that after measuring the amount of free acetate, as 
described above, addition of a commercial scintillation fluid which was designed for 
use with aqueous solutions, allowed measurement of the combined radioactivity of 
both the released and sialic acid-bound [3H]Ac. Even though this assay should have 
been sufficiently sensitive to detect release of a few percent of the [^HjAc, no free 
acetic acid was detected in the cell extract incubations.
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5.3 Flow cytometry analysis. A fluorescence activated cell scanning (FACS) 
analysis^ using anti-GD3 and anti-deNAcGD3 antibodies was performed on 
trypsinised Melur cells and on cells that had also been permeabilised with saponin so 
as to allow the antibodies access inside the cells. This experiment revealed that 
although GD3 was present on the surface of the cells, no deNAcGD3 could be 
detected at all (results not shown). DeNAcGD3 had previously been detected inside 
the cells of this Melur culture by the same assay. ^  However, in the three months 
since the last positive assay, the cells had been passaged (grown to confluence and 
then plated on) some thirty times. It is possible that the cells may have changed their 
phenotype over this period and were no longer expressing deNAc gangliosides. This 
would explain why no de-A-acetylase or A-acetyltransferase activities were detected. 
Further studies will be conducted using a fresh batch of Melur cells or with some of 
the other cancer cell lines that have been shown to express deNAc gangliosides. This 
work is being continued in collaboration with the Varki laboratory, UCSD.
5.4 Conclusions. Although no enzyme activities were detected, two assays for the 
de-A-acetylase activity have been developed and these should help in locating the 
enzyme in the near future. Similar deNAcGM3 analogues to 49, but with longer 
hydrophobic tails will be synthesised also. These compounds should help to further 
improve the A-acetyltransferase assay, which should, in turn, also lead to the 
discovery of this other potentially important enzyme.
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5.5 Experimental
5.5.1 General methods. Commercial reagents were used without further 
purification. [2-3H]Acetic anhydride (8.80 Ci/mmol, 326 GBq/mmol) was from 
Amersham and was dissolved in dry hexane (-400 mm^) before use. -Acetyl 
CoA (-27 Ci/mmol, -1 TBq/mmol), which had been prepared by a published 
enzymatic procedure,^ was already available in the Varki lab. Conversions between 
counts per minute (cpm) and Ci/Bq assumed a detection efficiency for 
disintegrations of 45% by liquid scintillation counting i.e. 1 mCi = 37 MBq = 1 x 10  ^
cpm. Arthrobacter ureafaciens neuraminidase (EC 3.2.1.18) was purchased from 
Calbiochem. Analytical TLC was performed on silica gel 60 (Whatman) with 
detection by charring, following immersion in orcinol dipping reagent, prepared as 
described in the main experimental section. The assay buffers used for incubations 
with cell fractions were HOMOPIPES (pH 5), MES (pH 6 ) and HEPES (pH 7), all at 
50 mM concentration. C-18 reverse phase Spice cartridges (Analtech) were washed 
with MeOH (10 cm^) and then with water (10 cm^) before use. The “shake and bake” 
stopping mixture was a citrate-phosphate buffer (pH 3.75), prepared by mixing 
solutions of citric acid (32 cm^; 100 mM) and dibasic sodium phosphate (18 cm^; 
200 mM) and diluting to 100 cm^ with distilled water. The “shake and bake” 
scintillation fluid was a solution of /?-bis[2-(5-phenyloxazolyl)]-benzene (POPOP) 
(1.2 g) and 2 ,5-diphenyloxazole (POP) (20 g) in a mixture of toluene (3200 cm^) and 
wo-amyl alcohol (800 cm^).^ Other liquid scintillation counting was performed using 
Scintiverse BD scintillation fluid (Fisher). The FACS buffer comprised phosphate 
buffered saline (PBS) containing 1% bovine serum albumin and 0.1% sodium azide.
5.5.2 Cell culture and preparation of cell fractions. Melur cells were grown to 
confluence in Dulbecco’s modified Eagle’s (DME) medium containing 2 mM L- 
glutamine and 10% fetal calf serum in an humidified incubator at 5% CO2 and 37 °C. 
The growth medium was removed from three 150 mm plates of confluent cells (-4 x 
10  ^ cells) and kept for the de-V-acetylase assay. The cells were washed with 
phosphate buffered saline (PBS), then scraped into HEPES buffer (5 cm^; 10 mM + 
100 mM NaCl, pH 7.2) and lysed by nitrogen cavitation by pressurising to 1250 psi 
for 15 minutes. The resulting white soup was centrifuged at 500 x g, 4°C for 15 
minutes in order to pellet nuclei and intact cells. The post-nuclear supernatant, thus 
obtained, was centrifuged at 100,000 x g, 4°C for 30 minutes to give the cytosol 
fraction as the supernatant and the membrane fraction as a pellet which was 
resuspended in HEPES buffer (2 cm^). Triton-X 100 was added to half of the 
membrane fraction to a final detergent concentration of 0.2% and this was
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centrifuged again at 100,000 x g, 4°C for 30 minutes. The pellet of detergent 
insoluble material was discarded and the supernatant was used as the detergent 
soluble membrane fraction. The cell fractions were kept at -20 °C until used.
5.5.3 Synthesis of octyl (sodium 5-pH]acetamido-3,5-dideoxy-D-g/yceré?-a-D-
ga/acto-2-nonuiopyranosylonate)-(2->3)-p-D-galactopyranosyI-(1^4)-p-D- 
glucopyranoside, 48
[2-^H]Acetic anhydride in hexane (125 mm^, 850 nmol; 7.5 mCi, 277.5 MBq) was 
added to a solution of 49 (240 pg, 340 nmol) in MeOH (250 mm^). After 2.5 h at 
room temperature, TLC (CHCI3-MeOH-H2 0 , 10:10:3) showed >90% conversion of 
49 to a compound that co-ran with octyl (potassium 5-acetamido-3,5-dideoxy-D-
glycero- a-D-ga\acto-2-nonulopyranosylonate)-(2 -y3)~f-D-galactopyranosyl-(1 ->4)-
f3-D~glucopyranoside, 52. After a further 1.5 h at room temperature, the solution was 
warmed to 30 °C and the solution was concentrated to a small volume under a stream 
of nitrogen. The residue was re-dissolved in water (300 mm^), and sodium 
bicarbonate solution (300 mm^; 1 M) was added. After 30 mins at room temperature, 
the mixture was transferred to a C-18 Spice cartridge and eluted with water (15 cm^), 
then with Me0 H-H2 0 , 1:1 (5 cm^), and finally with MeOH (5 cm^). An aliquot of 
each of these fractions ( 1 0  mm^) was diluted with water (1 cm^) and a small portion 
of the diluted material (10 mm^) was subjected to liquid scintillation counting. The 
results showed that 80% of the radioactivity (6  mCi, 222 MBq) eluted with water and 
20% of the radioactivity (1.5 mCi, 55 MBq) eluted in the MeOH-containing 
fractions. The MeOH containing fractions were combined and then concentrated to 
dryness under reduced pressure to give GM3 analogue 48 (1.5 mCi, 4.4 Ci/mmol; 
55MBq, 163 GBq/mmol). The product was divided equally between 10 vials, each 
containing -25 pg, 1.5 x 10  ^ cpm. The compound was stored at -20 °C until 
required.
A sample of the radio-labeled compound (50 ng, 67 pmol, -300,000 cpm) was 
subjected to enzymatic digestion by A. ureafaciens neuraminidase (4 mU) in MES 
buffer (pH 6 , 10 mm^) for 30 mins at 37 °C. The reaction was quenched by addition 
of water (1 cm^) and the mixture was loaded onto a C-18 Spice cartridge. The 
cartridge was eluted with water (10 cm^) and then with MeOH (5 cm^). Scintillation 
fluid (9.5 cm^) was added to an aliquot (0.5 cm^) of each of the elutions and after 
mixing, the radioactivity was measured using a scintillation counter. 98% of the 
radioactivity appeared in the water elutate, whereas a control experiment in which 48 
had been similarly incubated but in the absence of neuraminidase, showed 97% of
101
the radioactivity to be in the MeOH elution. Following a second purification by 
treating with bicarbonate and work-up by Spice cartridge as described above, 99% of 
the radioactivity was found in the MeOH elution.
5.5.4 Typical assay procedures
5.5.4.1 iV-Acetyltransferase assay. [^H-acetyl] CoA (-90,000 cpm) was incubated 
with each of the three cell fractions at pH 5, 6  and 7, with and without amino- 
compound 49 (10 pg). Incubations were conducted for 3 h at 37 °C in a total reaction 
volume of 50 mm^. The reaction was quenched by addition of water (1 cm^) and the 
mixture was loaded onto a C-18 Spice cartridge. The cartridge was eluted with water 
(4 cm^) and then with MeOH-HiO, 3:97 (5 cm^), 1:1 (5 cm^) and finally with MeOH 
(5 cm3). Scintillation fluid (18 cm^) was added to an aliquot (2 cm^) of each of the 
last two elutions and after mixing, the radioactivity was measured using a 
scintillation counter.
5.5.4.2 De-iV-acetylase assay - C-18 cartridge method. A-[^H-Acetyl] compound 
48 (-70,000 cpm) was incubated with each of the three cell fractions or with growth 
medium, each at pH 5, 6  and 7, with or without 1 mM Mg^+, Ca^+ and Zn^+ ions 
added to the assay buffers. Incubations were conducted for 3 h at 37 °C in a total 
reaction volume of 50 mm^. The reaction was quenched by addition of water (1 cm^) 
and the mixtme was loaded onto a C-18 Spice cartridge. The cartridge was eluted 
with NaCl solution (10 cm^; 250 mM) and then with water (5 cm^) and finally with 
either MeOH or acetonitrile (5 cm^). Scintillation fluid (18 cm^) was added to an 
aliquot (2  cm^) of each of the elutions and after mixing, the radioactivity was 
measured using a scintillation counter.
5.5.4.3 De-iV-acetylase assay - “shake and bake” method. TV-[^H-Acetyl]- 
compound 48 (-70,000 cpm) was incubated with each of the three cell fractions or 
with growth medium as for the C-18 cartridge method described above. The reaction 
was quenched by addition of citrate-phosphate buffer pH 3.75 (150 mm^) and 
transferred to a 20 cm^ scintillation vial. “Shake and bake” scintillation fluid (10 
cm^) was added and the samples were shaken well. After allowing the samples to 
settle for 15 mins at room temperature, the amount of free [2-^H] acetic acid was 
measured by scintillation counting. Scintiverse BD (10 cm^) was then added to each 
scintillation vial and after mixing, the total radioactivity was also measured by 
scintillation counting.
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5.5.5 FACS analysis. The FACS analysis was performed by a published procedure.^ 
Briefly, ~1 x 10  ^ trypsinised cells were stained with the primary antibody (R24 for 
GD3 and SGR37 for deNAcGD3), and then washed twice with FACS buffer. The 
cells were then stained with the secondary antibody (fluorescene isothiocyanate- 
conjugated goat anti-mouse IgG). Following washing with FACS buffer, as before, 
the cells were fixed with FACS buffer containing 1% formaldehyde. These cells were 
analysed by flow cytometry as described previously.^
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Chapter 6 
Experimental
6.1 General Methods
6.1.1 Synthetic Procedures. All reagents and solvents were dried prior to use 
according to standard methods. ^  Commercial reagents were otherwise used without 
further purification. Analytical TLC was performed on silica gel 6 O-F254 (Merck or 
Whatman) with detection by fluorescence and/or by chamng following immersion in 
a dilute ethanolic solution of sulfuric acid. Orcinol dipping reagent, prepared by the 
careful addition of conc. sulfuric acid ( 2 0  cm^) to an ice cold solution of 3 ,5 - 
dihydroxytoluene (360 mg) in EtOH (150 cm^) and water (10 cm^), was used for 
deprotected compounds. Flash chromatography was performed with silica gel 60 
(Fluka). Reverse phase chromatography was performed on 15 g C-18 silica gel 100 
(Fluka) eluting with H2O (80 cm^) and then Me0 H-H2 0 , 1:3 (20 cm^), 1:1  (20 cm^), 
3:1 (20 cm3) and finally with MeOH (20 cm^). For smaller scale work C-18 Sep-pak 
cartridges (Waters) were used and eluted with 2 cm  ^of each of the above eluents.
During work-up, organic solutions were washed two or three times with equal 
volumes of each of the aqueous solutions listed. Standard work-up A involved 
washing organic solutions successively with water, saturated NaHCOg solution and 
water; standard work-up B  involved washing organic solutions successively with IM 
HCl solution, saturated NaHCO) solution and water. All such organic solutions were 
then dried over anhydrous Na2S0 4  and concentrated. All concentrations were 
performed in vacuo.
Optical rotations were measured at the sodium D-line and at ambient temperature, 
with an Optical Activity AA-1000 polarimeter. [ajo Values are given in units of lO'  ^
deg cm2 g-i Melting points were measured using a Gallenkamp melting point 
apparatus and are uncorrected. IR spectia were recorded as thin films on NaCl plates 
using a Perkin-Elmer 1710 IRFT spectrometer. Fast atom bombardment (FAB) mass 
spectra were recorded on a Fisons VG Autospec spectrometer using a 3-nitrobenzyl 
alcohol matrix. Electrospray mass spectra (ES-MS) were recorded on a Fisons VG 
Biotech electrospray mass spectrometer. Unless stated otherwise, ^H NMR and ^^ C 
NMR spectra were recorded on a Varian Gemini 2000 spectrometer at 300 MHz and 
75 MHz, respectively. ^H NMR spectra were referenced to the following internal 
standards: CHCI3, ô r 7.26 in CDCI3 ; CD2HOD, Ôr 3.31 in CD3OD; CH3OH, Ôr 
3.43 in D2O. i^C NMR spectra were referenced to the following internal standards: 
CDCI3 , ÔC 76.9 in CDCI3; CD3OD, ôc 49.15 in CD3OD; CH3OH ôc 49.9 in D2O. /-  
values are given in Hz. For di- and tri-saccharides, the monosaccharide residues are 
labeled a, b, c from the reducing terminus. Only partial NMR data are given for some
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compounds; other spectial features were in accord with the proposed structures.
Signals for CF3 were not obseiwed in any of the NMR spectra of compounds
containing the trifluoromethanesulfbnyl group.
6.1.2 Enzymatic Procedures. ^rawi'-Sialidase experiments were conducted using a 
crude E. coli extract ( ~ 6  mg/cm^) of a 70 kDa recombinant construct of the 
Trypanosoma cruzi enzyme.2 Clostridium perfringens a2-3,6 -neuraminidase (EC 
3.2.1.18) was purchased from Sigma. [D-Glucose-l-i'^CJlactose (53 mCi/mmol, 200 
pCi/cm^; 1.96 GBq/mmol; 7.4 MBq/cm^) was from Amersham and was diluted 100- 
fold before use. Liquid scintillation counting was performed using Opti Phase 
‘Hisafe’ 3 scintillation fluid (Fisher). The “glycine stopping buffer” (pH 10) was a 
solution of glycine (4 g), sodium chloride (1.4 g) and sodium carbonate decahydrate 
(1.76 g) in distilled water (200 cm^).
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6.2 Synthetic Procedures
2,3,4,6-Tetra-(?-acetyl-p-D-galactopyranosyl-(1^4)-2,3,6-tri-0-acetyl-a“D- 
glucopyranosyl bromide, 55^ » ^
AcO ^O A c
-O AqOV 
OAc AcO
55
To a suspension of lactose 54 (15.00 g, 43.8 mmol) in acetic anhydride (75 cm^) at 0 
°C under N2 was added hydrogen bromide in acetic acid (15 cm^; 33% w/v solution) 
and the mixture was allowed to warm to room temperature. After stining for 1 h, 
TLC (hexane-EtOAc, 1:1) indicated that the lactose had been fully acetylated. The 
solution was cooled to 0  °C and more hydrogen bromide in acetic acid (75 cm^; 33% 
w/v solution) was added. After a further 2 h stirring at room temperature, the mixture 
was diluted with CH2CI2 (150 cm^) and subjected to standard work-up A. 
Concentration gave a syrup which crystallised on addition of EtOAc to give the 
bromide 55 (28.60 g, 95%), mp 137-138 °C (lit.,^ 138 °C, lit.,^ 145 °C decomp.); 
[a h  +109.6 (c 1.0 in CHCI3) (lit.,3 108.2, lit.,4 108.7); 0 h(CDC13) 1.95-2.20 (7 x 3  
H, 7  s, 7 X AcO), 3.8 (1 H, d, / 3a,4a 9.9, 4a-H), 4.50 (1 H, d, / i b . 2 b  7.7, Ib-H), 4.75 (1 
H, dd, / l a , 2 a  3.8, / 2a,3a 9.9, 2a-H), 4.95 (1 H, dd, / 2b,3b 10.2, / 3b,4b 3.3, 3b-H), 5.15 (1 
H, dd, /% b,2b, ^^ b ,3 b , 2b-H), 5.45 (1 H, d, /3b ,4b>  4b-H), 5.55 (1 H, t, J2a,3a> / 3a,4a» 3a- 
H), 6.50 (1 H, d , / l a , 2 a  4.1, la-H).
Octyl 2,3,4,6-tetra-0-acetyI-P-D-galactopyranosyI-(l-»4)“2,3,6-tri-6>“acetyl-p-D- 
glucopyranoside, 56
AcO ^ O A c  OAc
OAc OAc
56
Method one. A suspension of silver perchlorate (4.96 g, 22 mmol), 4Â molecular 
sieves (10 g), octanol (4.56 cm^, 50 mmol) and dry CH2CI2 (llOcm^) was stirred 
overnight at room temperature in a tin foil covered flask in order to exclude light. 
Silver carbonate (8,27 g, 30 mmol) was added, followed by compound 55 (8.27 g, 
30mmol) and the mixture was stirred at room temperature for 24 h. The mixture was 
then filtered through Celite and aqueous TEA (Icm^; 50% v/v solution) was added to
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the filtrate. After stirring for 2 h, the solution was subjected to standard work-up A. 
Concentration gave a syrup. Flash chromatography (silica gel; hexane-EtOAc, 
3:1->1:1) gave the desired acetylated octyl lactoside 56 as an amorphous mass (8.45 
g, 56%), (Found: C, 54.77; H, 7.26. C32H50O17 requires C, 54.54; H, 7.00%); 
0 h(CDC13) 0.86 (3 H, t , /6 .9 ,  CyHuCi/^), 1.25 (10 H, m, {CH2)s CH3), 1.55 (2 H, 
m, OCH2C//2), 1.94-2.14 (7 X 3 H, 7 s, 7 X AcO), 3.45 (1 H, m, OCH2 ), 4.40, 4.50 (2  
X 1 H, 2 d, /la ,2a ,« /lb ,2b  7.7, 8.0, la-H, Ib-H), 4.86 (1 H, dd, J ia ,2a, / 2a,3a 9.3, 2a-H), 
4.94 (1 H, dd, /2 b ,3 b  10.2, / 3b,4b 3.2, 3b-H), 5.09 (1 H, dd, /ib,2b, -^2b,3b» 2b-H), 5.17 
(1 H, t, .^a,3a, /3a ,4a  9.3, 3a-H), 5.33 (IH, d, u^b,4b 3.3, 4b-H); Ô^CDCls) 14.1, 20.5, 
20.7 (4), 20.9, 22.7, 25.85, 29.3 (2), 29.45 (2), 31.8, 60.9, 62.2, 6 6 .8 , 69.3, 70.3, 70.8,
71.1, 71.9, 72.7, 73.0, 76.5, 100.8, 101.2, 169.35, 169.85, 170.1, 170.3, 170.4, 170.6,
170.7.
AcO /O A c  ^OAc AcO /O A c
AcO- A, - ' ' ^— Ac O'
OAc OAc OAc H 0 _ _  ,
56  67
Method two. A suspension of silver perchlorate (4.96 g, 22 mmol), 4Â molecular 
sieves ( 1 0  g), and diy CH2CI2 (125cm^) was stirred overnight at room temperature in 
a tin foil covered flask in order to exclude light. Octanol was added (4.56 cm^, 50 
mmol) followed by silver carbonate (8.27 g, 30 mmol) and compound 55 (8.27 g, 
30mmol) and the mixture was stirred at room temperature for 24 h. The mixture was 
then filtered through Celite and gave a syrup on concentration. Flash chromatography 
(silica gel; hexane-EtOAc, 3:1->1:1) gave the desired acetylated octyl lactoside 56 as 
an amorphous mass (6.51 g, 43.5%) wliich gave identical analytical data to the
above. Further elution (hexane-EtOAc, 1:2) gave octyl 2,3,4,6-tetra-0-acetyl-J3-Ty-
galactopyranosyl-(l-^)-3,6-di-0-acetyl-a-D~glucopyranoside 67 as a glassy solid 
(3.90 g, 27.5%), (Found: C, 54.16; H, 7.09. C32H50O17 requires C, 54.18; H, 7.13%); 
[a]D +64.4 (c 1 in CHCI3); 0 h(CDC13) 0.86 (3 H, m, CjUuCHs), 1.26 (10 H, m, 
{CH2 ) 5  CH3), 1.55 (2 H, m, OCH2CJ/2) , 1.94-2.14 ( 6  x 3 H, 6  s, 6  x AcO), 4.49 (1 
H, d, /lb,2b 8.0, Ib-H), 4.81 (1 H, dd, /ia,2a 3.8, la-H), 4.93 (1 H, dd, / 2b,3b 10.4, 
^b,4b 3.5, 3b-H), 5.09 (1 H, dd, /ib,2b, ^2h,3h, 2b-H), 5.20 (1 FI, t, / 2 a,3a = «/3 a,4a 9.5, 
3a-H), 5.33 (IH, dd, / 3b,4b» /^b,5b 10, 4b-H). A sample was acetylated using 
pyridine-acetic anhydride and purified by flash chromatography (silica gel; hexane-
EtOAc 1:1) to give octyl 2,3,4,6-tetra-0-acetyl-P-V>-galactopyranosyl-(l->4)-2,3,6-
tri-O-acetyl-a-D-glucopyranoside. The following ^H NMR data are consistent with
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the peracetylated a  lactoside’. ôhCCDCIs) 0.85 (3 H, m, 1.28 (10 H, m,
{CH2 )s CH3), 1.55 (2 H, m, OCR2 CH2 ) , 1.94-2.20 (7 x 3 H, 7 s, 7 x AcO), 4.46 (1 
H, d, / ib , 2b 8.0, Ib-H), 4.74 (1 H, dd, J ia ,2a 3.6, / 2a,3a 10.1, 2a-H), 4.86 (1 H, dd, 
Jih,Zh 10.4, / 3b,4b 3.6, 3b-H), 4.94 (1 H, d, J i a , 2a» la-H), 5.09 (1 H, dd, J i b , 2b, ^b,3b, 
2b-H), 5.32 (IH, br d, V^ b,4b, 4b-H), 5.44 (1 H, t, ^2a,3a, J 3a,4a 10.1, 3a-H).
Octyl p“D-gaIactopyranosyl-(l->4)-p-D-glucopyraiioside, 57
HO / O H
HO- O
OH
O
OH HO)
57
-OOct
OH
A solution of both compound 56 (8.35 g, 11.2 mmol) and sodium metal (100 mg, 4.3 
mmol) in dry MeOH (80 cm^) was stirred for 1 h at room temperature. More MeOH 
(120 cm^) was added to dissolve the resulting precipitate and the solution was 
neutralised with Amberlite IRC-50 (H+) resin (1 g). Filtration and concentration gave 
the fully deprotected compound 57 as an amorphous white solid (5.02 g, 99%); [a]ü -
9.2 (c 1 in MeOH); 0 h[CD3 0 D-D2 0  (1 :1)] 0 .8 6  (3 H, t, J6 .9 , C7H 14C//5), 1.22-1.40 
(10 H, m, (0 7 /2)5 CH3), 1.62 (2 H, m, OCH2C//2) , 4.40, 4.41 (2 x 1 H, 2 d, Jia,2a, 
Jib,2b 7.4, 8.0, la-H, Ib-H); 0 c[CD3 0 D-D2 0  (1:1)] 13.7, 23.0, 26.4, 29.7, 29.9, 30.1,
32.0, 61.3, 61.8, 69.7, 70.3, 71.9, 74.15, 74.2, 75.9, 75.9, 76.5, 80.1, 103.6, 104.5; 
ES-MS (-ve): m/z 453 (M-H)', 489.5 (M+Cl)' (C20H38O11 requires m/z 454).
Octyl 3-d-aIIyI-2,4,6-tri"t>-benzyI-p-D-gaIactopyraiiosyl-(l->4)-2,3,6-tri-0- 
benzyl-p-D-glucopyranoside, 59
57
R O /O R
58 R = H
^Q\—^-^O O ct 
OR
R = Ac
OBn
OOctBnO-OBn OBn59
A suspension of dibutyl tin oxide (1.18 g, 4.7 mmol) and compound 57 (2.10 g, 4.6 
mmol) in MeOH (200cm^) was refluxed for 3.5 h at which point all the suspended
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material had dissolved. The mixture was concentrated to a white amorphous solid 
which was dried in vacuo overnight. The solid was dissolved in dry toluene (20cm^) 
and 4Â molecular sieves (2 g), allyl bromide (6,0 ml, 70.0 mmol) and 
tetrabutylammonium iodide (1.71 g, 4.7 mmol) were added. The mixture was stirred 
at 75 °C for 7 h, cooled to room temperature and concentrated to a yellow solid. The 
solid was suspended in CH2CI2 (10 cm^) and filtered through Celite to remove by­
products. The residue was washed exhaustively with MeOH and the combined 
filtrates were concentrated to a glassy yellow solid (2.64 g) which was used in the 
next step without further purification.
A small sample (25 mg) of this crude product was purified by flash chromatography 
(silica gel; MeOH-CH2Cl2, 1:4) to give octyl 3-0-allyl-j3-'D-galactopyranosyl-
(1 -^)-j3-D-glucopyranoside 58 as an amorphous solid; ôh(CDC13) 0.80 (3 H, t, J
6.9, C7H 14M6), 1.20 ( 1 0  H, m, (0 7 /2)5 CH3), 1.55 ( 2  H, m, OCH2C//2) 4.25, 4.40 (2 
X 1 H, 2 d, J ia ,2a, J ib ,2b 7.4, 7.7, la-H, Ib-H), 5.15 (1 H, d, 10.4, 3-H allyl), 5.25 
(1 H, dd, Jge,n  1.4, Jtrans 17.3, 3'-H allyl), 5.85 (1  H, m, 2-H allyl); ôdCDC^) 13.8,
22.4, 25.65, 26.0, 29.2, 29.4, 31.6, 61.4, 61.8, 6 6 .6 , 69.7, 70.3, 70.9, 73.0, 74.4, 74.6, 
74.95, 79.8, 80.3, 102.6, 103.45, 118.0, 134.4. The sample was acetylated using 
pyridine-acetic anhydride and purified by flash chromatography (silica gel; hexane-
EtOAc 1:1) to give octyl 2,4,6-tri-0-acetyl-3-0-allyl-/3-D-galactopyranosyl-(l—>4)-
2,3,6-tri-O-acetyl-^Ti-glucopyranoside as a syrup, (Found: C, 56.56; H, 7.33. 
C35H54O17 requires C, 56.29; H, 7.29%); [a]o+5.1 (c 1 .0  in CHCI3); v^ax/cm-l 3060 
(C=C-70, 2930, 2855 (CH2 , CH3), 1750 (0 =0 ), 1225, 1055 (C-O); 0 h(CDC13) 0 .8 6  
(3 H, t, J  6.9, C7H14C7 /5), 1.22-1.32 (10 H, m, (0 7 /5)5 OH3), 1.54 (2 H, m, 
OCH20^2), 2.00-2.13 ( 6  X 3 H, 6  s, 6  X AcO), 4.38, 4.44 (2 x 1 H, 2 d, Jia,2ayib,2b
8.0, 7.7, la-H, Ib-H) 4.87 (1 H, dd, Jia,2a, ^a,3a 9.6, 2a-H), 4.98 (1 H, dd. Jib,2b, 
72b,3b 9.9, 2b-H) 5.15 (1 H, d, Jgem 1.6, Jds 10.7, 3-H allyl), 5.18 (1 H, br t, J2a,3a, 
7 3 a,4a 9.3, 3a-H), 5.21 (1 H, dd, Jgem 1.6, Jtrans 17.3, 3 -H allyl), 5.36 (IH, d, 73b,4b
3.3, 4b-H), 5.66-5.81 (1 H, m, 2-H allyl).
To a solution of the crude compound 58 in DMF (50 cm^) at 0 °0 was added sodium 
hydride (60% dispersion in oil; 1.80 g, 45 mmol) in portions and the mixture stirred 
at 0 °0 for 1.5 h. Benzyl bromide (3.53 cm^, 30 mmol) was added dropwise and the 
mixture was stirred for a further 2 h. After careful addition of MeOH (5 cm^) and 
concentration, the residue was paititioned between diethyl ether and water, the 
aqueous phase being extracted twice with diethyl ether before washing the combined 
organic extracts with saturated NaCl solution, drying and concentration to an orange
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oil. Flash chromatography (silica gel; hexane-EtOAc, 6 :1-^4:1) gave compound 59 
as a colourless syrup (2.50 g, 52%); [a]o +4.0 (c 0.75 in CHCI3); Vmax/cm-i 2920, 
2840 (CH2, CH3), 1090 (C-O), 730, 695 (Ar-H); 0 h(CDC13) 0.87 (3 H, m, 
C7H14C//3), 1.22-1.42 ( 1 0  H, m, (0 7 /2)5 CH3), 1.62 (2  H, m, OCH2C//2) 4.15 (2  H, 
m, 1-H allyl), 4.20-5.02 (12x 1 H, 12 AB d, 6  x OC/ZzPh), 4.36, 4.43 (2 x 1 H, 2 d, 
Jia,2a, Jib,2b 8.0, 7.4, la-H, Ib-H) 5.17 (1 H, m, 3-H allyl), 5.31 (1 H, m, 3'-H allyl), 
5.85-5.99 (1 H, m, 2-H allyl), 7.10-7.40 (30 H, m, Ar-H); 0 c(CDCl3) 13.9, 22.5,
26.0, 29.1, 29.2, 29.6, 31.65, 68.0, 68.3, 69.9, 71.4, 72.85, 72.9, 73.3 (2), 73.4, 74.5,
74.8, 75.1 (2 ), 75.2, 79.8, 81.7, 82.3, 82.9, 127.0-128.31 (Ar C), 102.7, 103.55,
116.3, 135.0, 138.1, 138.5, 138.8, 138.9, 139.1, 139.2.
Octyl 2,4,6-tri-0-benzyl-p-D-galactopyranosyl-(l->4)-2,3,6-tri-0-benzyI-p-D- 
glucopyranoside, 60
BnO /O B n  OBn
OBn OBn60
A suspension of compound 59 (1.90 g, 1.8 mmol) and cyclooctadiene- 
bis(methyldiphenylphosphine)iridium (I) hexafluorophosphate in freshly distilled 
oxygen-free THF, was placed under dry N% in a flask sealed with a septum. The red 
mixture was degassed by evacuating the flask and refilling it with dry N% three times. 
The flask was evacuated once more and this time filled with H2 . Within 3 seconds 
the red suspension had become a colourless solution which was stirred for a further 5 
minutes before degassing as before and leaving the mixture to stir at room 
temperature overnight under N2 . ^H NMR of a small portion of the reaction mixture 
showed the isomérisation to be complete [0 h(CDC13) 6.15 (IH, m, H^CCH^CH-O- 
)]. The mixture was concentrated to a syrup and taken up in CH2CI2 (10 cm^), to 
which was added aqueous TFA (2 cm^; 50% v/v solution) and the mixture was 
stirred at room temperature for 1 h. The organic layer was subjected to standard 
work-up A, before concentration to a syrup. Flash chromatography (silica gel; 
hexane-EtOAc, 4:1-^3:1) gave the desired mono alcohol 60 as a colourless syrup 
(1.06 g, 53%), (Found: C, 74.92; H, 7.98. C62H74OU requires C, 74.82; H, 7.49%); 
[a]D +1.1 (c 0.47 in CHCI3); Vmax/cm-i 3090 (0 -H), 2925, 2860 (CH2, CH3), 1090 
(C-O), 730, 700 (Ar-H); 0 h(CDC13) 0.88 (3 H, m, C7H14C7 /3), 1.20-1.40 (10 H, m, 
(C7/2)5 CH3), 1.65 ( 2  H, m, OCH2C//2), 4.26-5.06 (1 2 x 1 H, 1 2  AB d, 6  x OC/Z^Ph), 
4.39, 4.44 (2 X 1 H, 2 d, J i a , 2a, J i b , 2b ~7.7, ~9, la-H, Ib-H), 7.00-7.30 (30 H, m, Ar- 
H).
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Octyl 2,4,6-tri“0-benzyl-3-0-trifluoromethanesulfonyl-P-D-galactopyranosyl- 
(1 -»4)-2,3,6-tri-0-benzyl-P“D-glucopyranoside, 61
BnO ^ O B n  OBn
OBn OBn
61
To a solution of compound 60 (492 mg, 494 p,mol) and pyridine (6 8  mm^, 840 pmol) 
in CH2CI2 (5 cm^) at 0 °C was added dropwise a dichloromethane solution (0.5 cm^) 
of trifluoromethanesulfonic anhydride (116 mm^, 692 pmol). The mixture was 
allowed to warm to room temperature, and after stirring for 30 min it was diluted 
with CH2CI2 (25 cm3) and subjected to standard work-up A, before concentration to 
a syrup. Flash chromatography (silica gel; hexane-EtOAc, 6:1) gave the desired 
triflate 61 as a colourless syrup (476 mg, 8 6 %), (Found: C, 67.61; H, 6 .8 6 . 
C63H73F3O13S requires C, 67.12; H, 6.53%); [a]o+0.9 (c 1.25 in CHCI3); v^ax/cm-  ^
2930, 2865 (CH2, CH3), 1415, 1210 (SO2-O), 1155 (-SO2-), 1090 (C-O), 735, 700 
(Ar-H); 5 h(CDC13) (assignments by COSY) 0.90 (3 H, m, C7H 14C//J), 1.20-1.45 (10 
H, m, (C//2)5 CH3), 1.64 (2 H, m, OCH2C//2) , 3.40 (1 H, dd, Jia,2a 7.6 J 2a,3a 9.4, 2a- 
H), 3.50 (1 H, t, J 2a,3a, Jsa,4a 9.4, 3a-H), 3.80 (1 H, dd, Jib,2b 7.6, J 2b,3b 10.0, 2b-H),
4.04 (IH, br d, V3b,4b 2.9, 4b-H) 4.27-4.95 (12x 1 H, 12 AB d, 6  x OCi/iPh), 4.35 (1 
H, d, Jia,2a, la-H), 4.36 (1 H, d. Jib,2b, Ib-H), 4.66 (1 H, m, 3b-H), 7.05-7.40 (30 H, 
m, Ar-H).
Octyl 3-(9-acetyl-2,4,6-tri-(9-beiizyl-p-D-gulopyranosyl-(l-»4)-2,3,6-tri-0-benzyl- 
p-D-glucopyranoside, 70
OBnBnO ^O B n
OOct + -OOct
OAc—  r, —  ' OBn
70 71
A mixture of compound 61 (33 mg, 29.3 pmol), tetrabutylammonium acetate (44 mg 
146 pmol), 4Â molecular sieves (10 mg) and DMF (0.3 cm^) were stirred at room 
temperature for 24 h. The mixture was diluted with diethyl ether (50 cm^), filtered 
through Celite and the filtrate was washed with water before drying and 
concentration to give a syrup. Flash chromatography (silica gel; hexane-EtOAc, 4:1) 
gave two products: the first compound eluted was the 3b,4b elimination product.
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octyl 2,4,6-tri-0-benzyl~3-deoxy~j3-'D-Qrythxo~hex-3-enopyranosyl-(l ->4)-2,3,6-tri-O- 
benzyl~f3-D~glucopyranoside, 71 (i?f 0.36) as a waxy white solid (15 mg, 52%); 
Vrnax/cm-i 2925, 2857 (CH2, CH3), 1664 (C-C-OR), 1091 (C-O), 797 (C=C-J7) 731, 
696 (Ar-H); ôcCCDCls) 13.9 (CyHi^m), 95.3 (3b-C), 101.8, 103.5 (la-C, Ib-C),
154.4 (4b-C); the second compound eluted was the inversion product, octyl 3-0-
acetyl-2,4,6-tri-0-benzyl-j3-D-gulopyranosyl-(I -^ ) -2 ,3,6-tri-0-benzyl-/3-D~ 
glucopyranoside, 70 (Rf 0.23) as a colourless syrup (12 mg, 39%); ôh(CDC13) 4.20-
5.02 (12x 1 H, 12 AB d, 6  X 0 % P h ) , 4.38 (1 H, d, Jia,2a, 7.4, la-H), 4.96 (1 H, d, 
Jib,2b 7.5, Ib-H), 5.47 (1 H, m, 3b-H), 7.00-7.45 (30 H, m, Ar-H). Compound 70 was 
deacetylated in a manner analogous to the preparation of compound 57 and gave an 
identical NMR spectrum to compound 62 ôh(CDC13) 4.20-5.02 ( 1 2 x 1 H, 12 AB 
d, 6  X OCÆ^Ph), 4.39 (1 H, d, Jia,2a, 7.9, la-H), 4.85 (1 H, d, Jib,2b 8.0, Ib-H)
Octyl 2,4,6-tri-(7-benzyl-(3-D-gulopyranosyI“(l-»4)“2,3,6-tri-0-benzyI-P-D- 
glucopyranoside, 62
B nO ^O B n oBn
OI_l OBn OBn
62
A mixture of compound 61 (0.441 g, 0.4 mmol), 4Â molecular sieves (0.10 g), 
tetrabutylammonium nitrite (2.26 g, 7.8 mmol) and toluene (4.5 cm^) were stirred for 
24 h at room temperature. The mixture was diluted with diethyl ether (150 cm^), 
filtered and washed with water before diying and evaporation to a syrup. Flash 
chromatography (silica gel; hexane-EtOAc, 3:1) gave the inverted alcohol 62 as a 
colourless syrup (0.25 g, 64%); [a]o -10.4 (c 0.85 in CHCI3); Vmax/cm-i 3470 (0-H), 
2925, 2865 (CH2, CH3), 1100 (C-O), 740, 705 (Ar-H); 0 h(CDC13) 4.20-5.02 (1 2 x 1 
H, 12 AB d, 6  X OCTf^Ph), 4.39 (1 H, d, Jia,2a. 7.9, la-H), 4.85 (1 H, d. Jib,2b 8.0, Ib- 
H), 7.10-7.45 (30 H, m, Ar-H); dc(CDCh) 13.9, 22.5, 26.0, 29.1, 29.3, 29.6, 31.7,
65.7, 67.75, 67.95, 68.7, 70.0, 71.5, 72.8, 73.0, 73.1, 73.2, 74.8, 75.1 (2), 75.4, 76.9,
81.8, 82.9, 99.7,103.5,127.1-139.2 (Ar C).
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Octyl 2,4,6-tri-0-benzyl-3-0-trifluorometlianesulfonyl-p-D-gulopyranosyI- 
(1 —>4)-2,3,6-tri-O-b enzyl- p -D-giucopyranoside, 63
BnO ^ O B n  OBn
Q-p|: OBn OBn
63
Compound 62 (28 mg, 28 p,mol) was treated in a manner analogous to the 
preparation of compound 61. TLC (hexane-EtOAc, 4:1) showed the reaction to be 
complete after 1 h at room temperature. The reaction was worked-up as described 
previously to give the triflate 63 as a colourless syrup (29 mg, 92%), (Found: C, 
67.33; H, 6.95. C63H73F3O13S requires C, 67.12; H, 6.53%); [ajo -11.0 (c 1.20 in 
CHCI3); Vrnax/cm-i 2935, 2865 (CH2, CH3), 1410, 1205 (SO2-O), 1135 (-SO2-), 1090 
(C-O), 735, 700 (Ar-H); 6 h(CDC13) (assignments by COSY) 0.90 (3 H, m, 
C7H14C7/5), 1.20-1.45 (10 H, m, {CHi) 5  CH3), 1.64 (2 H, m, OCH2C/72), 3.40 (1 H, 
dd, Jia ,2a  7.8 J]2a,3a 9.2, 2a-H), 3.50 (1 H, m, OCJfz) 3.53 (1 H, t, J2a,3a, J3a,4a 9.2, 3a- 
H), 3.64 (1 H, dd. Jib,2b 8.0, J 2b,3b 3.3, 2b-H), 3.94 (1 H, m, OCH2) 4.23-4.93 (12 x 1 
H, 12 AB d, 6  X 0 CJf2Ph), 4.36 (1 H, d, Jia,2a, la-H), 4.86 (1 H, d, Jib,2b, Ib-H),
5.01 (1 H, t, J 2b,3bs J 3b,4b 3.3, 3b-H) 7.10-7.40 (30 H, m, Ar-H).
2,3,4,6-Tetra-O-acetyl-a-D-galactopyranosyl bromide, 76^
AcO  
A cO —
Aco'r
7 6
Iodine (0.25 g, 0.98 mmol) was added to a suspension of D-galactose, 75 (4.90 g,
27.2 mmol) in acetic anhydride (25 cm^) and the mixture was stirred at room 
temperature overnight at which point all of the suspended material had dissolved. 
The solution was diluted with CH2CI2 (150 cm^) and washed with saturated Na2S2 0 4  
solution and with saturated Na2C0 3  solution before drying and concentration to a 
slightly brown syrup. The syrup was dissolved in CH2CI2 (200 cm^), cooled to 0 °C 
and hydrogen bromide in acetic acid (45 cm^; 45% w/v solution) was added 
drop wise. After stirring for 3 h the solution was poured into iced NaCl solution, the 
organic layer was separated and subjected to standard work-up A. Concentration 
gave a syrap which was crystallised from diethyl ether-hexane to give the bromide
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76 as needles (10.40 g, 93%), mp 82-83 °C (lit.,5 84-85 °C); 5 h(CDC13) 1.99, 2.04,
2.09, 2.13 (4 X 3 H, 4 s, 4 X AcO), 4.12 (2 H, m, 6 -H, 6 '-H), 4.47 (1 H, br t, Js ,6 = 
J 5,6 ' 6.3, 5-H), 5.02 (1 H, dd, J i ,2 3.8, J ^,3 10.4, 2-H), 5.39 (1 H, dd, ^3,4 3.3, 3- 
H), 5.51 (1 H, dd, J 3,4 , J 4,5 1.4, 4-H), 6 .6 8  (1 H, d, Ji,2, 1-H).
2-(TrimethyIsilyl)ethyl 2 ,3 ,456-tetra-O-acetyl-p-D-galactopyranoside, 77^
AcO
-QAcO -Y .- .y V 'O SE
GAc
77
Method one. A mixture of compound 76 (10.40 g, 25.3 mmol), 2- 
(trimethylsilyl)ethanol (9.06 cm^, 63.2 mmol), 4Â molecular sieves (26 g), and dry 
toluene (170 cm^) was stirred for 30 min at room temperature in a tin foil covered 
flask in order to exclude light. Silver carbonate (6.98 g, 25.3 mmol) was added and 
the mixture stiired as before overnight. TLC (CH2Cl2-acetone, 97:3) showed there 
was some donor remaining, so more silver carbonate, (1.75 g, 6.3 mmol) was added 
and the mixture was stirred for a further 3 h. The mixture was filtered through Celite 
and concentrated to a slightly coloured oil. Flash clrromatography (silica gel; 
CH2Cl2-acetone, 97:3) gave the acetylated galactoside 77 as colourless syrup (8.38 
g, 74%); aH(CDCl3, lit.,6) 0.01 (9 H, s, SiMgs), 0.96 (2 H, m, OCHzCTf^Si), 1.98, 
2.05, 2.05, 2.15 (4 x 3 H, 4 s, 4 x AcO), 3.56 (1 H, m, 0 CJ^CH2Si), 3.90 (1 H, td, 
J 4,5 1.0, = J 5.6 ' 6 .8 , 5-H), 3.99 (1 H, m, OCi72CH2Si), 4.12, 4.20 (2 x 1 H, 2 dd,
Js,6 6.9, Js,6' 6 .6 , Jefi- 11.1, 6 -H, 6 '-H), 4.48 (1 H, d, J i ,2 8.0, 1-H), 5.01 (1 H, dd, ^ , 3
10.4, J 3,4 3.6, 3-H), 5.20 (1 H, dd, J i ,2 8.0, J 2,3 10.4, 2-H), 5.38 (1 H, dd, J 3.4 3.3, ^4,5
1.1, 4-H).
Method two. A mixture of DDQ (4.15 g, 18.3 mmol), 2-(trimethylsilyl)ethanol (4.36 
cm^, 30.4 mmol), 4Â molecular sieves (10 g), and dry acetonitrile (50 cm^) were 
stirred for 1.5 h at room temperature before adding compound 76 (5.00 g, 12.2 
mmol) and stirring as before for 30 min. Iodine (4.64 g, 18.3 mmol) was added and 
the mixture stirTed for 50 min. The mixture was diluted with CH2CI2 (400 cm^) and 
washed with dilute Na2S2 0 4  solution, before drying and concentration to an orange 
syrup. Flash chromatography (silica gel; CH2Cl2-acetone, 97:3) gave the acetylated 
galactoside 11 as colomless syrup 93.88 g, 71%). Analytical data were identical to 
the above.
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2-(Trimethylsilyl)ethyl P-D-galactopyranosîde, 78^
H O - è ^ y o S E
OH
78
A solution of both compound 77 (8.38 g, 18.7 mmol) and sodium metal (100 mg, 4.3 
mmol) in dry MeOH (100 cm^) was stirred for 1 h at room temperatme. The solution 
was neutralised with Amberlite IRC-50 (H+) resin (1 g). Filtration and concentration 
gave the fully deprotected compound 78 as an amorphous white solid (5.19 g, 99%); 
0h(D20 , lit.,6) 0.01 (9 H, s, SiMes), 1.00 (2 H, m, O C H i^ S i) ,  3.46 (1 H, dd, J j ,2
8.0, / 2,3 9.9, 2-H), 3.61 (1 H, dd, ^2,3, ^3,4 3.3, 3-H), 3.90 (1 H, br d, ^3,4 , 4-H) 4.02 (1 
H, m, 0 C772CH2Si), 4.38 (1 H, d, Ji,2 , 1-H); 0 c(D2 0 ) -1.8 (3), 18.4, 61.7, 69.2, 69.5,
71.6, 73.8, 75.9, 103.1.
2-(TrimethylsiIyl)ethyI 3,4-O-isopropylidene-P-D-galactopyranoside, 81
OH
81
A solution of compound 78 (5.19 g, 18.5 mmol) and /?-toluenesulfonic acid (80 mg, 
0.4 mmol) in 2,2-dimethoxypropane (100 cm^) was stirred at room temperature for 
22 h. The reaction was quenched with triethylamine (0.5 cm^) and concentrated to a 
syrup which was dissolved in CH2CI2 (100 cm^). Aqueous TFA (0.75 cm^; 50% v/v) 
was added and after stirring for 30 min, the reaction was again quenched with 
triethylamine and washed with NaCl solution before drying and evaporation to a 
crystalline solid. This was recrystallised (EtOAc-hexane) to give compound 81 as 
needles (4.63 g, 78%), mp 89-90 °C (lit.,? 88-89.5 °C); 0h(CDC13) 0.01 (9 H, s, 
SiMg3), 1.00 (2 H, m, OCH2C772Si), 1.34, 1.50 (2 x 3 H, 2 s, CMc2), 4.07 (1 H, dd, 
Ji,3 7.1,73,4 5.8, 3-H), 4.14 (1 H, dd, 73,4, ^4,5 2.2, 4-H) 4.18(1 H, d, 7i,2 8.2, 1-H).
117
2-(TrimethylsiIyl)ethyl 2-0-benzoyl-(3-D-galactopyranoside, 83^
,OTBDMS
81 ► ,O SE
OBz 
82
^-Butyldimethylsilylchloride (2.64 g, 17.6 mmol) was added to a solution of 
compound 81 (4.33 g, 13.5 mmol) in pyridine (50 cm^) at 0 °C. The solution was 
stirred at room temperature for 2  h before cooling again to 0 °C. A dichloromethane 
solution (50% v/v) of benzoyl chloride (2.04 cm^, 17.6 mmol) was added dropwise 
and the mixture stirred at 0 °C for 1 b, before concentration and coevaporation with 
toluene. The residue was taken up in CH2CI2 (200 cm^), subjected to standard work­
up B and concentrated to give a syrup.
A small sample of the syrup (100 mg) was purified by flash chromatography (silica 
gel; bexane-EtOAc 9:1) to give 2~(trimethylsilyl) ethyl 2-0-benzoyl-6-0-t~
butyldimethylsilyl-3,4-0-isopropylidene~p-D-galactopyranoside 82 as needles, mp 
84-85 °C (Found: C, 60.60; H, 8.69. C27H4 6 0 ?Si2 requires C, 60.2; H, 8 .6 %); [ajp 
+1 2 .6  (c 1.40 in CHCI3); v^ax/cm-i 2930, 2855 (CH2, CH3), 1730 (C=0), 1385, 1365 
(Pr', Bu  ^ C-H), 1270, 835, shoulder -865 (Si-C), 1255, 1065 (C-O), 1110 (Si-0), 
775, 715 (Ar-H); 0 h(CDC13) -0.09 (9 H, s, ^\Me^\ 0.10 (6  H, s, SiMg^BuQ, 0.87 (2 
H, m, OCH2C ^ 2Si), 0.91 (9 H, s, SiMe2^w9  1.34, 1.62 (2 x 3 H, 2 s, CMez), 3.50 (1 
H, m, OC772CH2Si), 4.26 (1 H, dd, ^3,4 5.5, ^4,5 16, 4-H) 4.31 (1 H, dd, ^2,3 7.1, ^3,4,
3-H), 4.48 (1 H, d, J i ,2 8.2, 1-H), 5.21 (1 H, dd, Ji,2, ^ , 3, 2-H), 7.39-8.08 (5 H, m, 
Ai-H).
The crude syrup was dissolved in aqueous acetic acid (250 cm^; 80% v/v) and stin*ed 
at 75-80 °C for 1 h. After cooling, the solution was concentrated and co-evaporated 
several times with toluene. Flash chromatography (silica gel; EtOAc) gave 
compound 83 as an amorphous white solid (4.18 g, 80%); ôh(CDC13, lit.,^) -0.10 (9 
H, s, SiMe^), 0.86 (2 H, m, OCH2C7 f2Si), 3.81 (1 H, dd, ^2,3 9.9, ^3,4 3.0, 3-H), 4.14 
(1 H, d, 73,4, 4-H), 4.56 (1 H, d, 7i,2 8.0, 1-H), 5.23 (1 H, dd, 7i,2, 7 ,^3, 2-H), 7.39-
8.10 (5 H, m, ArH).
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2-(Trimethylsilyl)ethyl 2-0-benzoyl-4,6-0-benzylidene-p-D-galactopyranoside, 
848
PhL
OBz
84
A solution of compound 83 (4.03 g, 10.5 mmol), benzaldehyde dimethylacetal (2.36 
cm^, 15.75 mmol) and camphorsulfonic acid (80 mg) in acetonitrile (40 cm^) was 
stirred at room temperature for 20 h. The reaction was quenched with triethylamine 
(0.5 cm3) and concentrated to a syrup which was dissolved in CH2CI2 (250 cm^) and 
washed with NaCl solution before drying and concentration to a syrup which 
crystallised on standing. The crystals were filtered, washed with hexane and dried in 
vacuo, giving compound 84 as needles (4.65 g, 94%), mp 144-146 °C; ôh(CDC13  ^
lit.,8) -0.10 (9 H, s, SiMgg), 0.90 (2 H, m, OCÎÎ2 CH2 SÏ), 2.65 (I H, d, J 3,qh 11.3, 
OH), 3.54 (1 H, br s, 5-H), 3.58 (1 H, m, OC^zCHzSi), 3.89 (1 H, ddd, ^2,3 9.9, ^3,4 
3.8 / 3,oh, 3-H), 4.11 (1 H, dd, 19, Jô,6 ' 12.4, 6 -H), 4.26 (1 H, dd, ^3 4^, 74^5 1.1, 4- 
H), 4.38 (1 H, dd, ^5,6 ' 1.4, Je,6', 6  -H), 4.62 (1 H, d, J i ,2 8.0, 1-H), 5.36 (1 H, dd, 
Ji,2 , J2 ,2 , 2-H), 5.58 (1 H, s, PhCH), 7.30-8.10 (10 H, m, Ar-H).
2-(Trimethylsilyl)ethyl 2-0-benzoyl-4,6-0-benzylidene-p-D-gulopyranoside, 86
84
PhL
OBz
85
Ph 86
O SE
OBzOH
To a solution of compound 84 (1.00 g, 2.11 mmol) and pyridine (0.29 cm^, 3.59 
mmol) in CH2CI2 (10 cm^) at 0 °C was added dropwise a dichloromethane solution 
(1.0 cm^) of trifluoromethanesulfonic anhydride (0.5 cm^, 2.95 mmol). After stiiring 
for 30 min at this temperature, the mixture was diluted with CH2CI2 (90 cm^) and 
subjected to standard work-up A. Concentration and co-evaporation with toluene 
gave 2-(trimethylsilyl) ethyl 2-0-benzoyl-4,6-0-benzylidene-3-0-
trifluoromethanesulfonyl-/3-D-galactopyranoside 85 as a crystalline solid which was
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used in the next step without further purification; ôhCCDCIs) -0.10 (9 H, s, SiMes), 
0.90 (2 H, m, 0C H 2% S i), 3.55 (1 H, m, 0% C H 2S i), 3.57 (1 H, m, 5-H), 4.01 (1 
H, m, OCTfzCHzSi), 4.13 (1 H, dd, 75,6 L6 , 12.6, 6-H), 4.42 (1 H, dd, 7 5 .6 ' 1.4,
76,6-, 6 -H), 4.52 (1 H, dd, 73,4 3.8, 74,5 0.8, 4-H), 4.67 (1 H, d, 7i,2 8.0, 1-H), 5.10 (1 
H, dd, 72,3  10.2, 7 3 ,4 , 3-H), 5.61 (1 H, s, PhCH), 5.72 (1 H, dd, 7%,2 , 7 2 ,3 ,  2-H), 7.30-
8.10 (10 H, m, Ar-H). The crude product and tetrabutylammonium nitrite (1.83 g, 
6.33 mmol) were dissolved in DMF (4.5 cm^) and stirred under nitrogen for 24 h at 
room temperature. The mixture was diluted with CH2CI2 (300 cm^) and washed with 
water before drying and evaporation on to silica (4 g). Flash chromatography (silica 
gel, 40 g; toluene-EtOAc, 6:1) gave the inverted alcohol 86 as white needles (0.65 g, 
65%), mp 145-146 °C (Found: C, 63.40; H, 6.78. C25H32O7 requires C, 63.54; H, 
6.82%); [a]D -40.2 (c 1 in CHCI3); v^Jcm r^  2930, 2900 (CH2, CH3), 1725 (C=0), 
1270, 840 (Si-C), 1065 (C-O), 1120 (Si-0), 740, 715 (Ar-H); 0 h(CDC13) -0.05 (9 H, 
s, SiMe3), 0.91 (2 H, m, OCH2C772Si), 2.35 (1 H, br s, OH), 3.59 (1 H, m, 
OCi72CH2Si), 3.90 (1 H, m, 5-H), 4.06 (1 H, m, OC772CH2Si), 4.08-4.14 (2 H, m, 4- 
H, 6 -H), 4.35-4.42 (2 H, m, 3-H, 6  -H), 5.07 (1 H, d, 7 i ,2 8.5, 1-H), 5.36 (1 H, dd, 
7%,2, 72,3 3.3, 2-H), 5.58 (1 H, s, PhCH), 7.30-8.10 (10 H, m, Ar-H). A small sample 
sample was acetylated using pyridine-acetic anhydride and purified by flash 
chromatography (silica gel; hexane-EtOAc 3:2) to give 2-(trimethylsilyl)ethyl 2-0-
acetyl-2-0-benzoyl-4,6-0-benzylidene-fi-D-gulopyranoside as a colourless syrup; 
0 h(CDC13) -0.05 (9 H, s, 0.90 (2 H, m, OCHzCTT^Si), 2.15 (3 H, s, AcO),
3.60 (1 H, m, OCi72CH2Si), 3.80 (1 H, m, 5-H), 4.02-4.13 (3 H, m, 0 C772CH2Si, 4- 
H, 6 -H), 4.39 (1 H, dd, 7s,6 ' 1.4, 76,6' 12.4, 6  -H), 5.00 (1 H, d, 7%,2 8.5, 1-H), 5.43 (1 
H, dd, 7 i,2, 72,3 3.6, 2-H), 5.56 (1 H, s, PhCH), 5.60 (1 H, t, 7 2 ,3 , ^3,4 3.6, 3-H), 7.30-
8.10 (10 H, m, Ar-H).
2-(Trimethylsilyl)ethyl 3-5'-acetyl-2-0-benzoyI-4,6-0-benzylidene-3-thio-p-D- 
galactopyranoside, 88
86
Ph
OSE
OBzOTf
87
Ph
AcS O SE
OBz
Compound 8 6  (486 mg, 1.03 mmol) was treated in a manner analogous to the 
preparation of compound 85. TLC (hexane-EtOAc, 3:2) showed the reaction to be
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complete after 4.5 h at 0 °C. The reaction was worked-up as described previously to 
give 2-(trimethylsilyl) ethyl 2-0-benzoyl-4,6-0-benzylidene~3-0-
trifluoromethanesulfonyl-fi-D~gulopyranoside 87 as a syrup which was used in 
subsequent reactions without further purification; ÔhCCDCIs) -0.05 (9 H, s, SiMeg), 
0.90 (2 H, m, OCH2% S i) , 3.61 (1 H, m, O ^ C H iS i), 3.88 (1 H, m, 5-H), 4.02 (1 
H, m, OCTfzCHzSi), 4.16 (1 H, dd, 75,6 1.6, Je,6' 12.6, 6-H), 4.30 (1 H, ni, 4-H), 4.42 
(1 H, dd, 7 5 ,6 ' 1.4,76,6-, 6 -H), 5.01 (1 H, d,7j,2 8.5, 1-H), 5.40 (1 H, t, 72,3 = 73,4 3.0,
3-H), 5.50 (1 H, dd, 7i,2, 72,3, 2-H), 5.62 (1 H, s, PhCH), 7.30-8.10 (10 H, m, Ar-H). 
Potassium thioacetate (588 mg, 5.15 mmol) was added to a soultion of the crude 
triflate in DMF (2.5 cm^) and the mixture was stirred for 20 h at room temperature. 
The mixture was diluted with CH2CI2 (50 cm^) and washed with water before drying 
and evaporation. Flash chiomatography (silica gel; hexane-EtOAc, 7:3) gave the 
thioacetate 88 as a glassy solid (433 mg, 82%), mp 124-126 °C; v^ax/cm-^ 2955, 
2860 (CH2, CH3), 1735 (C=0 , ester), 1710 (C=0, thiol ester), 1250, 840 (Si-C), 
1030 (C-O), 1110 (Si-0), 760, 710 (Ar-H); 6 h(CDC13) -0.01 (9 H, s, SiMe3), 0.86 (2 
H, m, 0 CH2CÆ^Si), 2.20 (3 H, s, AcS), 3.55 (1 H, m, 0 C772CH2S1), 3.70 (1 H, m, 5- 
H), 4.02 (1 H, m, 0 C7^ CH2Si), 4.09 (1 H, dd, Js,e 1.6, 76,6' 12.4, 6 -H), 4.14 (1 H, 
dd, 73,4 3.3, 74,5 0.8, 4-H), 4.24 (1 H, dd, 7 2 ,3 1 1 .5 , 7 3 ,4 , 3-H), 4.38 (1 H, dd, 7s,6' 1.4,
76,6-, 6 -H), 4.73 (1 H, d, 7 i,2 7.7, 1-H), 5.44 (1 H, dd, 7 i,2, 7^ ,3, 2-H), 5.50 (1 H, s, 
PhCH), 7.30-8.00 (10 H, m, Ar-H); FAB-MS: m/z 553 (M+Na)\ (Found: [M+Na]^ 
553.1655. C27H3 4 0 ôSSiNa requires m/z 553.1692).
Methyl 5-aeetamido-4,7,8,9-tetra“0-acetyl-2-cbIorO“2,3,5-trideoxy-D-g/j;cero-P- 
D-^«/«ct<?-2-nonulopyranoson ate, 31^
-  «
AcHN-C/ V  'COzMe
TV-Acetyl neuraminic acid, 1 (5.00 g, 16.2 mmol) and Dowex 50WX8-200 (H+) resin 
(17 g) were stirred in dry methanol (500 cm^) at room temperature for 3 h. The 
mixture was filtered and the resin was washed with methanol (5 x 100 cm^). The 
combined extracts were concentrated to an amoiphous white solid which was 
suspended in acetic anhydride (40 cm^) and cooled to 0 °C. Pyridine (35 cm^) was 
added dropwise and the mixture was stined at room temperature for 4 days at which 
point all of the suspended material had dissolved. The mixture was concentrated and 
co-evaporated with toluene before being taken-up in CH2CI2 (250 cm^) and subjected
121
to standard work-up B. Concentration gave per acetate 89 as a glassy solid which was 
freeze-dried from dioxane to give a white powder. The powder was dissolved in 
acetyl chloride (150 cm^), cooled to -20 °C and hydrogen chloride gas was bubbled 
through the solution for 5 min. The flask was stoppered and allowed to giadually 
warm to room temperature without stirring. After 24 h, TLC (elution with EtOAc 3 
times) indicated that the reaction was not complete and so the mixture was cooled as 
before and hydrogen chloride gas was bubbled through the solution for a further 1 0  
min before allowing the solution to return to room temperature. After 24 h the 
mixture was concentrated and co-evaporated with toluene several times to give a 
glassy solid which was freeze-dried from dioxane to give the chloride 31 as a white 
powder (7.48 g, 91%); [a]ü -59.2 {c 1 .0  in CHCI3) (lit.,9 -63); 0 h(CDC13) 1.89 (3 H, 
s, AcN), 2.04-2.11 (4 X 3 H, 4 s, 4 X AcO), 2.26 (1 H, dd, 73ax,3eq 14.0, 73ax,4 1L5, 
3ax-H), 2.77 (1 H, dd, 73ax,3eq, *>^3eq,4 4.7, 3eq-H), 3.87 (3 H, s, C0 2 Me) 4.06 (1 H, 
dd, 78,9 6.0,7 g,9 ' 12.4, 9-H), 4.20 (1 H, q, 74,5 = J^fi — 7s,nh 10.4, 5-H), 4.35 (1 H, dd,
7 5 ,6, 7g,7 1.9, 6 -H), 4.43 (1 H, dd, 7g,9' 2.5, 7 9 ,9 ', 9'-H), 5.16 (1 H, td, 77,8 = J%p 6 .6 , 
7 g,9 ', 8 -H), 5.39 (1 H, m, 4-H), 5.46 (1 H, dd, 76,?, Ty.g, 7-H), 5.66 (1 H, d, 7 5 ,NH, 
NH).
Methyl 5-acetamido-4,7,8,9-tetra-0-acetyl-2-*S'-acetyl-3,5-dicleoxy-2-thio-D- 
^/j;cero-a-D-ga/flcto-2-nonulopyranosoiiate, 35^  ^
COgMe 
A A c  ■
'S A cAcHN
A mixture of potassium thioacetate (4.48 g, 39.2 mmol) and 31 (4.00 g, 7.84 mmol) 
in CH2CI2 (40 cm^) was stirred for 24 h at room temperature. The mixture was 
diluted with CH2CI2 (350 cm^) and washed with water before drying and 
decolourising with charcoal. Flash chromatography (silica gel; CH2Cl2-MeOH, 
100:1->100:3) gave the thioacetate 35 as a glassy solid which was freeze-dried fr'om 
dioxane to give a white powder (3.28 g, 76%),[a]o -12.5 (c 1 in CHCI3) (lit.,^ ® - 
15.6); 0 h(CDC13) 1.87 (4 H, m, AcN, 3^-H), 2.01-2.13 (4 x 3 H, 4 s, 4 x AcO), 2.27 
(3 H, s, AcS), 2.61 (1 H, dd, 73ax,3eq 12.9, 73eq,4 4.7, 3^-H), 3.78 (3 H, s, COzMe)
4.02 (1 H, dd, 7 g,9 6.0, 7 9 ,9- 12.4, 9-H), 4.09 (1 H, q, 74,5 = Js,e ~ 7s,NH 10.4, 5-H), 
4.40 (1 H, dd, 7 8 ,9 ' 2.5,7 9 ,9 ', 9 -H), 4.65 (1 H, dd, 7 5 ,5, Je,i 2.5, 6 -H), 4.90 (1 H, m, 4- 
H), 5.21 (1 H, td, 7 7 ,8, 7g,9 6.0,78,9', 8 -H), 5.35 (1 H, dd, 7g,7, 7 7 ,8, 7-H), 5.65 (1 H, d, 
NH).
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Bis[2“(trimethylsilyl)ethyl 2-0-benzoyl-4,6-0-benzylideiie-3-deoxy-P-D-
galactopyranosid-3-yl] disulfide, 91
88
OBz
90
Ph
OSEi
OBz
A solution of compound 8 8  (30 mg, 58.3 pmol) in dry MeOH (1.2 cm^) was 
degassed by evacuating the flask and refilling it with dry N2 three times. The flask 
was cooled to -40 °C and a solution of sodium methoxide in MeOH (12 mm^, 55.4 
jLimol) was added and stiiTed for 2.5 h at this temperature. The solution was 
neutralised with Amberlite IRC-50 (H+) resin (50 mg). Filtration and concentration 
gave the crude thiol 90; ôh(CD3 0 D) -0.01 (9 H, s, SlMbg), 0.80 (2 H, m, 
OCHiC^Si), 3.35 (1 H, dd, ^ , 3  11.0, A ,4 3.3, 3-H), 3.59 (1 H, m, OCj^CHiSi), 
3.74 (1 H, m, 5-H), 4.02 (1 H, m, OCTTzCHzSi), 4.17 (1 H, dd, J 5.6 16, Jô,6' 12.4, 6 - 
H), 4.24 (1 H, dd, ^3,4 , Ja,s 0.8, 4-H), 4.25 (1 H,dd, 7 5 ,6 ' 1.4,76.6', 6 -H), 4.70 (1 H, d, 
7 i,2 8.0, 1-H), 5.20 (1 H, dd, 7i,2,7^,3 11.0, 2-H), 5.66 (1 H, s, PhCH), 7.30-8.20 (10 
H, m, Ar-H). A solution of the crude thiol in DMF (300 mm^) and diethylamine (150 
mm3) was stiiTed overnight at room temperature, in a flask which was open to the air. 
The mixture was concentrated and redissolved in CH2CI2 (10 cm^) and subjected to 
work-up B. Flash chromatography (silica gel; toluene-EtOAc, 6:1) gave the disulfide 
91 as a glassy solid (26 mg, 91%), [a]o +72.0 (c 0.5 in CHCI3); Vmax/cm-i 2950 
(CH2, CH3), 1730 (C=0), 1260, 835 (Si-C), 1080 (C-O), 710 (Ar-H); 0 h(CDC13) - 
0.01 (9 H, s, SiMa3), 0.80 (2 H, m, 0 CH2CH2Si), 2.89 (1 H, br s, 5-H), 3.10 (1 H, dd,
72,311.5,73,4 3.3, 3-H), 3.45 (1 H, m, OCi72CH2Si), 3.88 (2 H, m, OC772CH2Si, 6 -H), 
4.17 (1 H, d, 7 3 ,4, 4-H), 4.20 (1 H, m, 6  -H), 4.28 (1 H, d, 7 i ,2 7.7, 1-H), 5.29 (1 H, 
dd, 7 i,2, 7 2 ,3, 2-H), 5.47 (1 H, s, PhCH), 7.30-8.20 (10 H, m, Ar-H); Ô^CDCb) -1.7,
17.7, 58.3, 66.5, 68.3, 68.7, 70.1, 74.5, 101.0, 101.4, 126.2 (2), 128.0 (2), 128.5 (2),
128.8, 129.9 (2), 130.2, 133.3, 137.4, 165.0; FAB-MS: m/z 997 (M+Na)+ 
(C50H6 2 0 1282812 requires m/z 974).
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Attempted reaction of 2-(trlmethylsilyl)ethyl 3-5-acetyl-2-0-benzoyl-4,6-t?-
benzylidene-3-thio-P-D-galactopyranoside, 88 and methyl 5-acetamido-4,7,8,9-
tetra~0-acetyl-2-chloro-2,3,5-trideoxy-D-g/j?cer£>-P-D“ga/flcr<?-2- 
nonulopyranosonate, 31
Ph
o? AcO Cl
8 8  ► "COgMe
OBz OAc
92 31
Compound 8 8  (30 mg, 58.3 pmol) was de-5'-acetylated in a manner analogous to the 
preparation of 91. However, instead of neutralising the reaction mixture as before, 
the solution was concentrated to dryness at 0 °C to give the sodium thiolate 92 as an 
amorphous solid. This was used in subsequent steps without further purification.
Method one. Compound 31 (30 mg, 58.8 pmol) was added to a solution of sodium 
thiolate 92 in DMF (0.5 cm^). After stirring the mixture under nitrogen for 2 days at 
room temperature, no foimation of the desired thio-disaccharide was observed. 
However, TLC (hexane-EtOAc, 1:1) indicated that some of the thiolate had oxidised 
to the disulfide.
Method two. A solution of 1,7,10-trioxa-4,13-diazacyclopentadecane (kryptofix 21) 
(4 mg, 12.6 pmol) in THF (50 mm^) was added to a suspension of compound 31 (30 
mg, 58.8 pmol) and the thiolate 92 (58.3 pmol) in freshly distilled oxygen-free THF 
(550 mm^). The mixture was stirred for two days at room temperature under dry N2 . 
TLC (hexane-EtOAc, 1:1) indicated that some of the thiolate had oxidised to the 
disulfide^ however, no formation of the desired thio-disaccharide was observed.
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Attempted reaction of methyl 5-acetamido-4,7,8,9-tetra-6>-acetyl-2-5'-acetyl-3,5> 
dideoxy-2-thio-D-g/jcer£>-a-D-^«/«ct€i-2-nonuIopyranosonate, 35 and 2- 
(trimethylsilyl)ethyl 2-0-benzoyl-4,6-0-benzylidene-3-0-
trifluoromethanesulfonyl“P-D-gulopyranoside, 87
Ph
OAc UU2IVII
"Na
3 5 --------.  ,0A c
AcHN + O SEOBzOTf
87
Method one. A solution of compound 35 (50 mg, 91 pmol) in dry MeOH (2 cm^) 
was degassed by evacuating the flask and refilling it with dry N2 three times. The 
flask was cooled to -40 °C and a solution of sodium methoxide in MeOH (20 mm^, 
87 pmol) was added and stirred for 1 h at this temperature. The solution was 
concentrated to dryness at 0 °C to give the sodium thiolate 2 1  as an amorphous solid. 
A solution of 2-(trimethylsilyl)ethyl 2-0-benzoyl-4,6-0-benzylidene-3-0- 
trifiuoromethanesulfbnyl-P-D-gulopyranoside, 87, (58 mg, 100 pmol), prepared as 
described in the synthesis of 8 8 , and the thiolate in DMF (0.5 cm^) was stirred for 5 
days at room temperature under N2. No formation of the desired thio-disaccharide 
was observed, however, TLC (EtOAc) indicated that the thiolate had degraded.
Ph Ph
COzMe 
/  'S A cAcHN + OSEOBzOTf
87
OSE
OBz 93
Method two. Diethylamine (0.1 cm^) was added dropwise to a stiiTed solution of 2- 
(trimethylsilyl)ethyl 2-0-henzoyl-4,6-0-benzylidene-3-0-trifluoromethanesulfonyl~J3- 
D-gulopyranoside, 87 (50 mg, 83 pmol, prepared as described in the synthesis of 88) 
and compound 35 (30 mg, 55 pmol), in DMF (0.2 cm^) at 0 °C. The reaction mixture 
was allowed to warm to room temperature overnight. The mixture was concentrated 
to a syrup, re-dissolved in EtOAc (10 cm^) and subjected to standard work-up B. No 
formation of the desired thio-disaccharide was observed. However, flash 
chromatography (silica gel; hexane-EtOAc, 4:1) gave 2-(trimethylsilyl)ethyl 2-0-
benzoyl-4,6-0-benzylidene-3-deoxy-j3-D-thi'Qo-hex-2-enopyranoside, 93 as a glassy
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solid (24 mg, 67%), [a]o -31.2 (c 0.25 in CHCI3); Vmax/cm-l 2925 (CH2, CH3), 1735 
(C=0), 1250, 835 (Si-C), 1065 (C-O), 1110 (Si-O), 760, 700 (Ar-H); 8 h(CDC13) - 
0.04 (9 H, s, SOHq), 0.89 (2 H, m, OCHsCHjSi), 3.71 (1 H, br s, 5-H),3.78 (1  H, m, 
OCi/jCHjSi), 3.94 (1 H, m, OC^CHzSi), 4.21 (1 H, dd, /j.e 2.5, /«.e- 12.9, 6 -H), 
4.42-4.49 (2 H, m, 4-H, 6  -H), 5.60 (1 H, s, PhCH), 5.64 (1 H, m, 1-H), 5.96 (1 H, d, 
J 3,4 5.5, 3-H), 7.33-8.11 (10 H, m, Ar-H); SdCDCla) -1.7, 18.0, 65.0, 66.25, 69.4,
69.7, 95.6, 101.0, 114.0, 126.4 (2), 128.2 (2), 128.5 (2), 128.8, 129.0, 130.2 (2),
133.75,137.9, 151.2,164.3.
Attempted reaction of methyl 5-acetamido-4,7,8,9-tetra-0-acetyl-2-A-acetyi-3,S- 
dideoxy-2-thio-D-gfrcero-a-D-g«/acto-2-nonulopyranosonate, 35 and octyl 2,4,6- 
tri-0-benzyl-3-0-trifluoromethanesuifonyl-|3-D-gulopyranosy]-(l->4)-2,3,6-tri-
O-benzyl-P-D-glucopyranoside, 63
AcO, .  CO^Me BnO .O B n  OBn
Q-j-jT OBn OBn
63
DMF/EtzNH
V
BnO /O B n
9 4
Diethylamine (50 mm^) was added dropwise to a stirred solution of triflate 63 (46 
mg, 41 pmol), and thioacetate 35 (15 mg, 27 pmol), in DMF (100 mm^) at 0 °C. The 
reaction mixture was allowed to warm to room temperature overnight. The mixture 
was concentrated to a syrup, re-dissolved in EtOAc (10 cm^) and subjected to 
standard work-up B No formation of the desired thio-trisaccharide was observed. 
However, flash chromatography (silica gel; hexane-EtOAc, 6:1) gave firstly
unreacted triflate (7 mg, 15%) and then octyl 2,4,6-tri-0-benzyl-3-deoxy-p-D-Û\ïQO-
hex-2-enopyranosyl-(l~>4)-236-tri-0-benzyl-J3-D-glucopyranoside 94 as a colourless 
syrup (21 mg, 62% based on triflate consumed); 5h(CDC13) 4.39-5.14 (1 2 x 1 H, 12 
AB d, 6  X OCHfPhf 4.36 (1 H, d, Jia,2a, 8.0, la-H), 5.09 (1 H, d, Jib,2b 8.0, Ib-H), 
5.35 (1 H, m, 3b-H), 7.00-7.45 (30 H, m, Ar-H); FAB-MS: m/z 999 (M+Na)" 
(C62H72O10 requires m/z 976).
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Octyl 2,4,6-tri-0-benzyI-3-0-metlianesulfonyl-P-D-gulopyraiiosyI-(l-»4)-2,3,6~
tri-O-benzyl-P-D-glucopyranoside, 100
BnO ^OBn OBn
OBn
100
A mixture of methanesulfonyl chloride (95 mg, 830 |imol), 62 (80 mg, 83 pmol) and 
pyridine (1 cm^) was stirred at room temperature over night. The mixture was 
concentrated, redissolved in CH2CI2 (10 cm^) and subjected to standard work-up B. 
Flash chromatography (silica gel; hexane-EtOAc, 5:1) gave the mesylate 100 as a 
colourless syrup, (74 mg, 82%), (Found: C, 70.56; H, 7.31%. CesHygOnS requires 
C, 70.50; H, 7.14%); [a h  -8.7 (c 1.1 in CHCI3); 0 h(CDC13) 0.90 (3 H, t, J  6 .8 , 
C7H 14C/73), 1.24-1.46 (10 H, m, (€7 /2)5 CH3), 1 .6 8  (2  H, m, OCH2C//2), 2.82 (3 H, 
s, S0 2 Me), 4.24-4.99 (12 x 1 H, 12 AB d, 6  x O C^Ph), 4.41 (1 H, d, Jia,2a 8.0, la- 
H), 4.92 (1 H, d, Jib,2b 8.0, Ib-H), 5.00 (1 H, m, 3b-H) 7.16-7.40 (30 H, m, Ar-H); 
0c(CDCl3) 13.9, 22.4, 26.0, 29.0, 29.2, 29.6, 31.6, 38.3, 67.4, 68.4, 69.9, 71.5, 73.0, 
73.15, 73.25, 73.5, 74.5, 74.8, 74.9, 75.1, 77.0, 77.2, 81.7, 82.65, 99.6, 103.55,
127.1, 127.3, 127.4, 127.5, 127.6, 127.9, 127.95, 128.0, 128.1, 128.2, 128.4, 128.45,
137.4, 137.6, 138.1, 138.3, 138.6, 139.0.
Octyl 3-0-methanesulfonyI-p-D-guIopyranosyl-(l ^ 4)-p-D-glucopyranoside, 101
HO ^OH OH
OMs^^ 101
A mixture of 100 (70 mg, 65.2 |rmol) and palladium on charcoal (280 mg; 10% w/w) 
in acetic acid (7 cm^) was stirred under an atmosphere of hydrogen for 6  h at room 
temperature. The mixture was filtered through Celite and the filtrate was 
concentrated onto silica (0.5 g). Flash chromatography (silica gel, 2.5g; CH2CI2- 
MeOH, 4:1) gave the title compound 101 as an amorphous solid (31 mg, 89%), 
0h(CD30D) 0.90 (3 H, t, J 6 .8 , C7H 14C//5), 1.23-1.42 (10 H, m, (€7/ 2)5% ) ,  1.62 (2 
H, m, OCR2 CH2 ), 3.18 (3 H, s, S0 2 Me), 4.28 (1 H, d, Jia,2a 8.0, la-H), 4.68 (1 H, d, 
Jib,2b 8.2, Ib-H), 4.81 (1 H, m, 3b-H); ôdCDgOD) 14.5, 23.8, 27.2, 30.5, 30.7, 30.9,
33.1, 38.5, 62.0, 62.2, 68.0, 69.45, 71.1, 74.9, 75.8, 76.5, 76.6, 81.1, 83.1, 102.8,
104.4.
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l,2:5,6-Di-0-isopropylidene-a-D-r/ôo-hexofuranos-3-uïose (hydrate), 103 &
1 0 4 :1
103
0 " - (h o
Ruthenium (IV) oxide hydrate (200 mg, ~1 mmol) was added to a cooled (0 °C), 
vigorously stined mixture of l,2:5,6-di-0~isopropylidene-a-D-glucofuranose 102 
(5.20 g, 20.0 mmol), potassium carbonate (0.66 g, 4.78 mmol) and potassium 
periodate (5.98 g, 26.0 mmol) in CH2CI2 (35 cm^) and H2O (35 cm^). The orange- 
brown mixture was stined for 20 minutes at 0 °C and then allowed to warm to room 
temperature. After 5.5 h, the mixture had turned black, indicating that there was no 
more oxidant remaining. More potassium carbonate (0.36 g, 2.60 mmol) and 
potassium periodate (3.22 g, 14.0 mmol) were added and the mixture became orange- 
brown, as before. After a further 1.5 h, the mixture became a pale yellow colour, 
indicating that there was no substrate remaining. The reaction was quenched with 
wo-propyl alcohol (3 cm^), turning it black. The mixture was filtered and the organic 
and aqueous phases separated. The aqueous extract was washed several times with 
CH2CI2 and the combined organic extracts were dried and concentrated to a syrup 
which partially crystallised on standing as a mixture of the ketone 103 and its hydrate 
104 (4.58g, -80%). The mixture was used in subsequent reactions without further 
purification. The ratio of hydrate to ketone could be varied by dissolving the mixture 
in either aqueous ether or dry acetone to give predominantly the hydrate or the 
ketone, respectively.
Ketone 103: ônCCDCl], lit.,:^) 1.33, (6  H, s, CMe2), 1.43, 1.45 (2 x 3 H, 2 s, CMe2),
4.03 (2 H, m, 4-H, 6 -H), 4.34 (2 H, m, 5-H, 6  -H), 4.39 (1 H, d, J i ,2 4.4, 2-H), 6.14 
(1 H, d, Ji,2, 1-H); 0c(CDCl3) 25.1, 25.8, 26.9, 27.3, 64.1, 76.2, 77.1, 78.8, 103.0,
110.3, 114.2, 209.0.
Hydrate 104: [a]o +36.4 {c 1.0 in H2O) (lit.,:: +4 9 .2 , c 1 in H2O); ôh(CDC13, lit.,:2)
1.35, 1.37, 1.48, 1.57 (4 X 3 H, 4 s, 2 X CMe2), 3.77 (1 H, s, OH), 3.89 (1 H, dd, ^4,5
6 .6 , 4-H) 4.08 (1 H, dd, Jsfi 6.0, ^6,6 ' 8 .8 , 6 -H), 4.14 (1 H, dd, 6.3, 6  -H),
4.20 (1 H, s, OH), 4.26 (1 H, d, / i ,2 3.8, 2-H), 4.45 (1 H, m, 5-H), 5.84 (1 H, d, J i,2,
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1-H); ôc(CDCÏ3) 24.9, 26.3, 26.4, 26.7, 6 6 .6 , 73.9, 78.5, 83.6, 101.0, 104.2, 110.0,
113.2.
3 -0 -Acetyl-l,2 :5 ,6 -di-<?-isopropylidene-a-D-e/j^/i#"<7-hex-3 -enofiiranose, 105^3
105
Triethylamine (45 cm^) was added dropwise to a cooled (0 °C), stirred solution of 
103/104 (4.58 g) in acetic anhydride (45 cm^). The mixture was warmed to room 
temperature and stirred for 5.5 h before concentrating to a syrup. The product 
mixture was redissolved in CH2CI2 and subjected to standard work-up B. 
Decolourising with charcoal and then flash chromatography (silica gel; toluene- 
EtOAc, 9:1) gave the enol acetate 105 as a syrup which became a waxy white solid
in the freezer over several days (3.64 g, 61% from l,2:5,6-di-0-isopropylidene-a-D- 
glucofumnose), [a]o -29.1 (c 1.0 in CHCI3) (lit., 3^ -3 3 ,0 , c 1 in CHCI3); Ôh(CDC13)
1.35, 1.42, 1.44, 1.50 (4 X 3 H, 4  s, 2  X CMc2), 2.18 (3 H, s, AcO), 4.04 (2 H, m, 6 - 
H, 6  -H), 4.65 (1 H, m, 5-H), 5.36 (1 H, d, Jy 2  5.5, 2-H), 6.00 (1 H, d, / i ,2, 1-H); 
8 c(CDCl3) 20.3, 25.4, 25.5, 27.6, 27.65, 65.7, 68.4, 80.7, 103.9, 110.3, 113.3, 128.9,
145.2, 169.0.
3-0-AcetyH,2:5,6-di-(7-isopropylidene-a-D-gulofuraiiose, 106^4
n
O kO A c O °
106
A mixture of 105 (3.45 g, 11.5 mmol) and palladium on charcoal (340 mg; 5% w/w) 
in EtOAc (35 cm^) was stirred under an atmosphere of hydrogen for 12 h at room 
temperature. The mixture was filtered through Celite and the filtrate concentrated to 
give a crystalline solid. Recrystallisation (hexane), gave needles (2.77 g). Flash 
chi'omatography of the filtrate (silica gel; toluene-EtOAc, 5:1-A4:1) gave a further 
portion (360 mg) of the title compound 106 (total yield: 3.13 g, 90%), mp 74 °C 
(lit.,14 73-74 °C); ÔH(CDCl3, lit.,12) 1.34, 1.38, 1.43, 1.57 (4 x 3 H, 4 s, 2  x CMez),
2.12 (3 H, s, AcO), 3.52 (1 H, dd, 7.1, ^6,6 ' 8.2, 6 '-H), 4.09 (2 H, m, 4-H, 6 -H),
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4.61 (1 H, m, 5-H), 4.81 (1 H, dd, J i ,2 3.8, 5.5, 2-H), 5.06 (1 H, dd, J 2.3, ^3,4
6.6, 3-H), 5.81 (1 H, d, /i,2, 1-H).
l,2:5,6-Di-0-isopropylidene-a-D-gulofuranose, 107^ 3
o
X ^OH 0 °
107
A solution of both compound 106 (2.33 g, 7.68 mmol) and sodium methoxide (40 
mg, 0.74 mmol) in dry MeOH (25 cm^) was stirred for 1 h at room temperature. The 
solution was neutralised with Amberlite IRC-50 (H+) resin (0.25 g). Filtration and 
concentration gave compound 107 as a white powder (1.95 g, 98%); [a]o +8.8 (c 1.0 
in CHCI3) (lit.,13 +7.5, c 1 in CHCI3); 0 h(CDC13) 1.33, 1.37, 1.40, 1.58 (4 x 3 H, 4 s, 
2 X CM62), 2.72 (1 H, d, 6.2, OH), 3.66 (1 H, dd, Jsfi- 7.3, Je.ô' 8.8, 6 '-H), 3.86 
(1 H, dd, J 3,4 5.6, J 4,5 8.8, 4-H) 4.18 (1 H, dd, Js,e 6.8, 6-H), 4.21 (1 H, m, 3-H),
4.45 (1 H, m, 5-H), 4.62 (1 H, dd, / i ,2 4.0, ^,3 6.2, 2-H), 5.74 (1 H, d, ^ 1,2 , 1-H).
1,2:5,6-Di-0-isopropylidene-3-0-trifluoromethanesulfonyl-a-D-gulofuraiiose, 
108 %O^& OTf O
108
Compound 107 (2.00 g, 7,68 mmol) was treated in a manner analogous to the 
preparation of compound 85. TLC (hex^e-EtOAc, 3:2) showed the reaction to be 
complete after 1 h at 0 °C. The reaction was worked-up as described previously to 
give the triflate 108 as a crystalline solid which was used in subsequent reactions 
without further purification (2.95 g, 98%); ôh(CDC13) 1.37, 1.43, 1.45, 1.61 (4 x 3 H, 
4 s, 2 X CMc2), 3.65 (1 H, dd, Js,e' 6.3, Jô.ô' 8.8, 6'-H), 4.05 (1 H, dd, ^3,4 5.8, ^4,5
8.8, 4-H) 4.15 (1 H, dd, ^5,6 6.6, 6-H), 4.56 (1 H, m, 5-H), 4.80 (1 H, dd, J i ,2
4.1, /2,3 5.8, 2-H), 5.09 (1 H, t, ^2,3, ^3.4, 3-H), 5.83 (1 H, d, Ji,2, 1-H).
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3-5-Acetyl-1,2:5,6-di-0-isopropylidene-3-tliio-a-D-gaIaetofuranose, 109
AcS^O.
OOV
109
A mixture of 108 (760 mg, 1.94 mmol), potassium thioacetate (434 mg, 3.80 mmol), 
potassium carbonate (1.31 g, 9.5 mmol) and tetrabutylammonium hydrogensulfate 
(645 mg, 1.90 mmol) in a mixture of EtOAc (8  cm^) and HgO (8  cm^) was 
vigorously stirred for 2 h at room temperature. The mixture was diluted with EtOAc 
(50 cm^) and washed with water before drying and concentration to give a syrup. 
Flash chromatography (silica gel; hexane-EtOAc, 8:2) gave the thioacetate 109 as a 
glassy solid which was ffeeze-dried from dioxane to give a white powder (524 mg, 
85%), [a]D -3.4 (c 1 in CHCI3); v^ax/cm-i 2985, 2935 (CH2, CH3), 1700 (0=0), 
1375 (Pr^ C-H), 1065 (C-O); 0 h(CDC13) 1.33, 1.38, 1.43, 1.60 (4 x 3 H, 4 s, 2  x 
CMez), 2.36, (3 H, s, AcS), 3.69 (1 H, dd, ^2,3 16, ^3,4 4.7, 3-H), 3.84 (1 H, dd, ^5,6 '
6 .6 , .7(5 (5' 8.5, 6  -H), 3.98 (1 H, dd, ^3  4 , 74  5 7.1, 4-H) 4.07 (1 H, dd, 75 g 6 .6 , 6 -
H), 4.41 (1 H, m, 5-H), 4.61 (1 H, dd, J i ,2 3.8, 7%,3, 2-H), 5.91 (1 H, d, 7%,2 , 1-H); 
FAB-MS: m/z 341 (M+Na)^ (C14H22O6S requires m/z 318).
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Attempted reaction of 3-.9-aeetyl-l,2:5,6-dl-0-isopropylidene-3-thio-a-D- 
galactofuranose, 109 and methyl 5-acetamido-4,7,8,9-tetra-0-acetyl-2-chloro- 
2,3,5“trideoxy-D-^/ycer<?-P-D-^a/flcto-2-nonuIopyranosonate, 31
OAc
AcO
AcHN
AcO
109
110
OAc
AcO^ P ^ 0 - ^ C 0 2 Me
AcHN
Diethylamine (0.3 cm^) was added dropwise to a stirred solution of glycosyl chloride 
31 ( 8 6  mg, 0.17 mmol) and thioacetate 109 (70 mg, 0.22 mmol), in DMF (0.6 cm^) 
at 0 °C. The reaction mixture was allowed to warm to room temperature overnight. 
The mixture was concentrated to a syrup, re-dissolved in EtOAc (10 cm^) and 
subjected to standard work-up B. No formation of the desired thio-disaccharide was 
observed. However, flash chromatography (silica gel; hexane-EtOAc, 7:3) gave
bis[3-deoxy-l,2:5,6-di-0-isopropylidene-a-D-galactofuranos-3-ylJ disulfide^ 110 as 
a glassy solid (50 mg, 83%), (Found: C, 52.86; H, 7.14, C24H38O10S2 requires C, 
52.35; H, 6.96%); [a]D-96.4 (c 1.025 in CHCI3); 8 H(CDCl3) 1.34, 1.36, 1.44, 1.56 (4 
X 6  H, 4  s, 4 X CMe2), 3.34 (2 H, dd, ^2,3 2.2, ^3,4 5.8, 3-H), 3.87 (4 H, m, 4-H, 6  -H) 
4.06 (2 H, dd, Jsfi 6.9, 8.5, 6 -H), 4.40 (2 H, m, 5-H), 4.77 (2 H, dd, J i ,2 3.8, ^2,3
2.2, 2-H), 5.84 (2 H, d, / i ,2, 1-H); 8 c(CDCl3) 25.1, 26.25, 26.6, 27.25, 54.1, 65.6,
75.4, 83.9, 86.7, 105.3, 110.1, 114.0; FAB-MS: m/z 573 (M+Na)\
Further elution (EtOAc) gave methyl 5-acetamido-4,7,8,9-tetra~0-acetyl-2,6- 
anhydro-3,5-dideoxy-D-g\yccro-a-D-g2i\diC\.o-non-2-enopyranosonate 33; Ôh(CDC13) 
1.93 (3 H, s, AcN), 2.05, 2.06, 2.07, 2.12 (4 x 3 H, 4 s, 4 x AcO), 3.80 (3 H, s, 
C0 2 Me) 4.19 (1 H, dd, 7.1, 12.3, 9-H), 4.38 (2 H, m, 5-H, 6 -H), 4.58 (1 H,
dd, 3.2, 9 -H), 5.21 (1 H, dd, 4.4, Jg 9, J^p', 8 -H), 5.50 (2 H, m, 4-H, 7-
H), 5.81 (1 H, d, J 5.NH 8.3, NH), 6.01 (1 H, d, ^3,4 3.3, 3-H).
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»Ç-(Methyl 5-acetamido-4,7,8,9-tetra~0"acetyl-3,5-dideoxy-D-^();cew-a-D-g^«/«c^<?-
2-nonulopyranosylonate)"(2->3)-l,2:5,6-di-0-isopropylideiie-3-thio-a-D- 
galactofuranose, 111
° % A c  Ç °2Me
'O-T^S^O.AcHN
Diethylamine (12.5 cm^) was added dropwise to a stirred solution of triflate 108 
(2.27 g, 5.80 mmol) and thioacetate 35 (2.44 g, 4.44 mmol), in DMF (25 cm^) at 0 
°C. The reaction mixture was allowed to warm to room temperature overnight. The 
mixture was concentrated to a symp, re-dissolved in EtOAc (250 cm^) and subjected 
to standard work-up B before evaporating the residue onto silica (5 g). Flash 
chromatography (silica gel, 50 g; hexane-EtOAc, 7:3) gave firstly bis[3-deoxy-
},2:5,6-di-0-isopropylidene-a-D-galactofuranos-3-ylJ disulfide 110 (63 mg) and 
then the unreacted triflate 108 (313 mg). Further elution (EtOAc) gave the desired 
thio-disaccharide 1 1 1  as an amorphous solid (2.26 g, 6 8 %) contaminated with the 
2,3-dehydro-sialic acid 33 (-5% by NMR). The product was used in subsequent 
reactions without further purification, but an analytical sample was obtained by gel 
permeation chromatography (Sephadex LH-20; MeOH), (Found: C, 50.92; H, 6.25, 
N, 1.74. C32H47NO17S requires C, 51.26; H, 6.32, N, 1.87%); [a h  -5.0 (c 1 in 
CHCI3); Vmax/cm-l 2990 (CH2 , CH3), 1740 (0 =0 , ester), 1660, 1540 (0=0, amide), 
1065 (0-0); 0 h(0 D0 1 3) 1.30, 1.34, 1.40, 1.56 (4 x 3 H, 4 s, 2 x 0 Me2), 1.87 (3 H, s, 
AcN), 1.99, 2.00, 2.05, 2.10 (4 x 3 H, 4  s, 4  x AcO), 2.76 (1 H, dd, V3bax,3beq 12.5, 
^beq,4b 4.7, 3bgq-H), 3.56 (1 H, m, 3a-H), 3.59 (1 H, dd, Jsafia 6 .6 , Jea,6a 8.5, 6 a'-H), 
3.74-3.83 (5 H, m, 4a-H, 6 b-H, 0 0 2 Me), 3.94 (1 H, q, / 4b,5b ”  -/sb,6b ~ ■/sb.NH 10.2, 
5b-H), 4.06-4.14 (2 H, m, 6 a'-H, 9b-H), 4.23 (1 H, dd, 2.5, 12.6, 9b'-
H), 4.43 (1 H, m, 5a-H), 4.76 (1 H, dd, A  a,2a 3.6, / 2 a,3a 0.8, 2a-H), 4.91 (1 H, m, 4b- 
H), 5.29 (1 H, dd, J 6b,7b 1.6, / 7b,8b 9.3, 7b-H), 5.34 (1 H, d, Jsb.NH, NH), 5.58 (1 H, 
m, 8b-H), 5.82 (1 H, d, /ia,2a» la-H); FAB-MS: m/z 772 (M+Na)"" (O32H47NO17S 
requires m/z 749).
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5'-(Methyl 5-acetamido-4,7,8,9-tetra-0-acetyl-3,5-dideoxy-D-g/j;cer<?“a-D-gfl/flcto- 
2-nonulopyranosylonate)-(2-^3)-3-thio-D-galactose, 112
ACO . JL PAC A C O . J  PAC
AcHN'^z
Compound 111 (400 mg, 533 p,mol) was dissolved in aqueous trifluoroacetic acid (4 
cm3; 90% v/v) and stirred at room temperature for 15 mins. The solution was 
concentrated and co-evaporated several times with toluene. Flash chromatography 
(silica gel; EtOAc then MeOH) gave compound 112, which was freeze dried from 
water as an o/p mixture of both furanose and pyranose isomers (251 mg, 70%); [a]o 
+51.0 (c 1 eqm. in MeOH); v^Jcrn-^ 3375 (OH, NH br), 2925, 2853 (CH2 , CH3), 
1735 (C=0, ester), 1660, 1560 (C=0, amide), 1065 (C-O); ÔH(pyridine-d5) 5.64 (d, 
A ,2 4.4, la-H a-pyi7fur), 5.69 (d, A ,2 7.4, la-H p-pyr), 5.88 (d, A ,2 4.4, la-H a- 
pyr/fur), 5.90 (s, la-H P-fur); FAB-MS: m/z 692 (M+Na)\ (Found: [M+Na]^ 
692.1841. C2ôH3 9 0 i7SNa requires m/z 692.1836).
*S-(Methyl 5-acetamido-4,7,8,9-tetra-0-acetyl-3,5-dideoxy-D-g(pcer<?“a-D-ga/«cr£?-
2-nonulopyranosylonate)-(2-+3)-l,2,4,6-tetra-0-acetyl-3-thio-a/p-D-
galactopyranose, -(2-^3)-l,2,5,6-tetra-(?“acetyI-3-thio-a/p-D-galactofuranose, 
l l3 p /f
A C O ^TPA C  CO,MeOAcoAc A c O ^ p A c  f
A c H N ^ / 7 ^  +  AcH N ^ .^ ^ 7 ^  / S  > - O A c
AcO GAcOAc AcO y— (  \
113p /f AcO 'PA c OAc
112 (100 mg, 149 pmol) was dissolved in a mixture of pyridine (1.0 cm^) and acetic 
anhydride (1.0 cm^) and stirred at room temperature overnight. The mixture was 
concentrated to an oil and flash chromatography (silica gel; CH2Cl2-acetone, 
9:1->3:1) gave the peracetate l l ^ p / f  (107 mg, 8 6 %) as an a/p mixture in both 
pyranose and furanose ring forms 20:60:10:10), (Found: C, 48.65;
H, 5.74, N, 1.62. C34H47NO21S requires C, 48.74; H, 5.65, N, 1.67%); [a]ü +35.4 (c 
1 in CHCI3); Vmax/crn-i 2965 (CH2 , CH3), 1745 (C=0 , ester), 1670, 1540 (C=0 , 
amide), 1060 (C-O); 0 h(CDC13) 2.60-2.76 (1 H, m, 3b^-H), 3.83 (3 H, s, C0 2 Me),
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5.64 (ddd, / 7b,8b 9.6, Jsb,9b 2.5, Jgb,9b' 6.9, 8b-H p-pyr), 6.03 (d, J\^2 8.2, la-H p~ 
pyr), 6.17 (s, la-H p-fur), 6.23 (d, /i,2 4.1, la-H a-pyr), 6.25 (d, J \^2 4.1, la-H a- 
fiir); ôcCCDCls) 36.8 (3b-C P-pyr), 37.3 (3b-C a-pyr), 37.4 (3b-C P-fur), 38.0 (3b-C 
a-flir), 80.45 (2b-C a-pyr), 80.8 (2b-C P-pyr), 82.6 (2b-C a-fur), 83.25 (2b-C P-fur),
89.1 (la-C a-pyr), 92.7 (la-C P-pyr), 92.8 (la-C a-fur), 99.4 (la-C p-fur).
»Ç-(Methyl 5-acetamido-4,7,8,9-tetra-0~acetyl-3,5-dideoxy-D-g^(Vcer<?-a-D-g«/«cro-
2-nonulopyranosyloiiate)-(2-->3)-5,6-di-0-acetyM,2“0-isopropylidene-3-thio-a- 
D-galactofuranose, 115
111
OAc OAc
AcO AcO
AcHN AcHN
AcO AcO
AcO t)A c  O 
115114
Compound 111 (200 mg, 267 p,mol) was dissolved in aqueous acetic acid (4 cm^; 
50% v/v) and stirred for 15 mins at 75 °C. After cooling, the solution was 
concentrated and co-evaporated several times with toluene. Flash clrromatography 
(silica gel; CH2CI2 then CH2Cl2-MeOH, 98:2-^95:5) gave S-(methyl 5-acetamido-
4,7,8,9-tetra-0-acetyl-3,5-dideoxy-D-^yoQXO-a-D-%dlds::Xo-2-nonulopyranosylonate)-
(2-~>3)-l,2-0~isopropylidene-3-thio-a-D-galactofuranose 114 as a solid foam (114 
mg); 0 h(CDC13) 1.30, 1.55 (2 x 3 H, 2 s, CMc2), 1.86 (3 H, s, AcN), 1.99, 2.00, 2.08,
2.12 (4 X 3 H, 4 s, 4 X AcO), 2.75 (1 H, dd, ^bax,3beq 12.6, J 3beq,4b 4.4, 3b^-H), 2.90 
(2 H, brs OH), 3.59 (1 H, dd, J 5a,6a' 5.2, V6a.6a' 11.8, 6 a'-H), 3.68 (1 H, dd, V5a,6a 3.0,
76a,6a'j 6 a-H), 3.79 (3 H, s, C0 2 Me), 4.26 (1 H, dd, Jsb,9b' 2.6, / 9b,9b' 12.5, 9b'-H),
4.80 (1 H, d, /la,2a, 3.85, 2a-H), 4.88 (1 H, m, 4b-H), 5.28 (1 H, dd, / 6b,7b 1.6, / 7b,8b
9.0, 7b-H), 5.55 (2 H, m, 8b-H, NH), 5.81 (1 H, d, Jia,2a> la-H). The diol was 
dissolved in a mixture of pyridine (2 cm^) and acetic anhydride (1.5 cm^) and stirred 
overnight at room temperature. The mixture was concentrated, redissolved in EtOAc 
and subjected to standard work-up B. Flash chromatography (silica gel; CH2CI2- 
acetone, 9:1->2:1) gave the title compound 115 as a glassy solid (124 mg, 58% from 
111), (Found: C, 50.28; H, 6.13, N, 1.70. C33H47NO19S requires C, 49.93; H, 5.97, 
N, 1.76%);[a]D +13.8 (c 1 in CHCI3); 0 h(CDC13) 1.33, 1.63 (2 x 3 H, 2 s, CMc2),
1.88 (3 H, s, AcN), 1.99-2.16 ( 6  x 3 H, 6  s, 6  x AcO), 2.76 (1 H, dd, Abax,3beq 12.6,
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^3beq,4b 4.7, 3b^-H), 3.60 (1 H, m, 3a-H), 3.74-3.80 (5 H, m, 4a-H, 6 b-H, COzMe)
3.89 (1 H, m, 5b-H), 4.12-4.19 (2 H, m, 6 a'-H, 9b-H), 4.25 (1 H, dd, /gb,9b' 2.5, 
J<)h,w  12.6, 9b'-H), 4.32 (1 H, dd, /5a,6a 3.8, Vga,6a' 12.1, 6 a-H), 4.76 (1 H, dd, /ia ,2a
3.6, / 2a,3a 11, 2a-H), 4.95 (1 H, m, 4b-H), 5.21-5.30 (2 H, m, 5a-H, 7b-H), 5.32 (1 H, 
d, / 5b,NH 9.6, NH), 5.64 (1 H, m, 8b-H), 5.73 (1 H, d, / j a ,2a, la-H); bc{CDCh) 20.44, 
20.47, 20.51, 20.56, 20.8, 23.0, 26.75, 27.0, 38.0, 46.0, 49.7, 61.2, 62.95, 53.2, 66.5,
68.3, 69.1, 69.3, 73.9, 80.6, 82.6, 89.8, 105.3, 114.4, 168.4, 169.3, 169.7, 170.2,
170.4, 170.5, 170.7.
5^-(Methyl 5-acetamido-4,7,8,9-tetra-0 -acetyl-3,5“dideoxy-D-g/j;cer<7-a-D--^ a/flcr<>-
2-nonulopyranosylonate)-(2->3)-l,2,5,6-tetra-0“acetyl-3-thio-a/p-D- 
galactofuranose, 113/
115
OAc
AcO OAc
AcHN
AcO ^
AcO t)A c
116
OAc 9 0 2 Me
AcHN
Compound 115 (60 mg, 75 p.mol) was dissolved in aqueous trifluoroacetic acid (1 
cm^; 90% v/v) and stirred for 15 mins at room temperature. The solution was 
concentrated and co-evaporated several times with toluene. Flash chromatography 
(silica gel; CH2CI2 then CH2Cl2-acetone, 2:1) gave S-(methyl 5-acetamido~4,7,8,9-
tetra-O-acetyl-3,5-dideoxy-D-^ycQX0~ a-D-ga\acto-2-nonulopymnosylonate)-(2—>3)-
5,6-di-0-acetyl-3-thio-a//3-D-galactofuranose 116 as a glassy solid (45 mg). The diol 
was dissolved in a mixture of pyridine (2cm^) and acetic anhydride (1.5 cm^) and 
stirred overnight at room temperature. The mixture was concentrated, redissolved in 
EtOAc and subjected to standard work-up B. Flash chromatography (silica gel; 
CH2Cl2-acetone, 9:1^3:1) gave the title compound 113/ as a glassy solid (50 mg, 
78% from 115; a:p, 1:2), (Found: C, 48.69; H, 5.49, N, 1.54. C34H47NO21S requires 
C, 48.74; H, 5.65, N, 1.67%); [a]o -5.6 (c 1 in CHCI3); 0 h(CDC13) 1.87 (3 H, s, 
AcN), 1.99-2.18 (24 H, overlapping signals, AcO), 2.68-2.76 (1 H, m, 3bgq-H), 3.82 
(s, COzMe a), 3.83 (s, COiMe p), 6.17 (s, la-H P), 6.25 (d, / i ,2 4.1, la-H a); 
0c(CDCl3) 20.25, 20.5, 20.6, 20.65, 20.75, 20.8, 23.0, 30.7, 37.4, 38.0, 41.7, 44.1,
49.4, 53.3, 53.4, 61.4, 62.0, 62.6, 66.3, 66.75, 67.2, 67.4, 6 8 .6 , 69.1, 69.3, 73.7, 74.0,
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79.8, 82.2, 82.6, 83.25, 85.6, 92.8, 99.4, 168.6, 168.8, 169.2, 169.75, 170.1, 170.2,
170.3, 170.4, 170.6, 170.75.
l,2:5,6-Di-0“isopropylidene-3-(9-trifluoromethaiiesulfonyl-a-D-allofuranose,
11715
l,2:5,6-Di-0-isopropylidene-a-D-allofuranose (100 mg, 0.38 mmol) was treated in a 
manner analogous to the preparation of compound 85. TLC (hexane-EtOAc, 3:2) 
showed the reaction to be complete after 1 h at 0 °C. The reaction was worked-up as 
described previously to give the triflate 117 as a symp which was used in subsequent 
reactions without further purification (147 mg, 97%); 6 h(CDC13  ^ lit., 15) 1.34, 1.38, 
1.44, 1.58 (4 X 3 H, 4 s, 2 X CMe^), 3.92 (1 H, dd, Js,e 4.4, ^5,6 ' 8.5, 5-H), 4.08-4.26 
(3 H, m, 4-H, 6-H, 6 -H), 4.77 (1 H, dd, 7%,2 3.8, ^2,3 5.2, 2-H), 4.91 (1 H, dd, ^ , 3, 
.73,4 6.9, 3-H), 5.84 (1 H, d, ^ 1,2 , 1-H); ôdCDCW 24.6, 26.0, 26.3, 26.7, 66.1, 75.0,
77.6, 77.7, 82.8, 104.1, 110.3, 114.4.
.^-(Methyl 5-acetamido-4,7,8,9-tetra-0-acetyl-3,5-dideoxy-D-^/j;cero-a-D-^a/ac^o-
2-iionulopyranosylonate)-(2->3)-l,2:5,6-di-0-isopropylidene-3-thio-a-D- 
glucofuranose, 11815
A cO ^ JL  p A cÇAc^ _^ COzMeQ, P
AcHN- /
A cd
118
Diethylamine (0.225 cm^) was added dropwise to a stined solution of 117 (71 mg, 
0.18 mmol) and 35 (65 mg, 0.12 mmol) in DMF (0.45 cm^) at 0 °C. The mixture was 
allowed to warm to room temperature overnight and then concentrated to a symp. 
The syrup was dissolved in EtOAc (10 cm^) and subjected to standard work-up B. 
Flash chromatography (silica gel; Et20 then EtOAc) gave the thio-disaccharide 118 
as an amorphous solid (65 mg, 72%), but contaminated with the 2,3-dehydro-sialic
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acid 33 (-5% by NMR). The product was used in subsequent reactions without 
further purification, but an analytical sample was obtained by gel permeation 
chromatography (Sephadex LH-20; MeOH), [a]o -12.8 (c 1.0 in CHCI3) (lit.,i5 _
1 0 .6 , c 0 .6 6  in CHCI3); ÔHLCDCls) 1.27, 1.29, 1.38, 1.48 (4 x 3 H, 4 s, 2  x CMc2),
1.85 (3 H, s, AcN), 2.00, 2.01, 2.12, 2.13 (4 x 3  H, 4 s, 4 x AcO), 2.79 (1 H, dd, 
‘73bax,3beq 12.6, J 3beq,4b 4.7, 3bgq-H), 3.57 (1 H, d, / 3a,4a 3.6, 3a-H), 3.80 (3 H, s, 
C0 2 Me), 3.83 (1 H, m, 6 b-H), 3.92 (1 H, dd, / 5a,6a4.1 / 5a,6a 8.5, 5a-H), 3.94-4.05 (2 
H, m, 6 a-H, 5b-H), 4,13-4.24 (3 H, m, 4a-H, 6 a'-H, 9b-H), 4.32 (1 H, dd, J 8b,9b' 2.5, 
/ 9b,9b' 12.6, 9b'-H), 4.87 (1 H, d, /ia,2a 3.3, 2a-H), 4.90 (1 H, m, 4b-H), 5.25-5.32 (2 
H, m, NH, 7b-H), 5.43 (1 H, m, 8b-H), 5.80 (1 H, d, /ia,2a 3.3, la-H); 0 c(CDCl3) 
20.5, 20.6 (2), 20.8, 23.0, 25.2, 25.8, 26.3, 26.9, 38.1, 49.4, 49.7, 53.0, 61.5, 67.3,
67.4, 69.2, 69.5, 74.2, 74.5, 79.0, 82.7, 87.5, 104.7, 109.2, 112.1, 168.1, 169.9,
170.2, 170.6. 170.9.
^ - ( M e th y l  5 -a c e ta m id o -4 ,7 ,8 ,9 - te tra -0 -a c e ty I -3 ,5 -d id e o x y -D -g (v c e # ‘<9-a-D -g«/«cro-
2-nonulopyranosylonate)"(2^3)“l,2,4,6-tetra-0-acetyl-3-thlG-a/p-D~ 
glucopyranose, 119
COzMeOAc
AcO
AcHN
OAc 
119
Compound 118 (116 mg, 155 pmol) was dissolved in aqueous trifluoroacetic acid 
(1.0 cm3; 90% v/v) and stirred at room temperature for 15 mins. The solution was 
concentrated and co-evaporated several times with toluene. Flash chromatography 
(silica gel; EtOAc then EtOAc-MeOH, 2:3) gave a glassy solid (84 mg) which was 
dissolved in a mixture of pyridine (1 .0  cnJ) and acetic anhydride (1 .0  cm^) and 
stirred at room temperature overnight. The mixture was concentrated to an oil, 
redissolved in EtOAc (10 cm^) and subjected to standard work-up B. Flash
chromatography (silica gel; CH2Cl2-acetone, 9:1->3:1) gave the peracetylated a/p  
pyranose 119 (104 mg, 80%; a-p\^-p, 42:58) as an amorphous solid, (Found: C, 
48.73; H, 5.96, N, 1.61. C34H47NO21S requires C, 48.74; H, 5.65, N, 1.67%); [a]o 
+23.2 (c 1 in CHCI3); 6 h(CDC13) 0 h(CDC13) 1.83-2.25 (28 H, m, AcN, AcO, 3b,,- 
H), 2.69, 2.75 (1 H, 2 dd, 3b^-H a, P), 3.82 (3 H, s, C0 2 Me), 5.98 (d, / i ,2 8.2, la-H 
P), 6.22 (d, / i ,2 3.8, la-H a); ôcCCDCls) 20.4, 20.5, 20.55, 20.6, 21.0, 21.2, 22.8,
22.9, 37.6, 38.3, 43.9, 45.9, 48.8, 49.3, 52.8, 61.3, 61.7, 61.8, 62.4, 66.9, 67.4, 67.5,
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68.0, 68.7, 69.0, 69.2, 69.3, 71.0, 74.15, 74.3, 74.7, 83.1, 83.3, 88.7, 92.5, 168.5,
169.0, 169.2, 169.4, 169.5, 169.6, 169.8, 169.85, 170.4, 170.5, 170.8.
terr-ButyldimethylsUyl 5-(methyl 5-acetamido-4,7,8,9-tetra-0--acetyl-3,5- 
dideoxy-D-g(vcer<?-a-D-^a/acto-2-nonulopyraiiosyIonate)-(2-^3)-2,4-di-0-acetyI- 
6-(9-(^er^butyldimethylsilyl)“3-thio-|3-D-galactopyranoside, 120
—■S7 -OTBDMS
AcO OAc
120
r-Butyldimethylsilylchloride (281 mg, 1.87 mmol) was added to a solution of 
compound 112 (250 mg, .0373 mmol) in pyridine (2.5 cm^) at 0 °C. After stirring for 
2 h at 0 °C more r-butyldimethylsilylchloride (281 mg, 1.87 mmol) was added and 
the mixture was allowed to warm slowly to room temperature overnight. The 
reaction mixture was quenched with MeOH (1 cm^) and concentrated. The residue 
was redissolved in pyridine (2 cm^) and acetic anhydride (1.5 cm^) and stirred at 
room temperature overnight. The mixture was concentrated again, and the residue 
was taken up in CH2CI2 (20 cm^), subjected to standard work-up B and concentrated 
to give a syrup. Flash chromatography (silica gel; CH2CI2 then CH2Cl2-MeOH, 
100:3) gave the bis-silylated compound 120 (331 mg, 90%) predominantly in the (3- 
pyranose form, but contaminated with a small quantity (~5%) of a furanose 
derivative. (Found: C, 51.11; H, 7.46, N, 1.36. C42H7 iNOi9SSi2 requires C, 51.36; 
H, 7.28, N, 1.43%); [a]o +9.9 (c 0.75 in CHCI3); v^ax/cm-i 2960, 2860 (CH2, CH3), 
1750 (C=0, ester), 1660, 1540 (C=0, amide), 1370 (Bu  ^ C-H), 1225, 840 (Si-C), 
1055 (C-O); 0 h(CDC13) -0.01, 0.03 (2 x 3 H, 2 s, SiMe2), 0.11 ( 6  H, s, SiMe2), 0.85, 
0.87 (2  X 9  H, 2 s, 2 X SiCMc3), 1.85 (4 H, m, AcN, 3b,,-H), 2.00, 2.03, 2.04, 2.05 (6  
H), 2.14, 2.18 (18 H, 5 s, 6  X AcO), 2.64 (1 H, dd, ^bax,3beq 12.6, / 3beq,4b 4.4, 3b,q- 
H), 3.46 (1 H, dd, Jsa,6a' 7.7, J|5a,6a', 6 a'-H), 3.56 (1 H, dd, 7$a,6a 5.8, /6a,6a' 9.9, 6 a- 
H), 3.58 (1 H, dd, 72a,3a 11-8, /3a,4a 3.3, 3a-H), 3.69 (1 H, dd, / 5b,6b H O, / 6b,7b 2.2, 
6 b-H), 3.78-3.86 (4 H, m, 5a-H, C0 2 Me) 4.05 (1 H, m, 5b-H), 4.08 (1 H, dd, /gb,9b
4.1, / 9b,9b' 12.6, 9b-H), 4.18 (1 H, dd, /gb,9b' 3.0, /gb.gb', 9b'-H), 4.77 (1 H, dd, /ia,2a
7.4, /2a,3a, 2a-H), 4.82 (1 H, m, 4b-H), 5.01 (1 H, dd, / 3 a,4a, /4a,5a 0.8, 4a-H), 5.08 (1 
H, d, /la,2a, la-H), 5.16 (1 H, d, / 5b,NH 10.2, NH), 5.35 (1 H, dd, / 6b,7b, / 7b,8b 10.2, 
7b-H), 5.56 (1 H, ddd, / 7b,gb, /sb,9b, /sb,9b', 8 b-H).
139
r^r^-Butyldimethylsilyl ^-(methyl 5-acetamido-4,7,8,9-tetra-0-acetyl-3,5- 
dideoxy-D-g/ycero~a-D-^«/ac^o-2-nonulopyranosylonate)-(2->3)-2,4,6-tri-0- 
acetyl-3-thio-P-D-galactopyranoside, 121
^ - O T B D M S  
AcO OAc
121
Trifluoroacetic acid (0.5 cm^) was added, with stirring, to a solution of 120 (50 mg, 
50.9 pmol) in CH2CI2 (0.5 cm^) at room temperature. After 30 mins, the mixture was 
diluted with EtOAc (10 cm^) and subjected to standard work-up A. The resulting 
crude product was treated with a mixture of pyridine (1 .0  cm^) and acetic anhydride 
(1 .0  cm3) overnight at room temperatuie and, following concentration, flash 
chromatography (silica gel; CH2CI2 then EtOAc) gave a mono-silylated derivative as 
a glassy solid (30 mg, 65%). The following NMR spectral data are consistent with 
the structure of the iQxX-butyldimethylsilyl p-D-galactopyranoside, 121: ôh(CDC13) 
0.11 (6  H, s, SiMe2), 0.87 (9 H, s, SiCMe3), 1.86 (4 H, m, AcN, 3b^-H), 2.00-2.20 
(21 H, 6  s, 7  X AcO), 2.63 (1 H, dd, / 3bax,3beq 12.6, / 3beq,4b 4.7, 3bgq-H), 3.61 (1 H, 
dd, / 2a,3a H .8, / 3a,4a 3.3, 3a-H), 3.70 (1 H, dd, / 5b,6b 11.0, / 6b,7b 2.2, 6 b-H), 3.82 (4 
H, m, 5a-H, C0 2 Me) 3.97-4.11 (4 H, m, 6 a-H, 6a'-H, 5b-H, 9b-H), 4.19 (1 H, dd, 
/s b ,9b' 3.0, / 9b,9b' 12.4, 9b'-H), 4.80 (2 H, m, 2a-H, 4b-H), 4.86 (1 H, d, / 3a,4a 3.3, 
4a-H), 5.10 (1 H, d, / i a , 2a 7.4, la-H), 5.18 (1 H, d, / 5b,nh 10.2, NH), 5.34 (1 H, dd, 
/ 6 b ,7b 2.2, / 7b,8b 10.2, 7b-H), 5.56 (1 H, ddd, /y b ,8b»  / 8b,9b 3.9, / g b , 9b ',  8b-H).
5'-(Methyl 5-acetamidio-4,7,8,9-tetra-0-aeetyI-3,5-di(ieoxy-D-^/yc^f<?-a-D-ga/flcr<?-
2-nonuiopyranosylonate)-(2->3)-l,2,4,6-tetra-0-acetyI-3-thio-a/(3-D- 
galactopyranose, 113p^ ^
A c O ^ r p A c  f  2MeOAcOAc
AcO GAcOAc
113p
A stirred solution of 120 (100 mg, 101 pmol) in a mixture of acetic anhydride (0.5 
cm^) and acetic acid (0.25 cm^) was cooled to 0 °C. Dilute sulfuric acid (0.25 cm^; 
10% v/v in acetic acid) was added and the mixture stirred for 10 mins at 0 °C and for 
1 h at room temperature. The mixture was diluted with CH2Cl2 (2 0  cm^) and 
subjected to standard work-up A. Flash chromatography (silica gel; CH2CI2 then
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CH2Cl2-MeOH, 99:1—>95:5) gave the peracetate 113p as a glassy solid (65 mg, 
76%; p:a, 83:14), but contaminated by a small quantity (~3%) of the p furanose 
derivative. NMR for p pyranose; ôh(CDC13, lit.,^^) 1.85 (3 H, s, AcN), 1.86 (1 H, 
m, 3bg,,-H), 1.99-2.20 (8 x 3 H, 8 s, 8 x AcO), 2.63 (1 H, dd, /3bax,3beq 12.6, /3beq,4b
4.4, 3b^-H), 3.69 (1 H, dd, /gb.Gb 10.7, Jcbjb 2.2, 6b-H), 3.79 (1 H, dd, / 2a,3a 115, 
/ 3a,4 a 3.6, 3a-H), 3.83 (3 H, s, C02Me) 3.89 (1 H, dd, /gb,9b 6.6, / 9b,9b' 12.0, 9b-H), 
3.95 (1 H, dd, /s a ,6a 6.9, /g a ,6a', H  5 , 6a-H), 4.05 (1 H, dd, /s a ,6a' 3.3, / 6a,6aS 6a'-H), 
4.07 (1 H, m, 5b-H), 4.30 (1 H, m, 5b-H), 4.33 (1 H, dd, /gb,9b' 2.2, /%,9b', 9b'-H),
4.80 (1 H, m, 4b-H), 4.91 (1 H, m, 4a-H), 4.95 (1 H, dd, /ia,2a 8.0, J%^ 3a, 2a-H), 5.18 
(1 H, d, / 5b,NH 10.4, NH), 5.24 (1 H, dd, /ôb,7b 2.2, / 7b,sb 10.2, 7b-H), 5.63 (1 H, m, 
8b-H), 6.02 (1 H, d, /la,2a, la-H).
^'-(Methyl 5-acetamido-4,7,8,9-tetra-6>-acetyl-3,5-dideoxy-D-g/j;cer£?-a-D-ga/ac/<?-
2-nonuIopyraiiosylonate)-(2-^3)-2,4,6-tri-(7-acetyl-3-thio-p-D-galactopyraiiose,
12217
COglVleO^OAc
AcHN
OAcOH
A solution of both 113p (210 mg, 0.25 mmol) and hydrazinium acetate (25 mg, 0.275 
mmol) in DMF (3.5 cm^) was heated at 50 °C for 7 h. The mixture was cooled to 
room temperature and concentrated to a syrup which was redissolved in CH2CI2 and 
subjected to standard work-up B. Flash chromatography (silica gel; toluene-MeOH, 
9:1) gave the title compound 122 as a colourless syrup (140 mg, 70%) contaminated 
with a small amount of a furanose isomer which proved difficult to remove despite 
repeated chromatography. [a]o +30.0 (c 0.7 in CHCI3) (lit., 17 +33.0); 5 h(CDC13)
1.86 (3 H, s, AcN), 1.88 (1 H, dd, / 3ax,3eq 12.6 /gax,4 11.8, 3b^-H), 2.01, 2.03, 2.04,
2.06, 2.07, 2.19, 2.22 (7 x 3 H, 7 s, 7  x AcO), 2.64 (1 H, dd, / 3bax,3beq 12.6, / 3beq,4b
4.7, 3b,q-H), 3.66-3.74 (2 H, m, 3a-H, 6 b-H), 3.83 (3 H, s, COzMe) 3.93-4.19 (5 H, 
m, 5a-H, 6 a-H, 6 a'-H, 5b-H, 9b-H), 4.29 (1 H, dd, /gb,9b' 2.7, / 9b,9b' 12.4, 9b'-H), 
4.70 (1 H, dd, /ia,2a 7.7, /ia,3a H-8 , 2a-H), 4.83 (1 H, m, 4b-H), 4.91 (1 H, dd, /sa,4a
3.6, /^a,5a 1.1, 4a-H), 5.04 (1 H, d, /ia,2a, la-H), 5.22 (1 H, d, /sb,NH 10.2, NH), 5.31 
(1 H, dd, / 6b,7b 2.2, / 7b,8b 10.2, 7b-H), 5.59 (1 H, m, 8b-H).
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5'-(Methyl 5-acetamido-4,7,8,9-tetra-0-acetyl-3,5-dideoxy-D-g/ycef’o-a-D-ga/ac^o- 
2-noiiulopyranosylonate)-(2^3)-0-2,4,6-tri-0-acetyl-3-thio-a/p-D- 
galactopyranosyl trichloroacetimidate, 123*7
 ^ COglVlepAqOAc 
O
AcHN O T -S . „ CCb 
123
I,8-Diazabicyclo[5.4.0]undec-7“ene (20 mm^) was added to a stirred solution of 122 
(63 mg, 67 |umol) in CH2CI2 (2.5 cm^) and trichloroacetonitrile (0.5 cm^). After 2 h 
at room temperature the dark brown solution was concentrated to a syrup and passed 
down a short column (silica gel; CH2CI2 then acetone) to remove most of the colour. 
Careful column chromatography (silica gel; CH2Cl2-MeOH, 100:3^95:5) gave the 
desired imidate 123 as a syrup (67 mg, 90%; P:a, 92:6) contaminated with - 2 % of a 
furanose isomer (as judged by *H NMR). [ajn +26.4 (c 1.1 in CHCI3) (lit.,*7 [p 
anomer] +27.5); 0 h(CDC13) 1.85 (3 H, s, AcN), 1.88 (1 H, m, 3b^-H), 1.99, 2.00,
2.02, 2.05, 2.09, 2.14, 2.21 (7 x 3 H, 7  s, 7  x AcO), 2.64 (1 H, dd, /^bax,3beq 12.6, 
/ 3beq,4b 4.4, 3bgq-H), 3.70 (1 H, dd, / 5b,6b 10.7, / 6b,7b 2.2, 6 b-H), 3.81 (1 H, dd, / 2a,3a
II.5, / 3a,4a 3.6, 3a-H), 3.84 (3 H, s, C0 2 Me) 3.93 (1 H, dd, /gb,9b 6.0, / 9b,9b' 12.4, 9b- 
H), 4.01 (1 H, dd, / 5a,6a 6.9, /ôa,6a' H.3, 6 a-H), 4.02-4.12 (2 H, m, 6 a'-H, 5b-H), 4.30 
(1 H, dd, /gb,9b' 2.2, / 9b,9b', 9b-H), 4.33 (1 H, m, 5a-H), 4.82 (1 H, m, 4b-H), 4.95 (1 
H, d, / 3a,4 a, 4a-H), 5.10 (1 H, dd, / i a , 2a 8.0, / 2a,3a, 2a-H), 5.16 (1 H, d, / 5b,n h  10.2, 
NH), 5.28 (1 H, dd, / 6b,7b 2.2, //b.gb 10.2, 7b-H), 5.62 (1 H, ddd, / 7b,gb, ^8b,9b 2.2, 
/gb,9b', 8b-H), 6.15 (1 H, d, / l a , 2a, la-H), 8.43 (1 H, s, C=NH).
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Octyl ^-(potassium 5-acetamido-3,5-dideoxy-D-g/j;cef<7-a-D-^a/ac^<i-2- 
nonulopyranosyIonate)-(2-+3)-3“thio-P-D-gaIactopyranoside, 125
OAc COoM epAcoAc
123 AcHN
COo' PH^QH
AcHN
A suspension of 123 (50 mg 53 pmol) and 4Â molecular sieves (200 mg) in dry 
CH2CI2 (2 cm^) was stirred for 3 h at room temperature. The mixture was cooled to 0 
°C and octanol (21 mm^, 130 pmol) was added, followed by boron trifluoride 
etherate (7.5 rmn^, 58.5 pmol) and the mixture was stirred at this temperature for 3 h. 
The mixture was then diluted with CH2CI2 (8 cm^), filtered through Celite and 
subjected to standard work-up B. Repeated column chromatography (silica gel; 
CH2Cl2-MeOH, 97:3) failed to purify the disaccharide fully and so the crude product 
was used in subsequent deprotection steps. Crude octyl S-(methyl 5-acetamido-
4,7,8,9-tetra-0-acetyl-3,5-/z/eoxy-D-glycero- a-D-galacto-2-nonulopyranosylonate)-
(2-^3)-2,4,6-tri-0-acetyl-3-thio-/3-D-galactopyranoside 124 (37 mg), § h (C D C 13) 
0.86 (3 H, t, J  6.9, CvHwCTfj), 1.26-1.44 (10 H, m, (C^2)sCH3), 1.56 (2 H, m, 
OCH2C7/ 2), 1.86 (4 H, m, AcN, 3b^-H), 2.00-2.20 (21 H, 6 s, 7 x AcO), 2.63 (1 H, 
dd, / 3bax,3beq 12.6, / 3beq,4b 4.7, 3bgq-H), 3.51 (1 H, m, OCHi), 3.63 (1 H, dd, / 2a,3a
10.7, / 3a,4a 3.3, 3a-H), 3.69 (1 H, dd, /gb,6b 10.7, /ôb ,7b 2.2, 6b-H), 3.81-3.89 (4 H, m, 
C02Me, OCH2 ), 3.96-4.12 (5 H, m, 5a-H, 6a-H, 6a'-H, 5b-H, 9b-H), 4.29 (1 H, dd, 
/g b ,9b' 2.7, / 9b,9b' 12.4, 9b -H), 4.75-4.86 (3 H, m, la-H, 2a-H, 4b-H), 4.88 (1 H, d, 
/ 3a,4 a 3.0, 4a-H), 5.16 (1 H, d, / 5b,nh 10.2, NH), 5.31 (1 H, dd, /b b ,7b 2.2, / 7b,sb 10.2, 
7b-H), 5.59 (1 H, ddd, /yb.sb 10.2, /gb,9b 2.7, /gb,9b' 5.2, 8b-H); 0c(CDCl3) 13.8, 20.4- 
20.5 (6), 21.2, 22.4, 22.9, 25.6, 29.0, 29.1, 29.3, 31.6, 36.8, 45.4, 49.0, 53.0, 62.2, 
62.25, 66.9, 67.2, 68.4, 69.1, 69.35, 70.0, 72.0, 73.5, 80.8, 101.6, 169.0, 169.7,
170.0, 170.2, 170.3, 170.4 (3), 170.9.
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A solution of both the crude octyl glycoside 124 (37 mg) and sodium methoxide (2 
mg) in dry MeOH (3 cm^) was stirred for 2 h at room temperature. The solution was 
neutralised with acetic acid and concentrated to a solid. The mixture was redissolved 
in potassium hydroxide solution (3 cm^; 1 M). After standing for 3 h at room 
temperature, the solution was desalted on a reverse phase column (C-18 silica gel; 
H2 0 ->Me0 H) to give the fully deprotected compound 125 as a glassy solid (17 mg, 
50% from 123), [a]o +42.9 (c 0.9 in MeOH); 0 h(CD3 0 D; 500 MHz) 0.90 (3 H, t, /  
6 .8 , CvHhC/Tj), 1.26-1.40 (10 H, m, (0 / 72)5^ 3), 1.62 (2 H, m, 0 % % ) ,  1.71 (1 
H, m, 3bax-H), 2.00 (3 H, s, AcN), 2,91 (1 H, dd, / 3bax,3beq 12.6 / 3beq,4b 4.2, 3bgq-H), 
4.28 (1 H, d, /la,2a 7.4, la-H); 0 c(CD3 0 D) 14.5, 22.7, 23.8, 27.3, 30.5, 30.7, 30.9,
33.1, 43.15, 52.9, 54.0, 63.2, 64.7, 69.4, 70.2, 70.3, 70.4, 70.7, 73.2, 77.1, 79.2, 85.9,
106.4, 175.5, 175.75; ES-MS (-ve): m/z 598 (M-K)' (C25H44NO13KS requires m/z 
637).
5-(5-acetamido-3,5-dideoxy-D-^/j;cer<7-a-D-gfl/flc^O“2-noiiulopyraiiosylonic acid)- 
(2~>3)-3-thio-D-galaetose, 126
, CO2H OH^OH 
O
o h 'o h  
126
A solution of both 111 (38 mg) and sodium methoxide (2 mg) in diy MeOH (400 
mm^) was stiired for 2 h at room temperatuie. The solution was neutralised with 
acetic acid and concentrated onto silica. Flash chromatography (silica gel; CH2CI2- 
MeOH, 9:1) gave a white solid which was redissolved in sodium hydroxide solution 
(1 cm3; 0.1 M). After standing for 24 h at room temperature, the solution was 
neutralised with acetic acid and concentrated. The crude product was dissolved in 
aqueous trifluoroacetic acid (1 cm^; 90% v/v) and stirred at room temperature for 30 
mins. The solution was concentrated and co-evaporated several times with toluene. 
Purification of the residue by gel permeation chromatography (Biogel F2; H2O) gave 
the title compound 126 as a white powder after freeze-drying (10 mg, 40%), [a]o 
+77.8 (c 0.65 in H2O); Ôh(D2 0 ) 1.91 (1 H, m, 3b^-H), 2.11 (3 H, s, AcN), 2.89 (1 H, 
m, 3b,q-H), 4.75, 5.36 (1 H, m, la-H); 0 c(D2 0 ) 23.0, 41.7, 41.8, 47.8, 48.5, 51.9,
52.6, 55.6, 62.3, 62.4, 63.6, 63.9, 67.1, 69.2, 69.5, 69.9, 70.4, 71.5, 72.3, 72.6, 72.9,
75.9, 78.5, 83.5, 85.0, 85.2, 92.9, 98.9, 103.2, 175.8, 176.2; ES-MS (-ve): m/z 486 
(M-H)" (C17H29NO13S requires m/z 487).
AcHN
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*S'-(5-acetamido-3,5-dideoxy-D-^/yc^r<?-a-D-ga/flcto-2-nonuiopyranosylonic acid)- 
(2->3)-3-thio-D-glucose, 127
H O ^ T p H  HO,
HO ‘OH
A solution of both 118 (90 mg, 120 pmol) and sodium methoxide (3 mg, 55 pmol) in 
dry MeOH (0.5 cm^) was stirred for 2 h at room temperature. The solution was 
neutralised with acetic acid and concentrated on to silica. Flash chromatography 
(silica gel; CH2Cl2-MeOH, 9:1) gave a white solid which was redissolved in sodium 
hydroxide solution (1.5 cm^; 0.1 M). After standing for 24 h at room temperature, the 
solution was neutralised with acetic acid and concentrated. The crude product was 
dissolved in aqueous trifluoroacetic acid (1 cm^; 90% v/v) and stirred at room 
temperature for 30 mins. The solution was concentrated and co-evaporated several 
times with toluene. Purification of the residue by gel penneation chromatography 
(Biogel P-2; H2O) gave the title compound 127 as a white powder after ffeeze-drying 
(23 mg, 39%), [a]D +26.4 (c 1 in H2O); 0 h(D2 0 ) 1.92-2.04 (1 H, m, 3b^-H), 2.10 (3 
H, s, AcN), 2.86-2.96 (1 H, m, 3b^-H), 4.76, 5.33 (1 H, m, la-H); 0 c(D2 0 ) 23.0 (6 ),
42.2, 42.3, 51.7, 52.6, 55.3, 62.1, 62.2, 63.7, 6 8 .8 , 68.9, 69.2, 69.6, 70.75, 72.5, 72.7,
73.3, 73.5, 76.15, 76.2, 79.5, 92.5, 98.3, 176.25 (2); ES-MS (-ve): 486 (M-H)'
(C17H29NO13S requires m/z 487).
Octyl ^-(potassium 5-ammo-3,S-dideoxy-D-glycero-a-T)-galacto-2-
nonuIopyranosyIoiiate)“(2->3)-3-thio-p-D-gaIactopyranoside, 128
OH^OH
H2N
HO
A solution of 125 (2 mg) in potassium hydroxide solution (0.5 cm^;l M) was heated 
for 20 h at 90 °C. After cooling to room temperature, the solution was neutralised 
with acetic acid and desalted on a reverse phase column (Sep-pak; H2O—>MeOH) to 
give the de-N-acetyl compound 128 as a glassy solid (~2 mg, -100%); 0 h(CD3 0 D) 
0.90 (3 H, t , /6 .9 ,  C7H14C773), 1.26-1.42 (10 H, m, ( ^ 2)5^ 3), 1.57-1.72 (3 H, m, 
OCHzCTf:, 3c^-H), 2.90 (1 H, dd, / 3bax,3beq 12.6 .^beq,4b 4.4, 3b^-H), 3.06 (1 H, t.
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-^ 4b,5b -  ^b ,6b 10 0, 5b-H), 4.27 (1 H, d, Jia,2a 6 .6 , la-H); ES-MS (+ve): m/z 596 
(M+H)^, 558 (M-K+2H)^ (C23H42NO12SK requires m/z 595).
Octyl 3,4-0-isopropyIidene-p-D-galactopyraiiosyl-(l->4)-p~D-gIucopyraiioside, 
129
57
^OH
-"'vA -^O O ct
OH
129
OH
O
, 0  /OAc
O
OAc
OAc AcO) OOctOAc
130
A solution of octyl lactoside 57 (2.00 g, 4.40 mmol) and p-toluenesulfonic acid (80 
mg, 0.4 mmol) in 2,2-dimethoxypropane (40 cm^) was stin*ed at room temperature 
for 60 h. The reaction was quenched with triethylamine (0.5 cm^) and concentrated to 
a solid foam which was suspended in EtOAc (30 cm^). Aqueous TEA (200 mm^; 
50% v/v) was added and after stirring for 1 h, the reaction was again quenched with 
triethylamine and evaporated onto silica (10 g). Flash chromatography (silica gel, 
100 g; EtOAc then EtOAc-MeOH, 19:1) gave the title compound 129 as an 
amorphous white solid (1.44 g, 6 6 %), [a]o +9.9 (c 0.865 in MeOH); 5 h(CD3 0 D) 
0.90 (3 H, t, J6 .9 , C7Hi4Me), 1.26-1.40 (13 H, m, ( 0 % % ,  CM^2), L48 (3 H, s, 
CMe2), 1.62 (2 H, m, 0 % % ) ,  4.28, 4.37 (2 x 1 H, 2 d, Jia,2a,Jlb,2b 7.4, 7.7, la-H, 
Ib-H); 5c(CD30D) 14.5, 23.8, 26.6, 27.2, 28.5, 30.5, 30.7, 30.9, 33.1, 62.1, 62.6, 
71.1, 74.6, 75.0, 75.2, 75.5, 76.5, 76.6, 81.0, 81.2, 104.4 (2), 111.3.
A small sample (80 mg) of the above was acetylated using pyridine-acetic anhydride 
and purified by flash chromatography (silica gel; toluene-EtOAc 2:1) to give octyl
2,6-di-0-acetyl-3,4-0-isopropylidene~p-D-galactopyranosyl-(1 ->4)-2,3,6-tri-O- 
acetyl-/3-D-glucopyranoside 130  as a colourless syrup, (Found: C, 56.48; H, 7.72, 
C33H52O16 requires C, 56.25; H, 7.44%); [a]o +6.4 (c 1 in CHCI3); v,-nax/cm-i 2930 
(C H 2 , CH3), 1750 (C = 0 ) ,  1370 (Pft, C-H), 1042 (C-O); 0 h(CDC13) 0.84 (3 H, t, J
6.9, C7H14C/75), 1.20-1.30 (13 H, m, (C % )5C H 3 , C M ei), 1 .50  (5 H, m, OCHzCTf;, 
c m 2 ), 2 .0 0 , 2 .0 1 , 2 .0 5 , 2 .0 8 , 3 .0 0  (5 x 3 H , 5 s, 5 x A cO ), 3 .4 2  (1 H , m , 0 C % ) ,  
3.58 (1 H, ddd, J4a,5a 9.9, J 5a,6a4.9, / 5a,6a' 19, 5a-H), 3.72 (1 H, m, 4a-H), 3.80 (1 H, 
m, OCHi\ 3.90 (1 H, m, 5b-H), 4.09-4.17 (3 H, m, 6 a-H, 3b-H, 4b-H), 4.25 (1 H, dd, 
*75b,6b 7.1, / 6b,6b' H*5, 6b-H), 4.30 (1 H, dd, JshfiV 5.2, /ôb.ôb', 6 b'-H), 4.31 (1 H, d,
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Jib,2b 7.7, Ib-H), 4.42 (2 H, m, la-H, 6 a'-H), 4.82 (1 H, m, 2b-H), 4.87 (1 H, dd, 
Jia,2a 8.0, / 2a,3a 9.6, 2a-H), 5.16 (1 H, m, 3a-H).
Octyl 2,6-di-0-benzyl-3,4-0-isopropyIidene-|3-D-galactopyranosyl-(l->4)-2,3,6- 
tri-O-benzyl-p-D-glucopyranoside, 131
X O  OBn oBn
OBn OBn
131
Sodium hydride (60% dispersion in oil; 350 mg, 8 .6  mmol) was added in portions to 
a cooled (0 °C), stirred solution of compound 129 (660 mg, 1.33 mmol) in DMF (13 
cm^) and the mixture was stirred at 0 °C for 30 mins. Benzyl bromide (0.87 cm^, 
7.32 mmol) was added dropwise and the mixture was allowed to warm to room 
temperatuie and stuTed for a further hour. After careful addition of MeOH (1 cm^) 
and concentration, the residue was partitioned between diethyl ether and water, the 
aqueous phase being extracted twice with diethyl ether before washing the combined 
organic extracts with saturated NaCl solution, drying and concentration to a 
colourless oil. Flash chromatography (silica gel; hexane-EtOAc, 6:1) gave compound 
131 as a colourless syrup (1.20 g, 95%), (Found: C, 73.89; H, 7.87, C58H72O11 
requires C, 73.70; H, 7.68%); [a]o+15.8 (c 1.05 in CHCI3); v^ax/cm-^ 3030 (Ai-H), 
2930, 2860 (CH2, CH3), 1370 (W  C-H), 735, 700 (Ar-H); bgCDCb) 0.90 (3 H, t, J
6.9, C7H14C773), 1.27-1.46 (16 H, m, (C;%)5CH3, CMe2% 1.68 (2 H, m, OCR2 CH2 ), 
4.32-4.99 (lOx 1 H, 10 AB d, 5 x OCTf^Ph), 4.41, 4.46 (2 x 1 H, 2 d, Jia,2a/ib ,2b 8.0,
7.7, la-H, Ib-H), 7.20-7.45 (25 H, m, Ar-H); 0 c(CDCl3) 13.9, 22.4, 25.9, 26.2, 27.7,
29.0, 29.2, 29.5, 31.6, 68.2, 68.7, 69.9, 71.8, 73.0 (2), 73.2, 73.5, 74.8, 74.9, 75.2,
76.3, 79.2, 80.5, 81.7, 82.8, 101.7, 103.6, 109.6, 127.2-128.2 (Ar C), 138.3, 138.4,
138.5.138.7.139.0.
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Octyl 2,6-di-0-benzyl-p-D-galactopyraiiosyI-(l->4)-2,3,6-tri-0-benzyl-P-D-
glucopyranoside, 132
131
OBn
HO OOctBnO'OBn OBn
132
AcO /O B n  
AcO' O
OBn
OBn BnO^ OOctOBn
133
Compound 131 (1.02 g, 1.08 mmol) was dissolved in aqueous acetic acid (50 cm^; 
80% v/v) and stirred at 80 °C for 2 h. After cooling, the solution was concentrated 
and co-evaporated several times with toluene. Flash chromatography (silica gel; 
hexane-EtOAc, 3:2) gave compound 132 as a colourless syrup (0.96 g, 98%), 
(Found: C, 73.25; H, 7.61, CssHggOn requires C, 72.98; H, 7.57%); [aJo+18.8 (c 1 
in CHCI3); Vmax/crn-i 3450 (OH hr), 3030 (Ar-H), 2925, 2860 (CH2 , CH3), 735, 700 
(Ar-H); 0 h(CDC13) 0.90 (3 H, t, J6.9, C7H 14C//3), 1.25-1.46 (10 H, m, (Ci72)5CH3), 
1.67 ( 2  H, m, OCH2C//2), 2.40 (2  H, brs, OH), 4.38-5.02 (lOx 1 H, 1 0  AB d, 5 x 
0 C ^ 2Ph), 4.40, 4.60 (2 x 1 H, 2 d, Ju^2a,J\h,2h 8  0, 8.0, la-H, Ib-H), 7.20-7.40 (25
H, m, Ar-H); Ô^CDCb) 13.9, 22.4, 25.95, 29.0, 29.2, 29.5, 31.6, 68.2, 68.5, 6 8 .6 ,
69.9, 72.7, 73.0, 73.3, 73.4, 74.7 (2), 75.0, 75.05, 76.7, 79.9, 81.7, 82.7, 102.5, 103.6, 
127.2-128.4 (Ar C), 137.95, 138.25, 138.3, 138.6, 139.2.
A small sample of the diol (100 mg) was acetylated using pyridine-acetic anhydride 
and purified by flash chromatography (silica gel; hexane-EtOAc 4:1) to give octyl
3,4-di-0-acetyl-2,6-di-0-benzyl-j3-D-galactopyranosyl-(l ->4)-2,3,6-tri-0-benzyl-f3~ 
D-glucopyranoside 133 as a colouidess syrup (100 mg, 92%), ôh(CDC13) 0.89 (3 H, t, 
J6 .9 , C7H14C773), 1.26-1.44 (10 H, m, (0 /72)5^ 3), 1.67 (2 H, m, OCHgCTT )^, 1.95,
I.99 ( 2  X 3 H, 2  s, 2  X AcO), 3.71 (1 H, dd, Vsa,6a 1-6, /ôa,6a' H.O, 6 a-H), 3.79 (1 H, 
dd, J5a,6a' 4.1, Vga,6a', 6 a'-H), 3.91-4.03 (2 H, m, 0 C %  4a-H), 4.19-4.98 (lOx 1 H, 
10 AB d, 5 X 0 C772Ph), 4.38 (1 H, d, J]a,2a 7.7, la-H), 4.53 (1 H, d. Jib,2b 7.7, Ib-H),
4.87 (1 H, dd. Jab,3b 10.2, J 3b,4b 3.3, 3b-H), 5.39 (1 H, d, ^b ,4b, 4b-H), 7.15-7.40 (25 
H, m, Ar-H).
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Methyl (methyl 5-acetamido-4,7,8,9-tetra-6>-acetyl-3,5-dideoxy-2-thio-D-^/j;cer<?- 
a/p-D-ga/acr<?-2-nonulopyranosid)oiiate, 134 ^ ^
° % A c
SMeAcHN
A suspension of peracetylated sialic acid methyl ester 89 (2.0 g, 3.75 mmol), 4Â 
molecular sieves (500 mg), (methylthio)trimethylsilane (1.96 cm^, 13.8 mmol), and 
trimethylsilyltrifluoromethanesulfonate (0.68 cm^, 3.75 mmol) in dry 1,2- 
dichloroethane (30 cm^) was stirred under nitrogen for 7 h at 50 °C. The mixture was 
cooled to 0 °C and sodium carbonate solution (25 cm^;l M) was added. The mixture 
was separated and the organic layer was washed with water before drying and 
concentration to an oil. Flash chromatography (silica gel; CH2CI2 then CH2CI2- 
MeOH, 200:1-^50:1) gave the methyl thioglycoside 134 as a foam which was freeze- 
dried from dioxan (1.61 g, 82%; a:P, 1:1); [a]o -32.2 {c 1.05 in CHCI3) (lit.,'  ^ [a 
anomer] +17.8); ôh(CDC13, lit.,”7 [a anomer]) 1.84, 1.85 (2 x 3 H, 2 s, aAcN, pAcN), 
2.49 (1 H, dd, J 3 ax,3 eq 14.0, J 3eq,b 4.9, p3^q-H), 2.69 (1 H, dd, J 3 ax,3 eq 12.9, / 3 eq,b 4.7, 
a3^-H), 4.85 (1 H, m, a4-H), 5.23 (1 H, m, P4-H); 0 c(CDCl3) 11.7, 20.5, 20.6, 20.7,
20.9, 22.8, 22.9, 36.7, 37.6, 49.1, 49.2, 52.6, 52.7, 62.05, 62.2, 66.9, 67.2, 68.3, 
68.55, 69.2, 69.6, 71.95, 72.4, 73.9, 82.8, 84.5, 167.9, 170.15, 170.2, 170.3, 170.5, 
170.65, 170.9, 171.0.
4-Nitrophenyl 0-(methyl 5-acetamido-4,7,8,9-tetra-(9-acetyl-3,5-dideoxy-D- 
g(vc^ro-a-D-ga/«ct<?-2-nonulopyranosylonate), 138 ^ ^
• -  C O g M e
-O / O - ^  / /
OAc 
138
4-Nitrophenol (210 mg, 1.51 mmol) was added to a vigorously stirred mixture of 31 
(500 mg, 0.98 mmol) and tetrabutylammonium hydrogensulfate (410 mg, 1.21 
mmol) in CH2CI2 (25 cm^) and 1 M NaOH solution (25 cm^). After 15 mins, the 
mixture was diluted with CH2CI2 (200 cm^) and subjected to standard work-up A. 
Flash chromatography (silica gel; EtOAc) gave the acetylated pNP glycoside 138 as 
a colourless syrup which crystallised on standing (293 mg, 49%), mp 110 °C (lit.,^^ 
107-112 °C, lit.,20 104-108 °C); 0 h(CDC13, lit.,^9) 1 .9 1  (3  h , s , AcN), 2.03-2.17 (4 x
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3 H, 4 s, 4 X AcO), 2.28 (1 H, t, /sax.Seq ~ <^ax,4 12.9, 2.73 (1 H, dd, Jsax.Seq
12.9, J 3 e q ,4  4.4, 3^-H), 3.64 (3 H, s, COzMe) 4.10 (2 H, m, 5-H, 9 -H), 4.21 (1 H, dd, 
Js ,9 2.2, / 9,9 ' 12.9, 9-H), 4.60 (1 H, dd, Js.ô 10.7, 1.4, 6 -H), 4.96 (1 H, m, 4-H),
5.35 (2 H, m, 7-H, 8 -H), 5.46 (1 H, d, Js^nh 10.2, NH), 7.13 (2 H, m, Ar-H), 8.17 (2 
H, m, Ar-H).
4-Nitrophenyl (9-(sodmm 5-acetamido-3,5-dideoxy-D-g/j;cer<?-a-D-ga/act<i-2- 
nonulopyranosylonate), 139 0^
HO, ÇOa-'-NaI / = \
HO
139
A solution of 138 and sodium methoxide (4 mg, 74 pmol) in dry MeOH (2 cm^) was 
stined for 2 h at room temperature. The solution was neutralised with acetic acid and 
concentrated to give a pale yellow solid which was redissolved in sodium hydroxide 
solution (1.63 cm^; 0.1 M). After standing for 24 h at room temperature, the solution 
was freeze dried to give the pNP sialoside 139 as a yellow solid (72 mg, 98%), [a]o 
+45.2 (c 0.5 in H2O) (lit.,20 [acid form] +48.5° c 1.3 in MeOH); 5 h(D2 0 , lit.,^9 [acid 
form]) 2.04 (4 H, m, AcN, 3^-H), 2.83 (1 H, dd, J 3ax,3eq 12.9, u^eq,4 4.4, 3^-H), 7.28, 
8.21 (2 X 2 H, 2 d, J8.9, Ar-H).
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Octyl (potassium 5-ammo-3,5-dideoxy-D-g(ycgro-a-D-ga/ac^o-2-
nonulopyranosylonate)-(2^3)-P-D-galactopyranosyl-(l->4)-p-D- 
glucopyranoside, 49 and octyl (sodium/potassium 5-acetamido-3,5-dideoxy-D- 
(^yc r^<?-a-D-^«/flc^o-2“nonuIopyranosylonate)-(2->3)-p-D-galactopyranosyl- 
(l->4)-P-D-glucopyranoside, 52
K""
COo“ OH HH
OH n n
AcHN
Method one: chemical glycosylation. A suspension of 132 (200 mg 220 pmol), 134 
(288 mg 550 pmol) and 3Â molecular sieves (600 mg) in dry acetonitrile (2 cm^) was 
stirred for 2 h at room temperature under nitrogen. The mixture was cooled to -35 °C 
and A-iodosuccinimide (247 mg, 1.10 mmol) was added, followed by 
trifluoromethanesulfonic acid (10 mm^, 110 pmol) and the mixture was stiiTed at this 
temperature for 2 h. The mixture was diluted with CH2CI2 (50 cm^), filtered through 
Celite and the filtrate was washed successively with 1 M solutions of sodium 
carbonate, sodium thiosulfate and sodium chloride, before drying and concentration 
to a symp. In order to facilitate separation of products from starting materials, the 
mixture was deacetylated prior to chromatography: a solution of the crude product 
mixture and sodium methoxide (6  mg, 110 pmol) in MeOH (10 cm^) was stirred for 
2 h at room temperature. The mixture was neutralised with acetic acid and 
concentrated on to silica (2 g). Flash chromatography (silica gel; CH2Cl2-MeOH, 
99:l->97:3) gave a mixture of tri-saccharides 135a/b (150 mg).
A small portion (20 mg) of this mixture was partially separated by careful column 
chromatography (silica gel; CH2Cl2-MeOH, 99:1->97:3) to give first, the lactone,
octyl (5-acetamido-3,5-dideoxy-D-g\ycQXO-a-D-g2i[2iQXo-2-nonulopyranosyloyl-
1 c —>4b-lactone)-(2—>3)-2,6-di-0-benzyl-jB-D-galactopyranosyl-(l - T4)-2, 3,6-tri~0-
benzyl-/3-D-glucopyranoside 135b; ôh(CD3 0 D; cf. compound 14 in Ref. 21) 1.69 (1
H, dd, / 3cax,3ceq 13 8 / 3cax,4c H 3, 3c^-H), 2.01 (3 H, s, AcN), 2.26 (1 H, dd.
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'^ 3cax,3ceqs >^ 3ceq,4c 5.5, 3Cçq-H), 3.25 (1 H, dd, c/ia,2a 8.0, J 2a,3a 9.3, 2a-H), 4.10 (1 H, 
dd, / 2b,3b 9.3, / 3b,4b 3.9, 3b-H), 4.42 (1 H, d, /ib,2b 7.7, Ib-H), 4.45 (1 H, d, /ia,2a, la-
H), and then octyl (methyl 5-acetamido-3,5-dideoxy-D-g\ycQro-a/f-D-galacXo-2-
nonulopymnosylonate)-(2—^ 3)-2,6-di-0-benzyl-/3-D-galactopyranosyl-(}-^)-2,3,6-
tri-0~benzyl-/3-D-glucopyranoside 135a as an anomeric mixture (a:p, 7:3); 
0H(CD30D) 1.73 (m, J^ cax,3ceq 12.9 / 3cax,4c 118, p3c.,-H), 2.01 (m, a/pAcN, a3c_.
H), 2.68 (m, a/p3Ceq-H), 3.58 (s, pC02Me), 3.80 (s, aC02Me). Both samples were 
acetylated with pyridine and acetic anhydride to verify their structures:
lactone 136b; 0 h(CDC13) 1.88 (3 H, s, AcN), 1.92, 2.00, 2.03, 2.15, (4 x 3 H, 4 s, 4 x 
AcO), 4.60 (1 H, dd, /2b,3b 9.3, Ab,4b 3.9, 3b-H), 4.18 (1 H, m, 5c-H), 4.37 (1 H, d, 
/ l a ,2 a 7.7 la-H), 5.05 (1 H, m, 8c-H), 5.25 (1 H, dd, Vbc,7c 19, / 7c,Sc 6.3, 7c-H), 5.30 
(1 H, d, /5c,NH 10.2, NH), 5.49 (1 H, m, 4c-H); FAB-MS: m/z 1369 (M+Na)+ 
(C74H91NO22 requires m/z 1346).
a/j3 methyl esters 136a; 5h (C D C 13, cf, compounds 25 and 26 in Ref. 22) 1.75, 1.96, 
1.99, 2.00, 2.08 (5 X 3 H, 5 s, 5 X pAcO), 1.85 (3 H, s, a/pAcN), 2.60 (m, a/p3c,q- 
H), 3.43 (s, pC0 2 Me), 3.83 (s, aC 0 2 Me), 5.05 (d, / 3b,4b 3.3, a4b-H), 5.32 (dd, /gc,7c
2.2, /7c,8c 8.5, a7c-H), 5.39 (t, / gcJ c =  /70,8c 2.0, P7c-H), 5.59 (1 H, m, a 8 c-H).
A suspension of the remaining tri-saccharide mixture (130 mg) and palladium 
hydroxide on charcoal (130 mg; 10% w/w) in MeOH (30 cm^) was stirred for 24 h 
under an atmosphere of hydrogen. The mixture was filtered through Celite and 
concentrated. A solution of the residue in potassium hydroxide solution (10 cm^;l 
M) was heated for 20 h at 90 °C. After cooling to room temperature, the solution was 
neutralised with acetic acid and desalted on a reverse phase column (C-18 silica gel;
H2 0 -+Me0 H) to give octyl (potassium 5-amino-3,5-dideoxy-D-g\ycQxo-a//3-D-
g&\2iCio-2-nonulopyranosylonate)-(2-^3)-l3~D-galactopyranosyl-(1 -^)~/3-D-
glucopyranoside 49a/p as a glassy solid (80 mg, 49%; a:p, 6:1), ôh(CD3 0 D) P 
anomer- 2.34 (dd, / 3cax,3ceq 12.6 / 3ceq,4c 4.4, 3c^-H), 2.90 (t, / 4c,sc = dsc,6c 9.6, 5c-H), 
a  anomer- 2.73 (t, / 4c,sc = ^c,6c 9.9, 5c-H), 2.79 (dd, /scax.Sceq 12.4 / 3ceq,4c 4.7, 3c^ q- 
H).
Repeated flash chromatography (silica gel; CH2Cl2-MeOH-H2 0 , 6:5:1) gave 49a as 
a glassy solid (35 mg, 21%), [a]o -24.8 (c 0.5 in MeOH); ôh(CD3 0 D) 0.90 (3 H, t, /
6.9, C7H14CA3), 1.26-1.42 (10 H, m, (C/7^)5CH3), 1.47-1.70 (3 H, m, OCH2CA2,
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3Cax“H), 2.73 (1 H, t, / 4c,5c -  /5c,6c 9.9, 5c-H), 2.79 (1 H, dd, /3cax,3ceq 12.4 /3ceq,4c
4.7, 3c,q-H), 4.28 (1 H, d, /ia,2a 8.0, la-H), 4.43 (1 H, d, /ib,2b 8.0, Ib-H); 
Ôc(CD30D) 14.5, 23.8, 27.2, 30.5, 30.7, 30.9, 33.1, 42.1, 54.6, 62.3, 62.9, 64.9, 68.9,
70.1, 71.1 (2), 72.25, 73.7, 74.9, 76.6 (2), 77.2, 77.5, 81.3, 101.3, 104.5, 105.3, 
175.75; ES-MS (+ve): m/z 704 (M-K+2H)^ (C29H52NO18K requires m/z 741).
Re-A-acetylation of 49. Acetic anhydride (64 mm^, 64 jumol; 1 M solution in 
MeOH) was added to a stirred solution of 49a (15 mg, 21.3 pmol) in MeOH. After 
18 h the solution was concentrated and the residue was redissolved in water (2  cm^). 
Reverse phase chromatography (C-18 silica gel; H2 0 ->MeOH) gave octyl
(potassium 5-acetamido-3,5-dideoxy-D-g\ycQxo- (%-D-galacto-2-
nonulopyranosylonate)-(2—>3)-f-D-galactopyranosyl-(l ->4)-j3-D-glucopyranoside,
52 as a glassy solid (14 mg, 8 8 %), [a]o -7.2 (c 1 in MeOH); 5 h(CD3 0 D) 0.90 (3 H, 
t, /  6.9, C7H 14CA3), 1.26-1.42 (10 H, m, (C7/ 2)5CH3), 1.62 (2 H, m, OCH2CH2),
1.73 (1 H, m, 3c,,-H), 2.00 (3 H, s, AcN), 2.86 (1 H, dd, / 3cax,3ceq 12.4 / 3ceq,4c 4.4, 
3Ceq-H), 4.28 (1 H, d, /la ,2 a  7.7, la-H), 4.43 (1 H, d, /ib ,2b  7.7, Ib-H); 5 c ( C D 3 0 D )
14.5, 22.7, 23.8, 27.2, 30.5, 30.7, 30.9, 33.1, 42.25, 54.1, 62.2, 62.9, 64.8, 69.2, 69.5,
70.3, 71.1, 73.2, 75.0, 75.1, 75.15, 76.6, 77.2, 77.9, 81.2, 101.3, 104.5, 105.3, 175.3, 
175.8; ES-MS (-ve): m/z 744 (M-K)' (C31H54NO19K requires m/z 783).
Method two: ^m«s-siaUdase glycosylation. pNP sialoside 139 (3 mg, 6.7 pmol) 
was added to a solution of octyl lactoside 57 (2 mg, 4.4 pmol) and Trypanosoma 
cruzi ^ra«5-sialidase (~1 mg) (see general methods, 7.1) in 50 mM phosphate buffer 
(pH 7, 1 cm^). The reaction mixture was incubated for 18 h at 30 °C. TLC (CHCI3- 
Me0 H-H2 0 , 6:4:1) indicated -50% turnover of the octyl lactoside. The reaction was 
quenched by addition of EtOH (0.5 cm^) to precipitate the protein and the resulting 
mixture was centrifuged at 13,000 x g  for 3 mins. The supernatants of five such 
incubations were combined and concentrated. The residue was redissolved in water 
(2  cm^) and subjected to reverse phase chromatography (C-18 silica gel; 
H2 0 ->Me0 H). 50% aqueous methanol gave the title compound 52 as a white 
powder following freeze-diying from water (7 mg, 42%). Analytical data were 
identical to those obtained for the chemically synthesised compound.
A solution of enzymatically synthesised 52 (5 mg) and potassium hydroxide (1 cm^;l 
M) was heated for 20 h at 90 °C. After cooling to room temperature, the solution was 
neutralised with acetic acid and desalted on a reverse phase column (C-18 silica gel; 
H2 0 ->Me0 H) to give the de-N~acetyl compound 49 as a glassy solid (4.5 mg, 95%) 
Analytical data were identical to those for the chemically synthesised compound.
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6.3 Enzyme Assays
6.3.1 Clostridium perfringens Neuraminidase Inhibition A ssay/  ^ pNP-sialoside 
139 (0.35 pmol) and the inhibitor (0.35 pmol) in 50 mM sodium acetate buffer (pH
4.5, 0.35 cm^) were incubated at 37 °C. Aliquots (50 mm^) were withdrawn after 5, 
10 and 15 minutes and immediately quenched with glycine stopping buffer (pH 10, 
0.95 cm3; see general methods, 7.1) and their UV absorbance was read at 400 nm 
against stopping buffer as blank. Twenty minutes after starting the incubation, C. 
perfringens neuraminidase (8  mU) was added, and the mixture was incubated at 37 
°C, as before. After a further 5, 1 0  and 15 minutes, aliquots (50 mm^) were 
withdrawn, diluted with stopping buffer and their UV absorbances were read as 
above. The rate of enzymatic hydrolysis of the substrate was determined by plotting a 
graph of absorbance vs. time for each inhibitor in the presence and absence of 
neuraminidase. Enzyme inhibition was calculated as a percentage of the rate of 
substrate turnover in the absence of inhibitors.
6.3.2 Clostridium perfringens Neuraminidase Turnover Assay. The potential 
substrates (0.2 p,mol) were incubated with C. perfringens neuraminidase (2 mU) in 
50 mM sodium acetate buffer (pH 4.5, 100 mm^) at 37 °C. TLC (CHCls-MeOH- 
H2O, 6:4:1) after 24 h showed that all of GM3 analogue 52 had been cleaved to sialic 
acid and octyl lactoside, but all of the other compounds which had been tested 
remained unchanged.
6.3.3 Trypanosoma cruzi ^m/is-Sialidase Inhibition A s s a y . ^ 3  ^raw^-Sialidase 
enzyme (10 mm^) (see general methods, 7.1) was added to 50 mM phosphate buffer 
(pH 7, 40 mm3) containing 2,3-sialyllactose (10 nmol), [I'^Cjlactose (-35,000 cpm,
0.38 nmol) and the inhibitor (50 nmol). Following incubation for 30 mins at 30 °C, 
the reaction mixture was quenched by diluting with water (0.95 cm^) an applied to a 
column of Sephadex A25 (0.5 cm^) which had been pre-equilibrated with water. 
[^^cjLactose was eluted from the column by washing with water (1  cm^) and then 
sialyl-[^"^C]lactose was eluted with ammonium acetate solution (2 cm^; 1 M). 
Scintillation fluid (8  cm^) was added to each of the elutions and after mixing, the 
radioactivity was measured using a scintillation counter.
6.3.4 Trypanosoma cruzi ^mws-Sialidase Turnover Assay. /^ ra«5 -Sialidase enzyme 
(10 mm3) (see general methods, 7.1) was added to 50 mM phosphate buffer (pH 7, 
40 mm^) containing [^^cjiactose (-35,000 cpm, 0.38 nmol) and the potential sialyl- 
donor (50 nmol). The mixture was incubated for 30 mins, 4 h or 22 h at 30 °C and 
then worked-up as described for the inhibition assay 7.3.3.
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Chapter 7 
Conclusions and Future Work
7.1 Conclusions
De-jV-acetyl gangliosides are naturally occurring glycosphingolipids that have been 
detected in several different cancer cell lines (section 1.6.3.2). It has been suggested 
that one such compound, deNAcGMS, has a potent effect on signal transduction, 
ultimately up-regulating cell growth (section 1.6.3.2). However, deNAc gangliosides 
are only expressed transiently and little is known about their biology. The aims of 
this project were to synthesise a number of analogues of gangliosides GM3 and 
deNAcGM3 and to use these compounds to develop assays for the de-A-acetylase 
and A-acetyltransferase activities which allow the inter-conversion of GM3 and 
deNAcGM3. Such assays could then be used to monitor the purification of the 
relevant enzymes and also to screen potential inhibitors for the enzymes.
To this end, several iS'-linked and O-linked sialosides were synthesised (sections 4.1 
and 4.2). Both chemical and enzymatic glycosylations were investigated for the 
synthesis of G-linked GM3 analogue 52 (Figure 7.1) (section 4.2). The enzymatic 
procedure using recombinant Trypanosoma cruzi trans-sidXi&^ SQ was found to be the 
method of choice allowing rapid, easy, stereo- and regio-selective synthesis of the 
target sialoside in good yield.
HO, OO2 OH^OH
AcHN ^
CO2' OH^OH 
-O
AcHN
125
Figure 7.1 GM3 analogue 52 and S-linked GM4 analogue 125.
Difficulties were encountered in trying to synthesise the corresponding thioglycoside 
analogues (sections 4.1.1 and 4.1.2). Literature procedures failed in my hands, but a 
novel strategy for the synthesis of Neu5Aca(2->3)-3-thio-Gal containing compounds 
was developed and successfully used to synthesise GM4 analogue 125 (Figure 7.1) 
(sections 4.1.4 and 4.1.5). The thioglycosides synthesised in this project were found 
to be resistant to enzymatic hydrolysis by Clostridium perfringens neuiaminidase 
and T. cruzi /ra«5-sialidase (section 4.3). GM4 analogue 125 was found to inhibit C. 
perfringens neuraminidase with an I C 5 0  o f  mM (section 4.3.1).
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Assays for the de-A-acetylase and A-acetyltransferase activities were developed in 
collaboration with Prof. Ajit Varki’s group at the UCSD Cancer Center (chapter 5). 
However, initial studies failed to locate the target enzymes. Further experiments 
suggested that the particular cell line which had been used in these studies had 
changed phenotypically and was no longer expressing deNAc gangliosides (section 
5.3). Studies towards the identification and characterisation of the de-A-acetylase and 
A-acetyltransferase enzymes are continuing in collaboration with the Varki group.
7.2 Future Work
Clearly, the first priority of future work is to identify and purify the de-A-acetylase 
and A-acetyltransferase enzymes. DeNAcGM3 analogues with longer hydrophobic 
tails need to be synthesised to improve the sensitivity of the A-acetyltransferase assay 
(section 5.2.1) and a panel of different cancer cell lines will need to be screened for 
the target enzymes. After the enzymes have been located and preferably purified, a 
range of GM3/deNAcGM3 analogues bearing modified sialic acids could be 
synthesised for structure-activity studies.
Potential inhibitors for the enzymes could be based on either the «S-linked or O-linked 
analogues that have been synthesised in this study. The de-iV-acetylation reaction 
presumably proceeds via a tetrahedral transition state. Transition state analogues 
could be prepared as potential inhibitors, by replacing the sialic acid acetamido group 
with a tetrahedral group e.g. a sulfonamide.
Inhibitors based on thioglycosides have been shown to he resistant to degradation by 
glycosidases. If such inhibitors were attached to a resin, they could potentially be 
used to purify the de-A-acetylase by affinity chromatography, in a manner analogous 
to the purification of cellulase described in section 2.4. It is also possible that 
inhibiting the synthesis or degradation of deNAc gangliosides in whole cells, could 
shed further light on the biological roles of these novel and illusive membrane 
components.
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Appendix 1. Core Structures of Glycosphingolipids
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Ganglio (Gg) 
Gaip3GalNAcp4Galp4Glc-
Lacto (Lc) 
Gaip3GlcNAcp3Gaip4Glc-
Neolacto (nLc) 
Gaip4GlcNAcp3Gaip4Glc-
Globo (Gb)
GaIN Acp3Gaia4Gal p4Glc-
Isoglobo (iGb) 
GalNAcp3Gala3Galp4Glc-
Mollu (Mu) 
GlcNAcp2M ana3M anp4Glc-
Arthro (At) 
GalNAcp4GlcNAcp3Manp4Glc-
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Appendix 2. and NMR Spectra of Compound 113
Fully acetylated sialyl galactose thioglycoside 113 was synthesised in tliree different 
reactions, each giving different mixtures of pyranose and furanose isomers. and 
NMR spectra of the product mixtures arising from each of the reactions shown 
below, are reproduced on the next two pages.
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iH NMR Spectra of compound 113
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